image_name
stringlengths 68
68
| type
stringclasses 2
values | gt_table
stringlengths 116
12.6k
|
|---|---|---|
064144df0ee904299390d99a9aad93a8114190c3770db04ea6daac6521e95e28.png | complex | <table><tr><td></td><td>ASD</td><td>Control</td></tr><tr><td colspan="3">Saccade error (absolute value in degree of visual angle)</td></tr><tr><td>10 deg</td><td>1.46 (0.43)*</td><td>1.27 (0.07)</td></tr><tr><td>20 deg</td><td>2.40 (0.72)***</td><td>1.86 (0.11)</td></tr><tr><td>30 deg</td><td>3.33 (1.12)**</td><td>2.60 (0.17)</td></tr><tr><td colspan="3">Trial-wise variability (SD) of saccade error (absolute value in degrees)</td></tr><tr><td>10 deg</td><td>1.11 (0.37)</td><td>1.03 (0.37)</td></tr><tr><td>20 deg</td><td>1.90 (0.58)***</td><td>1.31 (0.58)</td></tr><tr><td>30 deg</td><td>2.79 (0.58)**</td><td>2.07 (0.29)</td></tr><tr><td colspan="3">Saccade amplitude in degrees</td></tr><tr><td>10 deg</td><td>9.78 (0.82)</td><td>9.69 (0.82)</td></tr><tr><td>20 deg</td><td>19.11 (1.28)</td><td>19.20 (1.28)</td></tr><tr><td>30 deg</td><td>27.71 (1.68)</td><td>28.14 (1.68)</td></tr><tr><td colspan="3">Trial-wise variability (SD) of saccade amplitude in degrees</td></tr><tr><td>10 deg</td><td>1.91 (0.64)</td><td>1.86 (0.65)</td></tr><tr><td>20 deg</td><td>2.75 (0.83)*</td><td>2.30 (0.83)</td></tr><tr><td>30 deg</td><td>3.86 (1.19)***</td><td>2.10 (1.19)</td></tr><tr><td colspan="3">Saccade latency in ms</td></tr><tr><td>10 deg</td><td>255 (52)</td><td>248 (52)</td></tr><tr><td>20 deg</td><td>275 (58)</td><td>273 (58)</td></tr><tr><td>30 deg</td><td>313 (55)</td><td>300 (55)</td></tr><tr><td colspan="3">Trial-wise variability (SD) of saccade latency in ms</td></tr><tr><td>10 deg</td><td>80 (30)**</td><td>64 (21)</td></tr><tr><td>20 deg</td><td>90 (37)**</td><td>66 (37)</td></tr><tr><td>30 deg</td><td>90 (32)*</td><td>75 (32)</td></tr></table> |
c2b7f7e47f3920a8399a75859ba6da70118be278e73358c6d4387adf1810123c.png | simple | <table><tr><td>Model</td><td>Genotype</td><td>Controls (%)</td><td>Asthma Patients (%)</td><td>OR (95% CI)</td><td>P-value</td></tr><tr><td>rs2280090</td><td>C/C</td><td>166 (83)</td><td>331 (83)</td><td>1</td><td>0.33</td></tr><tr><td></td><td>C/T</td><td>34 (17)</td><td>65 (16.3)</td><td>1.03 (0.61–1.71)</td><td></td></tr><tr><td></td><td>T/T</td><td>0 (0)</td><td>3 (0.8)</td><td>NA (0.00-NA)</td><td></td></tr><tr><td>rs487377</td><td>G/G</td><td>82 (41)</td><td>142 (35.6)</td><td>1</td><td>0.79</td></tr><tr><td></td><td>G/A</td><td>90 (45)</td><td>197 (49.4)</td><td>1.15 (0.76–1.75)</td><td></td></tr><tr><td></td><td>A/A</td><td>28 (14)</td><td>60 (15)</td><td>1.03 (0.57–1.88)</td><td></td></tr><tr><td>rs511898</td><td>G/G</td><td>97 (48.5)</td><td>185 (46.2)</td><td>1</td><td>0.94</td></tr><tr><td></td><td>G/A</td><td>87 (43.5)</td><td>179 (44.8)</td><td>1.04 (0.70–1.55)</td><td></td></tr><tr><td></td><td>A/A</td><td>16 (8)</td><td>36 (9)</td><td>1.13 (0.55–2.31)</td><td></td></tr><tr><td>rs2787094</td><td>C/C</td><td>90 (45)</td><td>143 (35.8)</td><td>1</td><td>0.049</td></tr><tr><td></td><td>C/G</td><td>89 (44.5)</td><td>189 (47.2)</td><td>1.21 (0.80–1.82)</td><td></td></tr><tr><td></td><td>G/G</td><td>21 (10.5)</td><td>68 (17)</td><td>1.91 (1.02–3.60)</td><td></td></tr><tr><td>rs528557</td><td>G/G</td><td>124 (62)</td><td>248 (62)</td><td>1</td><td>0.56</td></tr><tr><td></td><td>G/C</td><td>66 (33)</td><td>133 (33.2)</td><td>0.96 (0.63–1.44)</td><td></td></tr><tr><td></td><td>C/C</td><td>10 (5)</td><td>19 (4.8)</td><td>1.61 (0.63–4.14)</td><td></td></tr><tr><td>rs678881</td><td>C/C</td><td>166 (83)</td><td>298 (74.7)</td><td>1</td><td>0.0083</td></tr><tr><td></td><td>G/C</td><td>30 (15)</td><td>97 (24.3)</td><td>1.92 (1.16–3.18)</td><td></td></tr><tr><td></td><td>G/G</td><td>4 (2)</td><td>4 (1)</td><td>0.68 (0.14–3.38)</td><td></td></tr><tr><td>rs2853215</td><td>C/C</td><td>128 (64)</td><td>250 (62.5)</td><td>1</td><td>0.39</td></tr><tr><td></td><td>C/T</td><td>64 (32)</td><td>127 (31.8)</td><td>1.02 (0.67–1.54)</td><td></td></tr><tr><td></td><td>T/T</td><td>8 (4)</td><td>23 (5.8)</td><td>1.91 (0.73–5.01)</td><td></td></tr><tr><td>rs554743</td><td>A/A</td><td>64 (32.3)</td><td>122 (30.5)</td><td>1</td><td>0.51</td></tr><tr><td></td><td>G/A</td><td>100 (50.5)</td><td>193 (48.2)</td><td>0.84 (0.54–1.30)</td><td></td></tr><tr><td></td><td>G/G</td><td>34 (17.2)</td><td>85 (21.2)</td><td>1.10 (0.63–1.94)</td><td></td></tr><tr><td>rs2853209</td><td>A/A</td><td>43 (21.5)</td><td>108 (27.2)</td><td>1</td><td>0.37</td></tr><tr><td></td><td>A/T</td><td>102 (51)</td><td>201 (50.6)</td><td>0.82 (0.51–1.33)</td><td></td></tr><tr><td></td><td>T/T</td><td>55 (27.5)</td><td>88 (22.2)</td><td>0.67 (0.39–1.17)</td><td></td></tr><tr><td>rs570269</td><td>G/G</td><td>66 (33)</td><td>140 (35)</td><td>1</td><td>0.49</td></tr><tr><td></td><td>G/C</td><td>93 (46.5)</td><td>199 (49.8)</td><td>1.01 (0.66–1.55)</td><td></td></tr><tr><td></td><td>C/C</td><td>41 (20.5)</td><td>61 (15.2)</td><td>0.74 (0.43–1.29)</td><td></td></tr><tr><td>rs44707</td><td>C/C</td><td>66 (33)</td><td>172 (43)</td><td>1</td><td>0.0084</td></tr><tr><td></td><td>C/A</td><td>90 (45)</td><td>178 (44.5)</td><td>0.73 (0.47–1.12)</td><td></td></tr><tr><td></td><td>A/A</td><td>44 (22)</td><td>50 (12.5)</td><td>0.47 (0.27–0.83)</td><td></td></tr><tr><td>rs512625</td><td>C/C</td><td>94 (47)</td><td>142 (35.5)</td><td>1</td><td>0.033</td></tr><tr><td></td><td>C/T</td><td>75 (37.5)</td><td>193(48.2)</td><td>1.60 (1.06–2.43)</td><td></td></tr><tr><td></td><td>T/T</td><td>31 (15.5)</td><td>65 (16.2)</td><td>1.32 (0.74–2.34)</td><td></td></tr><tr><td>rs677044</td><td>T/T</td><td>120 (60)</td><td>193 (48.6)</td><td>1</td><td>0.0033</td></tr><tr><td></td><td>C/T</td><td>69 (34.5)</td><td>167 (42.1)</td><td>1.51 (1.00–2.28)</td><td></td></tr><tr><td></td><td>C/C</td><td>11 (5.5)</td><td>37 (9.3)</td><td>2.77 (1.23–6.24)</td><td></td></tr></table> |
c21198a0a52cf8cd6c99cad77167f161a9af6e03c45fc0228c5ad0f589290caa.png | simple | <table><tr><td>Annotation Clusters</td><td>Official Symbol</td></tr><tr><td>Vascular development</td><td><i>Eph2, Chd7, Ereg, Foxc1, Gja1, Itgav, Lepr, Nus1, Pdpn,Prox1, S1pr1, Socs3, Zfp36l1</i></td></tr><tr><td>Embryonic morphogenesis</td><td><i>Eph2, Chd7, Chst11, Foxc1, Hes1, Il10, Mmp13, Pbx1,Prox1, Socs3, Spry2, Jag2</i></td></tr><tr><td>Sexual reproduction</td><td><i>Bcl6, Bcl2l11, Crem, Calca, Cadm1, Ereg, Fst, Foxc1,Jag2, Lepr, Pvrl3, Rgs2, Stat3</i></td></tr><tr><td>Response to wounding, Inflammatory and Defense responses</td><td><i>Bmp6, Cd14, Calca, Ddah2, Entpd1, Gja1, Hdac5, Il1f6,Il10, Saa1, Saa2, Stat3, Thbd, Thbs1</i></td></tr><tr><td>Growth factors, GF activity</td><td><i>Areg, Bmp6, Chst11, Csf3, Ereg, Foxc1, Gja1, Hgf, Inhbb,Jag2</i></td></tr><tr><td>DNA binding, Transcription regulation</td><td><i>Arid3b, Bcl6, Bach2, Gata2, Lhx8, Mxd1, Mxi1, Setbp1,Thap2, Crem, Chd7, Dedd2, Foxc1, Hes1, Hdac5, Lrrfip1,Nr4a2, Pbx1, Prox1, Runx2, Stat3, Fosl2, Sbno2, Tshz3, Tle1,Mafb, Zfp36, Zfp36l1</i></td></tr><tr><td>Disulfide bond</td><td><i>Nt53, Abca1, Cd14, Cd80, Edil3, Eph2, Gpr35, Areg,Antxr2, Bmp6, Calca, Cacna1d, Cadm1, Cbln3, CxCr7, Csf3,Entpd1, Ereg, Fst, Gja1, Havcr2, Hgf, Inhbb, Itgav, Il10,Jag2, Lepr, Lifr, Man1a, Mmp13, Mmp3, Mpzl1, Niacr1, Pla1a,Pvrl3, Ptger2, Lpar6, Ramp3, Sema6d, Tnfaip6, Thbd, Thbs1,Trem1, Tnfrsf9</i></td></tr></table> |
f98b9111e9799881cb8a869b8ead56191e7fbc4b00fc83aa39e0cb40c00ddad2.png | complex | <table><tr><td rowspan="2">Gene</td><td rowspan="2">Ensembl ID</td><td rowspan="2">Reference</td><td colspan="2">Sites found by RNA-seq for</td><td colspan="2">Sites found by HTA for</td><td rowspan="2">Concordant</td></tr><tr><td>exons</td><td>junctions</td><td>exons</td><td>junctions</td></tr><tr><td>TP63</td><td>ENSG00000073282</td><td>Lo Iacono et al. [57]</td><td>6</td><td>10</td><td>2</td><td>27</td><td>No</td></tr><tr><td>TP73</td><td>ENSG00000078900</td><td>Lo Iacono et al. [57]</td><td>0</td><td>2</td><td>2</td><td>6</td><td>No</td></tr><tr><td>CD44</td><td>ENSG00000026508</td><td>Wang et al. [58]</td><td>34</td><td>32</td><td>19</td><td>43</td><td>No</td></tr><tr><td>HLA-G</td><td>ENSG00000204632</td><td>Yan et al. [59]</td><td>2</td><td>0</td><td>0</td><td>0</td><td>No</td></tr><tr><td>POSTN</td><td>ENSG00000133110</td><td>Morra et al. [60]</td><td>3</td><td>5</td><td>1</td><td>7</td><td>No</td></tr><tr><td>RUNX1</td><td>ENSG00000159216</td><td>Ito et al. [61]</td><td>8</td><td>2</td><td>18</td><td>13</td><td>Yes</td></tr></table> |
6f5321c36af785c761ff536eb9ef648ac81c28e52af239cba30383da83bab638.png | complex | <table><tr><td rowspan="2"></td><td rowspan="2">Flock size</td><td colspan="2">2000</td><td colspan="2">2010</td></tr><tr><td>n</td><td>%</td><td>n</td><td>%</td></tr><tr><td rowspan="4">Flocks enrolled</td><td><26</td><td>1009</td><td>20.4</td><td>547</td><td>15.0</td></tr><tr><td>26–125</td><td>3651</td><td>73.9</td><td>2602</td><td>71.2</td></tr><tr><td>126–250</td><td>268</td><td>5.4</td><td>451</td><td>12.3</td></tr><tr><td>>250</td><td>13</td><td>0.3</td><td>54</td><td>1.5</td></tr><tr><td rowspan="4">Ewes enrolled in flocks</td><td><26</td><td>17,044</td><td>6.2</td><td>8355</td><td>3.1</td></tr><tr><td>26–125</td><td>214,086</td><td>77.4</td><td>170,358</td><td>63.1</td></tr><tr><td>126–250</td><td>41,542</td><td>15.0</td><td>73,551</td><td>27.2</td></tr><tr><td>>250</td><td>3959</td><td>1.4</td><td>17,847</td><td>6.6</td></tr></table> |
5a12c077b1ca9d7119c805bbd06bdffefdc9191c1f4af21ff7645d1899d7b54e.png | complex | <table><tr><td rowspan="2">Gene</td><td colspan="2">Location</td><td colspan="2">The length of protein(aa)</td></tr><tr><td>SNU8067</td><td>KM91</td><td>SNU8067</td><td>KM91</td></tr><tr><td>1a</td><td>529–12390</td><td>529–12387</td><td>3953</td><td>3952</td></tr><tr><td>1b</td><td>12465–20423</td><td>12357–20420</td><td>2652</td><td>2688</td></tr><tr><td>S</td><td>20374–23883</td><td>20371–23862</td><td>1169</td><td>1163</td></tr><tr><td>3a</td><td>23883–24056</td><td>23862–24008</td><td>57</td><td>48</td></tr><tr><td>3b</td><td>24056–24250</td><td>23995–24183</td><td>64</td><td>62</td></tr><tr><td>E</td><td>24234–24560</td><td>24167–24496</td><td>108</td><td>109</td></tr><tr><td>M</td><td>24532–25209</td><td>24465–25145</td><td>225</td><td>226</td></tr><tr><td>5a</td><td>25569–25766</td><td>25505–25702</td><td>65</td><td>65</td></tr><tr><td>5b</td><td>25763–26011</td><td>25699–25947</td><td>82</td><td>82</td></tr><tr><td>N</td><td>25954–27183</td><td>25890–27119</td><td>409</td><td>409</td></tr></table> |
a9072a7e5eb584a11d953a6541a02226919a9fb8cd54b94e94c467b8b9d2ae4d.png | simple | <table><tr><td>Field</td><td>Code</td><td>Character</td><td>Item amount</td><td>Scores (R)</td><td>Calculation method</td></tr><tr><td>Physical function</td><td>PF</td><td>Function</td><td>5</td><td>3</td><td>(Q1 + Q2 + Q3 + Q4 + Q5)/5</td></tr><tr><td>Role function</td><td>RF</td><td>Function</td><td>2</td><td>3</td><td>(Q6 + Q7)/2</td></tr><tr><td>Emotional function</td><td>EF</td><td>Function</td><td>4</td><td>3</td><td>(Q21 + Q22 + Q23 + Q24)/4</td></tr><tr><td>Cognitive function</td><td>CF</td><td>Function</td><td>2</td><td>3</td><td>(Q20+ Q25)/2</td></tr><tr><td>Social function</td><td>SF</td><td>Function</td><td>2</td><td>3</td><td>(Q26 + Q27)/2</td></tr><tr><td>Global QOL</td><td>QL</td><td></td><td>2</td><td>6</td><td>(Q29 + Q30)/2</td></tr><tr><td>Fatigue</td><td>FA</td><td>Symptom</td><td>3</td><td>3</td><td>(Q10 + Q12 + Q26)/3</td></tr><tr><td>Nausea and vomiting</td><td>NV</td><td>Symptom</td><td>2</td><td>3</td><td>(Q14 + Q15)/2</td></tr><tr><td>Pain</td><td>PA</td><td>Symptom</td><td>2</td><td>3</td><td>(Q9 + Q19)/2</td></tr><tr><td>Dyspnea</td><td>DY</td><td>Symptom</td><td>1</td><td>3</td><td>Q8</td></tr><tr><td>Sleep disturbance</td><td>SL</td><td>Symptom</td><td>1</td><td>3</td><td>Q11</td></tr><tr><td>Appetite loss</td><td>AP</td><td>Symptom</td><td>1</td><td>3</td><td>Q13</td></tr><tr><td>Constipation</td><td>CO</td><td>Symptom</td><td>1</td><td>3</td><td>Q16</td></tr><tr><td>Diarrhea</td><td>DI</td><td>Symptom</td><td>1</td><td>3</td><td>Q17</td></tr><tr><td>Financial difficulties</td><td>FI</td><td>Symptom</td><td>1</td><td>3</td><td>Q28</td></tr></table> |
aaa8ae1ce5ed56a6dd025e8630b32e82cfb99d54db27a0fefabcd688c2089e5b.png | simple | <table><tr><td></td><td>PMPs mean (SD) counts/μl</td><td>EMPs-CD31 mean (SD) counts/μl</td><td>EMPs-CD62 mean (SD) counts/μl</td><td>PMPs p <i>vs.</i>Ct</td><td>EMPs-CD31 p <i>vs.</i>Ct</td><td>EMPs-CD62 p <i>vs.</i>Ct</td></tr><tr><td>Control</td><td>15,646 (11,901)</td><td>2,202 (2,784)</td><td>418 (289)</td><td></td><td></td><td></td></tr><tr><td>CIS</td><td>30,936 (22,550)</td><td>7,964 (6,888)</td><td>646 (195)</td><td>n.s.</td><td><0.05</td><td><0.05</td></tr><tr><td>RRMS</td><td>28,929 (18,247)</td><td>7,136 (6,088)</td><td>511 (231)</td><td><0.001</td><td><0.001</td><td>n.s.</td></tr><tr><td>SPMS</td><td>34,188 (29,511)</td><td>7,512 (5,962)</td><td>629 (644)</td><td><0.01</td><td><0.001</td><td>n.s.</td></tr><tr><td>PPMMS</td><td>26,422 (9,865)</td><td>6,460 (3,610)</td><td>699 (621)</td><td><0.05</td><td><0.001</td><td>n.s.</td></tr></table> |
508abbcf0a7aa4ff752ada1e599fb8c1254d0c9e184512595f4f9d1cc7bd6ec7.png | simple | <table><tr><td>Patient</td><td>CA (years)</td><td>BA (years)</td><td>GH peak (ng/mL)</td><td>FT<sub>3</sub> (pmol/L)</td><td>FT<sub>4</sub> (pmol/L)</td><td>TSH (mIU/L)</td><td>TPOAb (IU/mL)</td><td>TgAb (IU/mL)</td><td>IGF-1 (ng/mL)</td><td>PRL (<i>μ</i>g/L)</td><td>Pituitary height (mm)</td></tr><tr><td>1 M</td><td>6.2</td><td>1.0</td><td>8.0</td><td>1.6</td><td>3.4</td><td>>150</td><td>42.1</td><td>23.9</td><td>145.0</td><td>49.1</td><td>11.0</td></tr><tr><td>2 M</td><td>9.8</td><td>6.0</td><td>2.7</td><td>0.1</td><td>3.0</td><td>>150</td><td>>500</td><td>>1300</td><td>78.0</td><td>32.2</td><td>14.0</td></tr><tr><td>3 M</td><td>11.2</td><td>8.0</td><td>5.1</td><td>1.2</td><td>4.3</td><td>>150</td><td>>500</td><td>>1300</td><td>97.7</td><td>12.5</td><td>16.0</td></tr><tr><td>4 M</td><td>10.7</td><td>6.0</td><td>7.5</td><td>2.0</td><td>3.3</td><td>>150</td><td>73.8</td><td>>1300</td><td>68.61</td><td>52.6</td><td>18.0</td></tr><tr><td>5 M</td><td>10.8</td><td>7.0</td><td>2.6</td><td>2.6</td><td>4.3</td><td>75.0</td><td>>500</td><td>>1300</td><td>56.7</td><td>27.5</td><td>20.3</td></tr><tr><td>6 M</td><td>7.9</td><td>4.0</td><td>1.5</td><td>3.0</td><td>6.6</td><td>>150</td><td>>500</td><td>404.5</td><td>106.98</td><td>52.4</td><td>19.0</td></tr><tr><td>7 M</td><td>15.0</td><td>13.0</td><td>6.7</td><td>4.9</td><td>6.7</td><td>65.5</td><td>>500</td><td>>1300</td><td>147.42</td><td>28.5</td><td>14.0</td></tr><tr><td>8 M</td><td>15.8</td><td>10.0</td><td>8.0</td><td>1.0</td><td>1.2</td><td>>150</td><td>627.3</td><td>36.9</td><td>148.3</td><td>41.5</td><td>14.0</td></tr><tr><td>9 F</td><td>5.0</td><td>3.0</td><td>7.1</td><td>0.2</td><td>3.6</td><td>>150</td><td>>500</td><td>>1300</td><td>75.26</td><td>75.4</td><td>13.0</td></tr><tr><td>10 F</td><td>9.3</td><td>8.5</td><td>5.2</td><td>6.5</td><td>7.3</td><td>78.0</td><td>>500</td><td>600.9</td><td>63.0</td><td>33.2</td><td>8.8</td></tr><tr><td>11 F</td><td>11.5</td><td>9.0</td><td>1.0</td><td>0.8</td><td>1.4</td><td>>150</td><td>>500</td><td>>1300</td><td>123.0</td><td>41.4</td><td>9.0</td></tr></table> |
c545bde3acbe0335930be4ab7f2e01aa09fc54e98a525ba705c6e4a2ae941597.png | complex | <table><tr><td>Primer name</td><td>Assay</td><td>Sequence (5′-3′)</td><td>Exon position</td><td>Target gene</td><td>Amplicon sizes (bp)</td></tr><tr><td>GHRL-1 F</td><td>RT-PCR</td><td>TTTCTGAGCCCTGAACATCAG</td><td>1</td><td><i>GHRL</i></td><td>305 canonical (wild-type) preproghrelin</td></tr><tr><td>GHRL-4R</td><td></td><td>GAGAACAGACAGGTGGTTGG</td><td>4</td><td></td><td></td></tr><tr><td>GHRL-5OF</td><td>RACE</td><td>ATGAATGAACACTGCGTTTGCT</td><td>N/A</td><td rowspan="2"><i>GHRL</i></td><td rowspan="2">174</td></tr><tr><td>GHRL-5OR</td><td></td><td>CAGTTTCTGATGTTCAGGGCTC</td><td>1</td></tr><tr><td>GHRL-5IF</td><td>RACE</td><td>GAACACTGCGTTTGCTGGCT</td><td>N/A</td><td rowspan="2"><i>GHRL</i></td><td rowspan="2">130</td></tr><tr><td>GHRL-5IR</td><td></td><td>GGCCAAGTCCATCCAGAGCA</td><td>1</td></tr><tr><td>GHRL-2F</td><td>qRT-PCR</td><td>CTAAGAAGCCGTCAGGCAGACT</td><td>2</td><td rowspan="2"><i>GHRL</i> (preproghrelin)</td><td rowspan="2">153</td></tr><tr><td>GHRL-2R</td><td></td><td>GGGACTGAGCCCCTGACA</td><td>3</td></tr><tr><td>GHRL1_3F</td><td>qRT-PCR</td><td>CAGAAACTGCAGTTCAATGC</td><td>1 / 3</td><td rowspan="2"><i>GHRL</i> (Δex2 preproghrelin)</td><td rowspan="2">224</td></tr><tr><td>GHRL-4R</td><td></td><td>CACGTGGTCTCGGAAGTGT</td><td>4</td></tr><tr><td>GHRL1_4F</td><td>qRT-PCR</td><td>CTGCAGAAACCCTGGCTGA</td><td>1 / 4</td><td rowspan="2"><i>GHRL</i> (Δex2,3 preproghrelin)</td><td rowspan="2">109</td></tr><tr><td>GHRL-4R</td><td></td><td>CACGTGGTCTCGGAAGTGT</td><td>4</td></tr><tr><td>GOAT-mF</td><td>qRT-PCR</td><td>GGTTTCAAGCTCGAGTTGAAGG</td><td rowspan="2">N/A</td><td rowspan="2"><i>MBOAT4</i> (GOAT)</td><td rowspan="2">212</td></tr><tr><td>GOAT-mR</td><td></td><td>AGTAGGTGAGTTTGAAGAGCCC</td></tr><tr><td>GAPDH-F</td><td>qRT-PCR</td><td>CCTGGAGAAACCTGCCAAGT</td><td rowspan="2">N/A</td><td rowspan="2"><i>GAPDH</i></td><td rowspan="2">209</td></tr><tr><td>GAPDH-R</td><td></td><td>GCCAAATTCATTGTCGTACCA</td></tr></table> |
614814861e95b624795b5bfd23913ec8437491ae6e1462ac7329b14b565c10b0.png | simple | <table><tr><td> </td><td>Case (N = 43)</td><td>Control (N = 179)</td><td><i>p</i></td></tr><tr><td>Primipara</td><td>24 (55.8%)</td><td>75 (41.9%)</td><td>0.14</td></tr><tr><td>Maternal transfer</td><td>28 (65.1%)</td><td>109 (60.9)</td><td>0.742</td></tr><tr><td>Preeclampsia/eclampsia or chronic hypertension</td><td>16 (37.2%)</td><td>42 (23.5%)</td><td>0.104</td></tr><tr><td>Vaginal bleeding</td><td>21 (48.8%)</td><td>98 (54.8%)</td><td>0.596</td></tr><tr><td>Abdominal pain</td><td>20 (46.5%)</td><td>57 (31.8%)</td><td>0.104</td></tr><tr><td>Abnormal ultrasonographic finding</td><td>35 (81.4%)</td><td>128 (71.5%)</td><td>0.257</td></tr><tr><td>Abnormal FHR patterns</td><td>42 (97.7%)</td><td>98 (54.7%)</td><td><0.0001</td></tr><tr><td> Bradycardia</td><td>32 (74.4%)</td><td>42 (23.5%)</td><td><0.0001</td></tr><tr><td> Persistent late decelerations</td><td>9(20.9%)</td><td>34 (19.0%)</td><td>0.919</td></tr><tr><td>Cesarean section</td><td>41 (95.3%)</td><td>171 (95.5%)</td><td>0.993</td></tr><tr><td>Gestational age at delivery (weeks)</td><td>34(24–39)*</td><td>35 (24–41)*</td><td>0.07</td></tr><tr><td>Gestational age at delivery <35 wks</td><td>19 (44.2%)</td><td>99 (55.3%)</td><td>0.253</td></tr><tr><td>Birth weight (g)</td><td>1997 (517–3504)*</td><td>2062 (774–3450)*</td><td>0.107</td></tr><tr><td>Male</td><td>22 (51.2%)</td><td>108 (60.3%)</td><td>0.568</td></tr><tr><td>Apgar score (1 min)</td><td>2(0–6)*</td><td>6 (0–9)*</td><td><0.0001</td></tr><tr><td>Apgar score (5 min)</td><td>5 (0–9)*</td><td>8 (0–10)*</td><td><0.0001</td></tr><tr><td>Blood transfusion</td><td>21 (48.8%)</td><td>37 (20.7%)</td><td>0.006</td></tr></table> |
2d23b35022e9e31bf4f91298d946ce5d03299aa34ec6b90c01b1d6cf152d3cbb.png | complex | <table><tr><td rowspan="2">Health Variable</td><td colspan="4">Coefficient (Standard Error)</td></tr><tr><td>NR Score</td><td>NR Self</td><td>NR Perspective</td><td>NR Experience</td></tr><tr><td>Depression</td><td>−0.11(0.07)</td><td>−0.02(0.06)</td><td>−0.04(0.06)</td><td>−0.17(0.06) **</td></tr><tr><td>Anxiety</td><td>−0.08(0.08)</td><td>0.05(0.06)</td><td>−0.04(0.07)</td><td>−0.17(0.06) **</td></tr><tr><td>Stress</td><td>−0.03(0.07)</td><td>0.00(0.00)</td><td>0.07(0.06)</td><td>−0.12(0.06) *</td></tr><tr><td>Self-reported health</td><td>0.26(0.08) ***</td><td>−0.15(0.06) *</td><td>−0.03(0.07)</td><td>0.38(0.06) ***</td></tr></table> |
4edc7b8966e486cbaef4fccea84337c96927ca20f4d535cdafe42b8a98e3db5d.png | simple | <table><tr><td>Altitudinal band (m)</td><td>Bryophyte</td><td>Fern</td><td>Seed plants</td><td>Overall plants</td></tr><tr><td>800</td><td>20</td><td>24</td><td>14</td><td>58</td></tr><tr><td>900</td><td>28</td><td>29</td><td>80</td><td>137</td></tr><tr><td>1000</td><td>39</td><td>43</td><td>254</td><td>336</td></tr><tr><td>1100</td><td>52</td><td>42</td><td>319</td><td>413</td></tr><tr><td>1200</td><td>64</td><td>54</td><td>766</td><td>884</td></tr><tr><td>1300</td><td>81</td><td>61</td><td>767</td><td>909</td></tr><tr><td>1400</td><td>92</td><td>66</td><td>692</td><td>850</td></tr><tr><td>1500</td><td>111</td><td>73</td><td>656</td><td>840</td></tr><tr><td>1600</td><td>112</td><td>61</td><td>637</td><td>810</td></tr><tr><td>1700</td><td>122</td><td>61</td><td>611</td><td>794</td></tr><tr><td>1800</td><td>138</td><td>57</td><td>607</td><td>802</td></tr><tr><td>1900</td><td>139</td><td>51</td><td>593</td><td>783</td></tr><tr><td>2000</td><td>141</td><td>52</td><td>625</td><td>818</td></tr><tr><td>2100</td><td>132</td><td>43</td><td>501</td><td>676</td></tr><tr><td>2200</td><td>134</td><td>40</td><td>510</td><td>684</td></tr><tr><td>2300</td><td>132</td><td>40</td><td>504</td><td>676</td></tr><tr><td>2400</td><td>114</td><td>36</td><td>421</td><td>571</td></tr><tr><td>2500</td><td>120</td><td>38</td><td>415</td><td>573</td></tr><tr><td>2600</td><td>112</td><td>28</td><td>337</td><td>477</td></tr><tr><td>2700</td><td>115</td><td>29</td><td>304</td><td>448</td></tr><tr><td>2800</td><td>99</td><td>28</td><td>316</td><td>443</td></tr><tr><td>2900</td><td>93</td><td>22</td><td>222</td><td>337</td></tr><tr><td>3000</td><td>94</td><td>21</td><td>236</td><td>351</td></tr><tr><td>3100</td><td>91</td><td>9</td><td>178</td><td>278</td></tr><tr><td>3200</td><td>70</td><td>8</td><td>170</td><td>248</td></tr><tr><td>3300</td><td>56</td><td>4</td><td>127</td><td>187</td></tr><tr><td>3400</td><td>44</td><td>4</td><td>120</td><td>168</td></tr><tr><td>3500</td><td>40</td><td>4</td><td>145</td><td>189</td></tr><tr><td>3600</td><td>29</td><td>1</td><td>84</td><td>114</td></tr><tr><td>3700</td><td>1</td><td>1</td><td>64</td><td>66</td></tr><tr><td>All bands pooled</td><td>257</td><td>110</td><td>1491</td><td>1858</td></tr></table> |
92b0e32aa6a1ab82e2b78ff5cd8e0c5479585edf186e8ecfee03611f4f126c31.png | simple | <table><tr><td>Sub-group</td><td>Overall sample</td><td>Bicycle ridership</td></tr><tr><td> </td><td>n=26 078</td><td>n<sup>1</sup>=19 410 (row % 74.4)</td></tr><tr><td> </td><td>Sub-group totals in n (% of n)</td><td>Sub-group totals in n<sup>1 </sup>(% of n<sup>1</sup>)</td></tr><tr><td>Sex:</td><td> </td><td> </td></tr><tr><td>Boys</td><td>12 815 (49.2)</td><td>10 085 (52.0) (row % 78.7)</td></tr><tr><td>Girls</td><td>13 254 (50.8)</td><td>9322 (48.0) (row % 70.3)</td></tr><tr><td>Age:</td><td> </td><td> </td></tr><tr><td>Mean (SD)</td><td>13.3 (1.6)</td><td>13.3 (1.6)</td></tr><tr><td>Range in years</td><td>9 to 19</td><td>10 to 19</td></tr><tr><td>Grade level:</td><td> </td><td> </td></tr><tr><td>< 8</td><td>10 370 (39.8)</td><td>8180 (42.2) (row % 78.9)</td></tr><tr><td>8-9</td><td>10 661 (40.9)</td><td>7708 (39.8) (row % 72.3)</td></tr><tr><td>≥ 10</td><td>5047 (19.3)</td><td>3521 (18.1) (row % 69.8)</td></tr><tr><td>Socio-Economic status:</td><td> </td><td> </td></tr><tr><td>Above average</td><td>13 998 (56.9)</td><td>10 817 (58.0) (row % 77.3)</td></tr><tr><td>Average</td><td>8276 (33.6)</td><td>6176 (33.1) (row % 74.6)</td></tr><tr><td>Below average</td><td>2339 (9.5)</td><td>1652 (8.9) (row % 70.6)</td></tr><tr><td>Urban–rural Location:</td><td> </td><td> </td></tr><tr><td>Large Urban Centre</td><td>8589 (32.9)</td><td>6161 (31.7) (row % 71.7)</td></tr><tr><td>Medium Urban Centre</td><td>5739 (22.0)</td><td>4174 (21.5) (row % 72.7)</td></tr><tr><td>Small Town</td><td>10 767 (41.3)</td><td>8329 (42.9) (row % 77.4)</td></tr><tr><td>Rural</td><td>983 (3.8)</td><td>746 (3.8) (row % 75.9)</td></tr><tr><td>Years in Canada:</td><td> </td><td> </td></tr><tr><td>Lifetime (born in Can.)</td><td>18 466 (71.5)</td><td>13 855 (72.0) (row % 75.0)</td></tr><tr><td>Immigrant > 5 yrs</td><td>6143 (23.8)</td><td>4642 (24.1) (row % 75.6)</td></tr><tr><td>Immigrant ≤ 5 yrs</td><td>1212 (4.7)</td><td>750 (3.9) (row 61.9)</td></tr></table> |
a45ede39898394866bd6e1a800baaf7ae6ac9a5baa3f717a987be957de713a24.png | simple | <table><tr><td>How did you know when to take your child for his/her most recent immunization?</td><td>ChoseResponse<sup>c </sup>% (95% CI)<sup>d</sup></td><td>UTD4:3:1:3:3 Chose Response % (95% CI)</td><td>UTD4:3:1:3:3 Did Not Chose Response % (95% CI)</td><td>UTD 4:3:1:3:3 Difference % points (95% CI)</td></tr><tr><td>Doctor/Nurse at Previous Immunization Visit <sup>e</sup></td><td>70.3 (68.3, 72.3)</td><td>77.2 (74.9, 79.5)</td><td>70.1 (66.0, 74.1)</td><td>7.1 (2.5, 11.8)</td></tr><tr><td>Shot Card/Record</td><td>19.5 (17.6, 21.3)</td><td>70.6 (65.2, 76.0)</td><td>76.2 (74.0, 78.3)</td><td>-5.6 (-11.3, 0.2)</td></tr><tr><td>Reminder/Recall<sup>f</sup></td><td>8.6 (7.4, 9.8)</td><td>71.0 (63.8, 78.1)</td><td>75.5 (73.4, 77.6)</td><td>-4.5 (-11.9, 2.9)</td></tr><tr><td>Other<sup>g</sup></td><td>18.3 (16.7, 19.9)</td><td>75.4 (71.4, 79.5)</td><td>75.0 (72.7, 77.3)</td><td>0.4 (-4.3, 5.1)</td></tr></table> |
7947b27b3f809d473fd3961d69111df75eed47d8fbf3342e62b9131060f66154.png | simple | <table><tr><td> </td><td>CD8<sup>+</sup>T cells</td><td>CD4<sup>+</sup>T cells</td><td>References</td></tr><tr><td>Characteristics</td><td>Decreased HBV-specific CD8<sup>+</sup> T cells; impaired cytotoxicity (IL-2, IFN-<i>γ</i> and TNF-<i>α</i>); increased inhibitory receptors including PD-1, TIM-3, CTLA-4 and 2B4</td><td>Impaired proliferation without obvious defect in Th-1-type cytokines; high PD-1 and low expression of CTLA-4, TIM-3, KLRG1 and 2B4</td><td><sup>1, 9, 11, 25, 26, 27, 28, 106, 107</sup></td></tr><tr><td>Evidence for immunotherapy</td><td>Blockade of the PD-1/PD-L1 pathway restored proliferation and function of HBV-specific CD8<sup>+</sup> T cells; blockade of CD244 or its ligand CD48 may recover proliferation, cytokine production and cytotoxicity of exhausted HBV-specific CD8<sup>+</sup> T cells; blockade of CTLA-4 was able to increase the proliferation of IFN-<i>γ</i>-producing HBV-specific CD8<sup>+</sup> T cells; by blocking Tim-3/galectin-9 interactions, expansion of HBV-specific CD8<sup>+</sup> T cells was enhanced, which were able to produce cytokines and mediate cytotoxicity</td><td>PDGF-BB inhibited CD4<sup>+</sup> T-cell proliferation; antibody specific for the PDGF-B chain was able to reduce the development of liver fibrosis; neutralization of PD-L1/2 was able to improve the ability of CD4<sup>+</sup> T cells to produce Th-1 cytokines</td><td><sup>11, 26, 35, 47, 49, 51, 61, 62, 63, 106, 107</sup></td></tr></table> |
90ffd2422abec1e988b083181a460fd214056c0d925fef6411adf0a7142cf37e.png | simple | <table><tr><td> </td><td>Mucosal Biopsy</td><td>Surgical Resection</td></tr><tr><td>Actin</td><td>Positive</td><td>Positive</td></tr><tr><td>Vimentin</td><td>Positive</td><td>Positive</td></tr><tr><td>Bcl-2</td><td>Positive</td><td>Positive</td></tr><tr><td>CD138</td><td>Positive</td><td>Not done</td></tr><tr><td>Calponin</td><td>Not done</td><td>Positive</td></tr><tr><td>Collagen type IV</td><td>Not done</td><td>Pericellular net-like pattern</td></tr><tr><td>EMA</td><td>Not done</td><td>Focal Positive</td></tr><tr><td>AE1/3</td><td>Negative</td><td>Focal Positive</td></tr><tr><td>Cam5.2</td><td>Negative</td><td>Negative</td></tr><tr><td>CK20</td><td>Negative</td><td>Not done</td></tr><tr><td>CD56</td><td>Negative</td><td>Negative</td></tr><tr><td>Desmin</td><td>Negative</td><td>Negative</td></tr><tr><td>S100</td><td>Negative</td><td>Negative</td></tr><tr><td>MPO</td><td>Negative</td><td>Not done</td></tr><tr><td>CD20</td><td>Negative</td><td>Not done</td></tr><tr><td>CD21</td><td>Negative</td><td>Not done</td></tr><tr><td>CD99</td><td>Negative</td><td>Not done</td></tr><tr><td>CD30</td><td>Negative</td><td>Not done</td></tr><tr><td>C-Kit</td><td>Negative</td><td>Negative</td></tr><tr><td>DOG1</td><td>Negative</td><td>Negative</td></tr><tr><td>PLAP</td><td>Negative</td><td>Not done</td></tr><tr><td>WT1</td><td>Not done</td><td>Negative</td></tr><tr><td>CD10</td><td>Not done</td><td>Negative</td></tr><tr><td>Chromogranin</td><td>Not done</td><td>Negative</td></tr><tr><td>Synaptophysin</td><td>Not done</td><td>Patchy Positive</td></tr><tr><td>NSE</td><td>Not done</td><td>Focal Positive</td></tr><tr><td>Myogenin</td><td>Not done</td><td>Negative</td></tr><tr><td>EWS translocation</td><td>Not done</td><td>Negative</td></tr><tr><td>SYT translocation</td><td>Not done</td><td>Negative</td></tr><tr><td>CIC-DUX4 translocation</td><td>Not done</td><td>Negative</td></tr></table> |
6f347459c574ab9b5640bc88941f05ed094825d4fe8918e45fb4607c01a3b545.png | simple | <table><tr><td>Area</td><td>Median</td><td>Range</td><td>Inter Quartile Range (IQR)</td><td>Z*</td><td><i>P </i>value</td></tr><tr><td>Shenzhen (N = 1,826)</td><td>6</td><td>0-8</td><td>4-7</td><td>-12.547</td><td><0.001</td></tr><tr><td>Xiuning (N = 2,572)</td><td>5</td><td>0-8</td><td>3-6</td><td></td><td></td></tr></table> |
ab2831a88b4c3d5b8758d388f92e62eca22f626f84a2b7024f3b567b5e1fad19.png | complex | <table><tr><td rowspan="2"></td><td colspan="2">Young group</td><td colspan="2">Middle-aged and elderly group</td></tr><tr><td>Men</td><td>Women</td><td>Men</td><td>Women</td></tr><tr><td>Number</td><td>310</td><td>357</td><td>273</td><td>861</td></tr><tr><td>Age (years)</td><td>29 ± 7</td><td>29 ± 7</td><td>60 ± 12</td><td>60 ± 11</td></tr><tr><td>Height (cm)</td><td>173.2 ± 5.6</td><td>160.4 ± 5.9</td><td>168.7 ± 6.3</td><td>155.7 ± 5.8</td></tr><tr><td>Weight (kg)</td><td>68.6 ± 8.8</td><td>53.9 ± 7.2</td><td>63.9 ± 6.7</td><td>52.0 ± 5.8</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>22.9 ± 2.8</td><td>20.9 ± 2.5</td><td>22.4 ± 1.5</td><td>21.4 ± 1.9</td></tr><tr><td>WC (cm)</td><td>79.2 ± 7.9</td><td>73.0 ± 8.4</td><td>82.1 ± 5.6</td><td>79.6 ± 7.2</td></tr><tr><td>Percent body fat (%)</td><td>16.7 ± 4.8</td><td>24.4 ± 5.7</td><td>20.0 ± 3.9</td><td>28.0 ± 5.2</td></tr><tr><td>Handgrip strength (kg)</td><td>44.5 ± 7.1</td><td>29.3 ± 5.3</td><td>38.6 ± 7.3</td><td>25.1 ± 4.5</td></tr><tr><td>ASM/Ht<sup>2</sup> (kg/m<sup>2</sup>)</td><td>8.66 ± 0.89</td><td>6.80 ± 0.75</td><td>8.05 ± 0.68</td><td>6.47 ± 0.58</td></tr><tr><td>ASM/Wt × 100 (%)</td><td>38.1 ± 3.0</td><td>32.7 ± 3.2</td><td>35.9 ± 2.6</td><td>30.3 ± 2.9</td></tr></table> |
7bc6698baa5d4f2667b85f7356a836049dc43b5bdf3fe0ed611186cc9be576bc.png | simple | <table><tr><td>Cell Line</td><td>MTT Assay</td><td>CellTiter-Glo Assay</td></tr><tr><td>MCF10a</td><td>ND</td><td>ND</td></tr><tr><td>MCF-7</td><td>24±2</td><td>27±2</td></tr><tr><td>T47D</td><td>26±2</td><td>28±3</td></tr><tr><td>MDA-MB-231</td><td>30±3</td><td>30±3</td></tr></table> |
e9f221bc3cbbbbb52da9e4611fdc9c7e1ef83ab291d26edf7e6f3c5ec4fd49ff.png | complex | <table><tr><td>Sno</td><td>Sub-District</td><td>Health Facility</td><td>ANC Attendance</td><td>% of Total Attendance</td><td>Quota Sampled</td></tr><tr><td colspan="6">Wa Municipality</td></tr><tr><td> 1</td><td>Kambale Sub</td><td>Kambale HC</td><td>697</td><td>5.64</td><td>14</td></tr><tr><td> 2</td><td>Bamahu Sub</td><td>Bamahu HC</td><td>407</td><td>3.30</td><td>8</td></tr><tr><td> 3</td><td>Charingu Sub</td><td>Charingu HC</td><td>282</td><td>2.28</td><td>6</td></tr><tr><td> 4</td><td>Busa Sub</td><td>Busa HC</td><td>279</td><td>2.26</td><td>5</td></tr><tr><td> 5</td><td>Wa Sub</td><td>Wa Reg. Hospital</td><td>8942</td><td>10.87</td><td>180</td></tr><tr><td> 6</td><td>Wa sub</td><td>Wa Central HC</td><td>1341</td><td>72.50</td><td>27</td></tr><tr><td> 7</td><td>Charia Sub</td><td>Dobile CHPS</td><td>392</td><td>3.18</td><td>8</td></tr><tr><td colspan="3"> Total</td><td>12,340</td><td>100.00</td><td>248</td></tr><tr><td colspan="6">Lawra District</td></tr><tr><td> 8</td><td>Eremon Sub</td><td>Eremon HC</td><td>107</td><td>8.89</td><td>19</td></tr><tr><td> 9</td><td>Lawra Sub</td><td>Lawra Dist. Hosp</td><td>715</td><td>59.43</td><td>125</td></tr><tr><td> 10</td><td>Lawra Sub</td><td>Lawra Sub HC</td><td>28</td><td>2.33</td><td>5</td></tr><tr><td> 11</td><td>Babile Sub</td><td>Babile Polyclinic</td><td>194</td><td>16.13</td><td>34</td></tr><tr><td> 12</td><td>Domwini Sub</td><td>Domwini HC</td><td>42</td><td>3.49</td><td>7</td></tr><tr><td> 13</td><td>Zambo Sub</td><td>Zambo HC</td><td>117</td><td>9.73</td><td>20</td></tr><tr><td colspan="3"> Total</td><td>1203</td><td>100.00</td><td>210</td></tr></table> |
2663c865dcb737c38ab27abe34b84611af99d2f9f707374830dbc1412c3b015c.png | simple | <table><tr><td>Biomarker</td><td>Abbreviation</td><td>Biological Sample Type</td><td>Marker Characteristics</td></tr><tr><td>Ethanol</td><td>EtOH</td><td>BloodUrineBreath</td><td>Restricted to conditions where ethanol is still present in circulation.</td></tr><tr><td>Ethyl glucuronide /Ethyl sulfate</td><td>EtG/EtS</td><td>UrineSerumCerebrospinal fluidVitreous humourHairNails</td><td>Ethanol metabolite, which remains positive in urine samples 2–5 days after stopping ethanol use. Window of detection dependent on sample type.</td></tr><tr><td>Phosphatidylethanol</td><td>PEth </td><td>BloodDry blood spots</td><td>Ethanol metabolite, which remains detectable 1–2 weeks after alcohol use. Measured by LC-MS or immunological techniques.</td></tr><tr><td>Fatty acid ethyl esters</td><td>FAEE</td><td>PlasmaHairMeconium</td><td>Ethanol metabolite derived from a combination of fatty acid with alcohol. </td></tr><tr><td>Acetaldehyde adducts and associated immune responses</td><td>AA-Ab </td><td>BloodTissue specimens</td><td>IgA response towards acetaldehyde adducts most specific for alcohol-related disorders.</td></tr><tr><td>Carbohydrate-deficient transferrin</td><td>CDT</td><td>SerumCerebrospinal fluid</td><td>Specific marker of chronic alcohol consumption. Lacks sensitivity for screening purposes. </td></tr><tr><td>Gamma-glutamyltransferase</td><td>GGT</td><td>Serum/plasma</td><td>Sensitive marker of alcohol use, liver dysfunction and oxidative stress. Several sources of unspecificity. Normalization time 2–3 weeks.</td></tr><tr><td>GGT-CDT combination</td><td>GGT-CDT</td><td>Serum/plasma</td><td>Improves sensitivity and specificity of detecting alcohol abuse. Relies on a mathematical model. </td></tr><tr><td>Blood cell counts </td><td></td><td>Blood</td><td>Mean corpuscular volume (MCV) of erythrocytes typically elevated in alcoholics. Normalization time 2–4 months. Mean corpuscular haemoglobin (MCH) and thrombocytes (platelet counts) are also frequently altered in alcohol abusers. Several sources of unspecificity.</td></tr><tr><td>Transaminase enzymes</td><td>ALT, AST</td><td>Serum/plasma</td><td>Suitable for screening for liver dysfunction in alcohol users. Sensitive to effects of excess body weight. AST/ALT ratio increases in alcoholic liver disease.</td></tr></table> |
6150343a0095a66c6876cf01dab5b42c84732604c384b44039d7bec60b90babc.png | simple | <table><tr><td></td><td>n</td><td>5-year survival rate (%)</td><td><i>P</i> value</td></tr><tr><td>Gender</td><td></td><td></td><td>0.759</td></tr><tr><td> Male</td><td>1102</td><td>52</td><td></td></tr><tr><td> Female</td><td>479</td><td>53</td><td></td></tr><tr><td>Age (yr)</td><td></td><td></td><td>< 0.001</td></tr><tr><td> ≤ 60</td><td>891</td><td>58</td><td></td></tr><tr><td> >60</td><td>690</td><td>45</td><td></td></tr><tr><td>Tumor size (cm)</td><td></td><td></td><td>< 0.001</td></tr><tr><td> ≤ 5</td><td>1136</td><td>59</td><td></td></tr><tr><td> >5</td><td>445</td><td>36</td><td></td></tr><tr><td>Tumor location</td><td></td><td></td><td>< 0.001</td></tr><tr><td> Upper third</td><td>563</td><td>39</td><td></td></tr><tr><td> Middle third</td><td>275</td><td>49</td><td></td></tr><tr><td> Lower third</td><td>702</td><td>65</td><td></td></tr><tr><td> Two-third or more</td><td>41</td><td>32</td><td></td></tr><tr><td>TNM stage</td><td></td><td></td><td>< 0.001</td></tr><tr><td> Stage I</td><td>403</td><td>94</td><td></td></tr><tr><td> Stage II</td><td>382</td><td>61</td><td></td></tr><tr><td> Stage III</td><td>796</td><td>27</td><td></td></tr><tr><td>Type of Gastrectomy</td><td></td><td></td><td>< 0.001</td></tr><tr><td> Subtotal</td><td>1342</td><td>56</td><td></td></tr><tr><td> Total</td><td>239</td><td>34</td><td></td></tr><tr><td>Operation time (min)</td><td></td><td></td><td>< 0.001</td></tr><tr><td> < 180</td><td>1025</td><td>58</td><td></td></tr><tr><td> ≥ 180</td><td>556</td><td>43</td><td></td></tr><tr><td>Albumin level at admission (g/dl)</td><td></td><td></td><td>0.006</td></tr><tr><td> < 3.5</td><td>379</td><td>47</td><td></td></tr><tr><td> ≥ 3.5</td><td>1202</td><td>54</td><td></td></tr><tr><td>Hemoglobin level at admission (g/dl)</td><td></td><td></td><td>< 0.001</td></tr><tr><td> < 12</td><td>575</td><td>46</td><td></td></tr><tr><td> ≥ 12</td><td>1006</td><td>56</td><td></td></tr><tr><td>Perioperative blood transfusion</td><td></td><td></td><td>< 0.001</td></tr><tr><td> Yes</td><td>298</td><td>40</td><td></td></tr><tr><td> No</td><td>1283</td><td>55</td><td></td></tr></table> |
ea4008ec90779c007603324e996addac66da61ff7a76fa0bffd5ab2a7ec94c7b.png | complex | <table><tr><td> </td><td colspan="2">Unstandardized coefficients</td><td>Standardized coefficients</td><td> </td></tr><tr><td>Herbs (g/day)</td><td>Estimate</td><td>Std. error</td><td>Estimate</td><td><i>P </i>value</td></tr><tr><td>Garlic</td><td>0.21</td><td>0.03</td><td>0.08</td><td>0.01</td></tr><tr><td>Cinnamon</td><td>1.24</td><td>0.19</td><td>0.08</td><td>0.01</td></tr><tr><td>Black pepper</td><td>0.57</td><td>0.15</td><td>0.05</td><td>0.01</td></tr><tr><td>Dried rosemary</td><td>3.43</td><td>1.17</td><td>0.03</td><td>0.01</td></tr><tr><td>Fresh dill</td><td>4.83</td><td>2.00</td><td>0.03</td><td>0.02</td></tr><tr><td>Fresh peppermint</td><td>−6.77</td><td>2.80</td><td>−0.03</td><td>0.02</td></tr></table> |
7652010d5ea5534f862636115815a32a675b95bc6e9e30c052c1484df9a40b57.png | simple | <table><tr><td> </td><td>Chinese</td><td>Non-Chinese</td><td><i>P</i></td></tr><tr><td>Case-fatality rate, %</td><td> </td><td> </td><td> </td></tr><tr><td>n, all patients</td><td>1,339</td><td>97,939</td><td> </td></tr><tr><td>At 30 days</td><td> </td><td> </td><td> </td></tr><tr><td>Crude, %</td><td>12.3</td><td>10.9</td><td>0.10</td></tr><tr><td>Risk-adjusted, % (95% CI)</td><td>12.3 (10.7-13.9)</td><td>10.9 (10.7-11.0)</td><td>-</td></tr><tr><td>At 1 year</td><td> </td><td> </td><td> </td></tr><tr><td>Crude, %</td><td>31.7</td><td>30.2</td><td>0.24</td></tr><tr><td>Risk-adjusted, % (95% CI)</td><td>31.3 (29.1-33.6)</td><td>30.2 (29.9-30.5)</td><td>-</td></tr><tr><td>Readmission rate, %</td><td> </td><td> </td><td> </td></tr><tr><td>n, discharged alive</td><td>1,211</td><td>89,022</td><td> </td></tr><tr><td>For HF</td><td> </td><td> </td><td> </td></tr><tr><td>At 30 days</td><td> </td><td> </td><td> </td></tr><tr><td>Crude, %</td><td>5.2</td><td>6.0</td><td>0.23</td></tr><tr><td>Risk-adjusted, % (95% CI)</td><td>5.1 (3.8-6.4)</td><td>6.0 (5.9-6.2)</td><td>-</td></tr><tr><td>At 1 year</td><td> </td><td> </td><td> </td></tr><tr><td>Crude, %</td><td>16.6</td><td>19.4</td><td>0.014</td></tr><tr><td>Risk-adjusted, % (95% CI)</td><td>16.4 (14.2-18.6)<sup>†</sup></td><td>19.4 (19.2-19.7)</td><td>-</td></tr><tr><td>For any reason</td><td> </td><td> </td><td> </td></tr><tr><td>At 30 days</td><td> </td><td> </td><td> </td></tr><tr><td>Crude, %</td><td>16.2</td><td>16.5</td><td>0.80</td></tr><tr><td>Risk-adjusted, % (95% CI)</td><td>16.1 (14.1-18.2)</td><td>16.5 (16.2-16.7)</td><td>-</td></tr><tr><td>At 1 year</td><td> </td><td> </td><td> </td></tr><tr><td>Crude, %</td><td>50.0</td><td>51.5</td><td>0.28</td></tr><tr><td>Risk-adjusted, % (95% CI)</td><td>49.8 (47.0-52.5)</td><td>51.5 (51.2-51.9)</td><td>-</td></tr><tr><td>Composite rate, %*</td><td> </td><td> </td><td> </td></tr><tr><td>n, all patients</td><td>1339</td><td>97,939</td><td> </td></tr><tr><td>At 30 days</td><td> </td><td> </td><td> </td></tr><tr><td>Crude, %</td><td>16.6</td><td>16.0</td><td>0.58</td></tr><tr><td>Risk-adjusted, % (95% CI)</td><td>16.2 (14.3-18.1)</td><td>16.0 (15.8-16.2)</td><td>-</td></tr><tr><td>At 1 year</td><td> </td><td> </td><td> </td></tr><tr><td>Crude, %</td><td>41.4</td><td>42.0</td><td>0.65</td></tr><tr><td>Risk-adjusted, % (95% CI)</td><td>41.0 (38.5-43.5)</td><td>42.0 (41.7-42.3)</td><td>-</td></tr></table> |
33501222b76c94f8129dbf3962974ebef861893cf8c89837034b5ed8877b4285.png | simple | <table><tr><td>Group</td><td>Age (years)</td><td>Gender</td><td>Iris Color*</td><td>BMI (kg/m<sup>2</sup>)</td><td>Carotenoid Intake Score</td><td>Smoking Status</td><td>Years Smoking</td></tr><tr><td>StatinUsers</td><td>58.05 ± 11.08</td><td>n = 13 malesn = 7 females</td><td>2.1 ± 0.9</td><td>27.51 ± 5.19</td><td>14.1 ± 5.25</td><td>n = 13 nonsmokersn = 7 past smokersn = 0 current smokers</td><td>5.3 ± 9.18</td></tr><tr><td>Non-Users</td><td>57.95 ± 11.03</td><td>n = 14 malesn = 6 females</td><td>1.9 ± 0.8</td><td>26.34 ± 2.73</td><td>13.93 ± 3.63</td><td>n = 12 nonsmokersn = 4 past smokersn = 4 current smokers</td><td>9.10 ± 12.47</td></tr></table> |
8c26d9882e88c66bd677a2137ac04093330ab68793716b17ea2b942b6edfa4e4.png | simple | <table><tr><td>Forecast period</td><td>GMT</td><td>SST</td></tr><tr><td>1 year: 2018</td><td>58%</td><td>75%</td></tr><tr><td>2 years: 2018–2019</td><td>64%</td><td>74%</td></tr><tr><td>3 years: 2018–2020</td><td>70%</td><td>71%</td></tr><tr><td>4 years: 2018–2021</td><td>72%</td><td>69%</td></tr><tr><td>5 years: 2018–2022</td><td>58%</td><td>69%</td></tr><tr><td>6 years: 2018–2023</td><td>55%</td><td>65%</td></tr><tr><td>7 years: 2018–2024</td><td>45%</td><td>58%</td></tr><tr><td>8 years: 2018–2025</td><td>50%</td><td>59%</td></tr><tr><td>9 years: 2018–2026</td><td>49%</td><td>60%</td></tr><tr><td>10 years: 2018–2027</td><td>50%</td><td>62%</td></tr></table> |
dea3b502fbe26284d40b25600522838f68b42e4870e180cd3edabcae4f23a197.png | complex | <table><tr><td>Items</td><td>Test-retest reliability ICC (Confident interval)</td><td>Kappa</td><td>Weighted kappa</td><td>Cronbach’s alpha (Dialysis group)</td></tr><tr><td>Symptom/problem</td><td>0.997 (0.991-0.999)</td><td>0.826-1</td><td>0.851-1</td><td>0.833</td></tr><tr><td>Effects of kidney disease</td><td>0.983 (0.951-0.994)</td><td>0.75-1</td><td>0.828-1</td><td>0.794</td></tr><tr><td>Burden of kidney disease</td><td>1</td><td>1-1</td><td>1-1</td><td>0.651</td></tr><tr><td>PCS</td><td>0.993 (0.981-0.998)</td><td rowspan="2">0.688-1</td><td rowspan="2">0.737-1</td><td>0.322</td></tr><tr><td>MCS</td><td>0.996 (0.989-0.999)</td><td>0.537</td></tr></table> |
9ec0ffb7a70dd07a217efd84317a55255de7b71882ba85c755a9a49063a06a60.png | simple | <table><tr><td>GI transit study (<i>n </i>= 11)</td><td>%GE</td><td>GC</td></tr><tr><td><i>Nonseptic animals</i></td><td><i>88.96 ± 8.13</i></td><td><i>4.86 ± 0.45</i></td></tr><tr><td>Sham + vehicle + CLP</td><td>53.27 ± 10.32</td><td>2.53 ± 0.42</td></tr><tr><td>Sham + GTS-21 8 mg/kg + CLP</td><td>83.62 ± 5.91*</td><td>4.26 ± 0.35*</td></tr><tr><td>SPLX + vehicle + CLP</td><td>79.49 ± 8.98*</td><td>3.86 ± 0.44*</td></tr><tr><td>SPLX + GTS-21 8 mg/kg + CLP</td><td>77.64 ± 11.81*</td><td>3.55 ± 0.52</td></tr><tr><td>Cytokine level in serum (<i>n </i>= 8 to 11)</td><td>IL-6</td><td>TNFα</td></tr><tr><td><i>Nonseptic animals</i></td><td><i>2.57 ± 0.48</i></td><td><i>4.95 ± 0.29</i></td></tr><tr><td>Sham + vehicle + CLP</td><td>243.56 ± 54.89</td><td>63.72 ± 21.25</td></tr><tr><td>Sham + GTS-21 8 mg/kg + CLP</td><td>90.26 ± 31.31*</td><td>54.23 ± 25.14</td></tr><tr><td>SPLX + vehicle + CLP</td><td>74.31 ± 17.45*</td><td>11.52 ± 1.99<sup>#</sup></td></tr><tr><td>SPLX + GTS-21 8 mg/kg + CLP</td><td>64.98 ± 7.15*</td><td>12.81 ± 3.91<sup>#</sup></td></tr><tr><td>Cytokine levels in colonic tissue (<i>n </i>= 5 to 11)</td><td>IL-6</td><td>TNFα</td></tr><tr><td><i>Nonseptic animals</i></td><td><i>20.43 ± 4.87</i></td><td><i>41.30 ± 4.47</i></td></tr><tr><td>Sham + vehicle + CLP</td><td>1281.85 ± 932.10</td><td>137.15 ± 61.36</td></tr><tr><td>Sham + GTS-21 8 mg/kg + CLP</td><td>134.88 ± 36.15</td><td>46.46 ± 5.03*</td></tr><tr><td>SPLX + vehicle + CLP</td><td>214.22 ± 75.88</td><td>29.97 ± 8.60*</td></tr><tr><td>SPLX + GTS-21 8 mg/kg + CLP</td><td>487.49 ± 343.87</td><td>46.03 ± 17.22*</td></tr></table> |
752f8517e19db45b9c662e6b77d7a8e8167f821e37d8478734cd8555a01cd6c8.png | complex | <table><tr><td colspan="9">Pairs of raters</td></tr><tr><td>PDs</td><td> </td><td colspan="2">Rater TW</td><td>% Agreement</td><td> </td><td colspan="2">Rater NW</td><td>% Agreement</td></tr><tr><td> </td><td>Rater SR</td><td>No (N)</td><td>Yes (Y)</td><td> </td><td>Rater SR</td><td>No (N)</td><td>Yes (Y)</td><td> </td></tr><tr><td>Avoidant</td><td>No (N)</td><td>9</td><td>0</td><td>100</td><td>No (N)</td><td>7</td><td>1</td><td>88</td></tr><tr><td> </td><td>Yes (Y)</td><td>0</td><td>1</td><td> </td><td>Yes (Y)</td><td>0</td><td>0</td><td> </td></tr><tr><td>Dependent</td><td>N</td><td>9</td><td>1</td><td>90</td><td>N</td><td>7</td><td>0</td><td>100</td></tr><tr><td> </td><td>Y</td><td>0</td><td>0</td><td> </td><td>Y</td><td>0</td><td>1</td><td> </td></tr><tr><td>Obsessive-Compulsive</td><td>N</td><td>8</td><td>0</td><td>100</td><td>N</td><td>6</td><td>0</td><td>100</td></tr><tr><td> </td><td>Y</td><td>0</td><td>2</td><td> </td><td>Y</td><td>0</td><td>2</td><td> </td></tr><tr><td>Passive-aggressive</td><td>N</td><td>9</td><td>0</td><td>90</td><td>N</td><td>6</td><td>1</td><td>88</td></tr><tr><td> </td><td>Y</td><td>1</td><td>0</td><td> </td><td>Y</td><td>0</td><td>1</td><td> </td></tr><tr><td>Depressive</td><td>N</td><td>10</td><td>0</td><td>100</td><td>N</td><td>7</td><td>0</td><td>100</td></tr><tr><td> </td><td>Y</td><td>0</td><td>0</td><td> </td><td>Y</td><td>0</td><td>1</td><td> </td></tr><tr><td>Paranoid</td><td>N</td><td>9</td><td>0</td><td>90</td><td>N</td><td>8</td><td>0</td><td>100</td></tr><tr><td> </td><td>Y</td><td>1</td><td>0</td><td> </td><td>Y</td><td>0</td><td>0</td><td> </td></tr><tr><td>Schizotypal</td><td>N</td><td>9</td><td>0</td><td>100</td><td>N</td><td>8</td><td>0</td><td>100</td></tr><tr><td> </td><td>Y</td><td>0</td><td>1</td><td> </td><td>Y</td><td>0</td><td>0</td><td> </td></tr><tr><td>Schizoid</td><td>N</td><td>7</td><td>1</td><td>90</td><td>N</td><td>6</td><td>0</td><td>88</td></tr><tr><td> </td><td>Y</td><td>0</td><td>2</td><td> </td><td>Y</td><td>1</td><td>1</td><td> </td></tr><tr><td>Histrionic</td><td>N</td><td>10</td><td>0</td><td>100</td><td>N</td><td>8</td><td>0</td><td>100</td></tr><tr><td> </td><td>Y</td><td>0</td><td>0</td><td> </td><td>Y</td><td>0</td><td>0</td><td> </td></tr><tr><td>Narcissistic</td><td>N</td><td>9</td><td>0</td><td>100</td><td>N</td><td>8</td><td>0</td><td>100</td></tr><tr><td> </td><td>Y</td><td>0</td><td>1</td><td> </td><td>Y</td><td>0</td><td>0</td><td> </td></tr><tr><td>Borderline</td><td>N</td><td>8</td><td>1</td><td>90</td><td>N</td><td>7</td><td>0</td><td>100</td></tr><tr><td> </td><td>Y</td><td>0</td><td>1</td><td> </td><td>Y</td><td>0</td><td>1</td><td> </td></tr><tr><td>Total Antisocial</td><td>N</td><td>10</td><td>0</td><td>100</td><td>N</td><td>7</td><td>0</td><td>100</td></tr><tr><td> </td><td>Y</td><td>0</td><td>0</td><td> </td><td>Y</td><td>0</td><td>1</td><td> </td></tr></table> |
c384a926ef4cee2ef1149791463f291bb887304c5af7e5fae5b8e58b7bd63c41.png | simple | <table><tr><td>Rank</td><td>Journal</td><td># citations</td></tr><tr><td>1</td><td><i>Journal of the American Chemical Society</i></td><td>351</td></tr><tr><td>2</td><td><i>Journal of Organic Chemistry</i></td><td>65</td></tr><tr><td>3</td><td><i>Journal of Physical Chemistry A</i></td><td>64</td></tr><tr><td>4</td><td><i>Journal of Chemical Physics</i></td><td>58</td></tr><tr><td>5</td><td><i>Angewandte Chemie</i></td><td>38</td></tr><tr><td>6</td><td><i>Chemical Physics Letters</i></td><td>25</td></tr><tr><td>7</td><td><i>Organic Letters</i></td><td>24</td></tr><tr><td>8</td><td><i>Tetrahedron Letters</i></td><td>22</td></tr><tr><td>8</td><td><i>Journal of Physical Chemistry</i></td><td>22</td></tr><tr><td>10</td><td><i>Journal of Computational Chemistry</i></td><td>17</td></tr></table> |
79c1135be997b94fd14d3bde0ea919dd2ccaddc4f0da04da256b95b030070ba0.png | complex | <table><tr><td>Study (Author-Date)</td><td>Representativeness</td><td>Demonstration that outcome not present at outset</td><td>Assessment of outcome (proven infection vs suspected infection based on other criteria)</td><td>Adequacy of follow-up (<5% loss)</td></tr><tr><td>Alleyne 2000 [31]</td><td>*</td><td>*</td><td>*</td><td>*</td></tr><tr><td>Arabi 2005 [36]</td><td>*</td><td></td><td></td><td>*</td></tr><tr><td>Bota 2005 [35]</td><td>*</td><td>*</td><td>*</td><td>*</td></tr><tr><td>Camacho 2011 [8]</td><td>*</td><td>*</td><td></td><td>*</td></tr><tr><td>Chi 2009 [24]</td><td>*</td><td>*</td><td>*</td><td>*</td></tr><tr><td>Dasic 2006 [10]</td><td>*</td><td></td><td>*</td><td>*</td></tr><tr><td colspan="2">Fichtner 2010 [28]</td><td>*</td><td>*</td><td></td></tr><tr><td>Hader 2000 [17]</td><td>*</td><td>*</td><td>*</td><td>*</td></tr><tr><td>Hoefnagel 2008 [2]</td><td>*</td><td>*</td><td>*</td><td></td></tr><tr><td colspan="2">Holloway 1996 [25]</td><td></td><td></td><td>*</td></tr><tr><td>Khalil 2005 [9]</td><td>*</td><td>*</td><td>*</td><td>*</td></tr><tr><td>Kim 2012 [34]</td><td>*</td><td>*</td><td>*</td><td>*</td></tr><tr><td>Kitchen 2011 [6]</td><td></td><td></td><td>*</td><td>*</td></tr><tr><td>Lemcke 2012 [20]</td><td>*</td><td>*</td><td>*</td><td>*</td></tr><tr><td>Leverstein Van-Dall 2010 [21]</td><td>*</td><td></td><td></td><td>*</td></tr><tr><td>Lo 2007 [18]</td><td>*</td><td>*</td><td></td><td>*</td></tr><tr><td colspan="2">Lundberg 2000 [16]</td><td>*</td><td>*</td><td></td></tr><tr><td>Lwin 2012 [27]</td><td>*</td><td></td><td>*</td><td>*</td></tr><tr><td>Lyke 2001 [13]</td><td>*</td><td>*</td><td>*</td><td>*</td></tr><tr><td>Mahe 1995 [7]</td><td>*</td><td></td><td></td><td>*</td></tr><tr><td>McLaughlin 2012 [19]</td><td></td><td></td><td></td><td>*</td></tr><tr><td>Moon 2007 [12]</td><td>*</td><td></td><td>*</td><td>*</td></tr><tr><td>Park 2004 [29]</td><td>*</td><td>*</td><td>*</td><td>*</td></tr><tr><td>Rafiq 2011 [15]</td><td>*</td><td>*</td><td>*</td><td>*</td></tr><tr><td>Rivero-Garvia 2011 [26]</td><td>*</td><td></td><td></td><td>*</td></tr><tr><td colspan="2">Roitberg 2001 [30]</td><td></td><td></td><td>*</td></tr><tr><td>Scheithauer 2009 [23]</td><td>*</td><td>*</td><td></td><td>*</td></tr><tr><td>Scheithauer 2010 [22]</td><td>*</td><td>*</td><td></td><td>*</td></tr><tr><td>Schodel 2012 [32]</td><td>*</td><td></td><td>*</td><td>*</td></tr><tr><td colspan="2">Schultz 1993 [11]</td><td>*</td><td>*</td><td>*</td></tr><tr><td>Sloffer 2005 [33]</td><td></td><td>*</td><td>*</td><td>*</td></tr><tr><td colspan="2">Smigoc 2012 [5]</td><td>*</td><td>*</td><td>*</td></tr><tr><td>Smith 1976 [4]</td><td>*</td><td></td><td>*</td><td></td></tr><tr><td>Williams 2011 [14]</td><td>*</td><td>*</td><td>*</td><td>*</td></tr><tr><td>Wyler 1972 [3]</td><td>*</td><td></td><td>*</td><td>*</td></tr></table> |
b58cdd9628fbb25822c478a385a5aed62551808613179b0fefd336ea46544246.png | complex | <table><tr><td colspan="3">EU Rarotonga</td><td colspan="3">EU southern group</td><td colspan="3">EU northern group</td></tr><tr><td>Village surveyed</td><td>No. of people surveyed</td><td>% Ag positive</td><td>Island surveyed</td><td>No. of people surveyed</td><td>% Ag positive</td><td>Island surveyed</td><td>No. of people surveyed</td><td>% Ag positive</td></tr><tr><td>Tupapa/Maraerenga</td><td>200</td><td>0.00</td><td>Atiu</td><td>150</td><td>0.00</td><td>Pukapuka</td><td>200</td><td>3.50</td></tr><tr><td>Takuvaine/Tutakimoa</td><td>200</td><td>0.50</td><td>Aitutaki</td><td>300</td><td>7.33</td><td>Penrhyn</td><td>100</td><td>0.00</td></tr><tr><td>Ruatonga/A Vaitu</td><td>200</td><td>0.50</td><td>Mauke</td><td>150</td><td>0.00</td><td>Manihiki</td><td>100</td><td>0.00</td></tr><tr><td>Pokoinu/Nikao</td><td>200</td><td>0.00</td><td>Mangaia</td><td>200</td><td>0.50</td><td>Rakahanga</td><td>100</td><td>2.00</td></tr><tr><td>Takitumu</td><td>200</td><td>0.00</td><td>Mitiaro</td><td>100</td><td>0.00</td><td>Suwarrow</td><td>2</td><td>0.00</td></tr><tr><td>Puaikura</td><td>200</td><td>0.00</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td></tr><tr><td>Total</td><td>1000</td><td>0.20</td><td>–</td><td>900</td><td>2.56</td><td>–</td><td>502</td><td>1.79</td></tr></table> |
2f2d85fb82a0d519ab6fa48ba4c2aa8b71524d4c99c7aa01c433c7c75f6819e7.png | complex | <table><tr><td></td><td colspan="2">HIV-2 infected</td><td colspan="2">HIV-uninfected</td><td></td></tr><tr><td></td><td>Number died/total per category (%)</td><td>Mortality rate per 100 person-years (95% CI)</td><td>Number died/total per category (%)</td><td>Mortality rate per 100 person-years (95% CI)</td><td>Rate ratio (95% CI)</td></tr><tr><td><i>Age group</i><sup><i>a, b</i></sup></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> <40</td><td>15/37 (41)</td><td>3.4 (2.0, 5.6)</td><td>7/56 (13)</td><td>0.8 (0.4, 1.7)</td><td>4.2 (1.7, 10.2)</td></tr><tr><td> 40-59</td><td>23/59 (39)</td><td>3.4 (2.3, 5.1)</td><td>15/63 (24)</td><td>1.6 (1.0, 2.7)</td><td>2.1 (1.1, 4.1)</td></tr><tr><td> ≥ 60</td><td>28/36 (78)</td><td>8.5 (5.9, 12.3)</td><td>27/39 (69)</td><td>5.8 (4.0, 8.5)</td><td>1.5 (0.9, 2.5)</td></tr><tr><td><i>Sex</i></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Male</td><td>27/42 (64)</td><td>6.1 (4.2, 8.8)</td><td>20/43 (46)</td><td>3.7 (2.4, 5.8)</td><td>1.6 (0.9, 2.9)</td></tr><tr><td> Female</td><td>39/91 (43)</td><td>3.9 (2.8, 5.3)</td><td>29/115 (25)</td><td>1.7 (1.2, 2.4)</td><td>2.3 (1.4, 3.7)</td></tr><tr><td colspan="2"><i>Calendar time</i></td><td></td><td></td><td></td><td></td></tr><tr><td> 1991-1998</td><td>37/133 (28)</td><td>4.3 (3.1, 6.0)</td><td>24/158 (15)</td><td>1.9 (1.3, 2.8)</td><td>2.3 (1.4, 3.8)</td></tr><tr><td> 1999-2009</td><td>29/84 (35)</td><td>4.8 (3.4, 7.0)</td><td>25/120 (21)</td><td>2.5 (1.7, 3.7)</td><td>1.9 (1.1, 3.3)</td></tr><tr><td><i>Overall</i></td><td>66/133 (50)</td><td>4.5 (3.6, 5.8)</td><td>49/158 (31)</td><td>2.2 (1.6, 2.9)</td><td>2.1 (1.5, 3.0)</td></tr></table> |
4bcac2e83761daf1d1a11849a0de158c132917631b955c9442a86883d02826ea.png | complex | <table><tr><td>Group</td><td>Null model</td><td>Full model (OR < 95 % CI)</td></tr><tr><td colspan="3">Individual</td></tr><tr><td colspan="3"> Gender</td></tr><tr><td>Male</td><td></td><td>1.00</td></tr><tr><td>Female</td><td></td><td><i>0.45 (0.23, 0.88)**</i></td></tr><tr><td colspan="3"> Education</td></tr><tr><td>Elementary school or less</td><td></td><td>1.00</td></tr><tr><td>Junior high school</td><td></td><td>1.14 (0.64,2.04)</td></tr><tr><td>High school</td><td></td><td>0.60 (0.31,1.14)</td></tr><tr><td>Junior college or more</td><td></td><td><i>0.35 (0.18, 0.69)**</i></td></tr><tr><td colspan="3"> Occupation</td></tr><tr><td>Managers and clerks</td><td></td><td>1.00</td></tr><tr><td>Professionals</td><td></td><td>0.95 (0.53,1.70)</td></tr><tr><td>Commerce and service</td><td></td><td>1.20 (0.63,2.30)</td></tr><tr><td>Operations</td><td></td><td>0.79 (0.42,1.51)</td></tr><tr><td>Students</td><td></td><td><i>0.32 (0.16, 0.65)**</i></td></tr><tr><td>Retired</td><td></td><td><i>0.28 (0.11, 0.73)**</i></td></tr><tr><td>Other</td><td></td><td><i>0.25 (0.08, 0.72)**</i></td></tr><tr><td colspan="3"> Per capita income (Yuan)</td></tr><tr><td><10,000</td><td></td><td>1.00</td></tr><tr><td>10,000–19,999</td><td></td><td>0.80 (0.54,1.27)</td></tr><tr><td>20,000–29,999</td><td></td><td><i>0.55 (0.35, 0.87)**</i></td></tr><tr><td>30,000–39,999</td><td></td><td><i>0.24 (0.09, 0.64)**</i></td></tr><tr><td>40,000–49,999</td><td></td><td><i>0.23 (0.10, 0.55)**</i></td></tr><tr><td>50,000+</td><td></td><td><i>0.34 (0.14, 0.79)**</i></td></tr><tr><td colspan="3"> Exposure to tobacco advertising</td></tr><tr><td>No</td><td></td><td>1.00</td></tr><tr><td>Yes</td><td></td><td><i>2.83 (1.23, 6.48)**</i></td></tr><tr><td colspan="3">City-level</td></tr><tr><td colspan="3"> GDP per capita</td></tr><tr><td><40,000</td><td></td><td>1.00</td></tr><tr><td>40,000–49,999</td><td></td><td>1.02 (0.39,3.17)</td></tr><tr><td>50,000+</td><td></td><td><i>0.39 (0.16, 0.92)*</i></td></tr><tr><td colspan="3"> Anti-smoking media news coverage</td></tr><tr><td><20</td><td></td><td>1.00</td></tr><tr><td>20–29</td><td></td><td>1.33 (0.42,4.24)</td></tr><tr><td>30 and over</td><td></td><td><i>0.26 (0.09, 0.79)**</i></td></tr><tr><td>Random parameters between regions</td><td>3.12</td><td><i>2.25*</i></td></tr><tr><td>Fixed parameters</td><td>2.92**</td><td>2.43*</td></tr></table> |
7fd6b063d9dfb1b55cc01dde0939965dc3325149ddfd3d252d2e5406f056e4dd.png | simple | <table><tr><td>Gene<sup>a</sup></td><td><i>Oedogonium</i></td><td><i>Stigeoclonium</i></td><td><i>Scenedesmus</i></td><td><i>Chlamydomonas</i></td></tr><tr><td><i>infA</i></td><td>+</td><td>-</td><td>+</td><td>-</td></tr><tr><td><i>petA</i></td><td>-</td><td>-</td><td>+</td><td>+</td></tr><tr><td><i>psaM</i></td><td>+</td><td>+</td><td>-</td><td>-</td></tr><tr><td><i>rpl12</i></td><td>-</td><td>-</td><td>+</td><td>-</td></tr><tr><td><i>rpl32</i></td><td>+</td><td>+</td><td>-</td><td>-</td></tr><tr><td><i>trnL</i>(caa)</td><td>+</td><td>+</td><td>-</td><td>-</td></tr><tr><td><i>trnR</i>(ccu)</td><td>+</td><td>-</td><td>-</td><td>-</td></tr><tr><td><i>trnR</i>(ucg)</td><td>+</td><td>-</td><td>-</td><td>-</td></tr><tr><td><i>trnS</i>(gga)</td><td>-</td><td>+</td><td>-</td><td>-</td></tr></table> |
5ae2e9aa532279b4f1097fed8b820409c4d6f4cd17d96e9b538507545fc7f631.png | complex | <table><tr><td colspan="2">Set A</td><td colspan="2">Set B</td><td></td></tr><tr><td>CV</td><td>AoA</td><td>CV</td><td>AoA</td><td></td></tr><tr><td>CHAT</td><td>3.80</td><td>PIED</td><td>3.60</td><td><i>Children + Adults</i></td></tr><tr><td>OEIL</td><td>4.10</td><td>RUE</td><td>5.20</td><td><i>Children + Adults</i></td></tr><tr><td>OEUF</td><td>4.50</td><td>BOUE</td><td>5.80</td><td><i>Children + Adults</i></td></tr><tr><td>BEAU</td><td>4.50</td><td>PLUIE</td><td>4.40</td><td><i>Children + Adults</i></td></tr><tr><td>DOUX</td><td>5.10</td><td>OIE</td><td>5.60</td><td><i>Children + Adults</i></td></tr><tr><td>TRAIN</td><td>5.10</td><td>JOUR</td><td>4.70</td><td><i>Children + Adults</i></td></tr><tr><td>MAIN</td><td>3.60</td><td>NUIT</td><td>4.10</td><td><i>Children + Adults</i></td></tr><tr><td>BRAS</td><td>4.20</td><td>LOUP</td><td>4.70</td><td><i>Children + Adults</i></td></tr><tr><td>DOIGT</td><td>3.70</td><td>FEU</td><td>4.90</td><td><i>Adults</i></td></tr></table> |
7a24e2fbd29b2e618fcd1ffa24d5b622cfe9a46a85cfb890517c789b23bfc5da.png | simple | <table><tr><td></td><td><i>Relapse group (n=30)</i></td><td><i>Remission group (n=35)</i></td><td><i>P</i></td></tr><tr><td>Withdrawal MPV (fL)</td><td>8.0±1.2</td><td>8.0±1.0</td><td>0.81</td></tr><tr><td>Withdrawal TSH (uIU/ml)</td><td>1.5±1.0</td><td>2.0±1.0</td><td>0.03</td></tr><tr><td>Withdrawal fT3 (pmol/L)</td><td>4.8±1.2</td><td>4.7±0.5</td><td>0.46</td></tr><tr><td>Withdrawal fT4 (pmol/L)</td><td>14.8±2.9</td><td>13.6±1.6</td><td>0.04</td></tr></table> |
8d315da87b1bc1970f5c51a19a611d9a581de20ee31221aa5e93e1a62c8f3060.png | simple | <table><tr><td>Isolates</td><td>Identification by API system (% similarity)</td><td>Identification by rep-PCR (% identity)</td></tr><tr><td>1S</td><td><i>Lactobacillus plantarum (99.9%)</i></td><td><i>Lactobacillus plantarum (72.5%)</i></td></tr><tr><td>2S</td><td><i>Lactobacillus plantarum (99.9%)</i></td><td><i>Lactobacillus plantarum (80.0%)</i></td></tr><tr><td>3S</td><td><i>Lactobacillus plantarum (99.9%)</i></td><td><i>Lactobacillus plantarum (75.8%)</i></td></tr><tr><td>4S</td><td><i>Lactobacillus plantarum (75.9%)</i></td><td><i>Lactobacillus plantarum (74.6%)</i></td></tr><tr><td>5S</td><td><i>Lactobacillus plantarum (99.9%)</i></td><td><i>Lactobacillus plantarum (74.9%)</i></td></tr><tr><td>6S</td><td><i>Lactobacillus plantarum (99.9%)</i></td><td><i>Lactobacillus plantarum (74.5%)</i></td></tr><tr><td>7S</td><td><i>Lactobacillus plantarum (99.9%)</i></td><td><i>Lactobacillus plantarum (72.6%)</i></td></tr><tr><td>8S</td><td><i>Lactobacillus plantarum (99.9%)</i></td><td><i>Lactobacillus plantarum (73.0%)</i></td></tr><tr><td>9S</td><td><i>Lactobacillus plantarum (72.0%)</i></td><td><i>Lactobacillus plantarum (72.9%)</i></td></tr><tr><td>10S</td><td><i>Lactobacillus plantarum (79.0%)</i></td><td><i>Lactobacillus plantarum (73.9%)</i></td></tr><tr><td>11S</td><td><i>Lactobacillus plantarum (77.0%)</i></td><td><i>Lactobacillus plantarum (73.6%)</i></td></tr><tr><td>15S</td><td><i>Lactobacillus plantarum (85.9%)</i></td><td><i>Lactobacillus plantarum (65.8%)</i></td></tr><tr><td>16S</td><td><i>Lactobacillus plantarum (89.9%)</i></td><td><i>Lactobacillus plantarum (65.7%)</i></td></tr><tr><td>18S</td><td><i>Lactobacillus rhamnosus (97.5%)</i></td><td><i>Unidentified</i></td></tr><tr><td>19S</td><td><i>Lactobacillus rhamnosus (86.0%)</i></td><td><i>Unidentified</i></td></tr><tr><td>1K</td><td><i>Lactobacillus rhamnosus (86.0%)</i></td><td><i>Lactobacillus rhamnosus (73.1%)</i></td></tr><tr><td>3K</td><td><i>Lactobacillus rhamnosus (88.5%)</i></td><td><i>Lactobacillus rhamnosus (65.0%)</i></td></tr><tr><td>1K1</td><td><i>Lactobacillus rhamnosus (96.5%)</i></td><td><i>Lactobacillus rhamnosus (70.4%)</i></td></tr><tr><td>2K</td><td><i>Lactobacillus fermentum (74.1%)</i></td><td><i>Lactobacillus fermentum (69.2%)</i></td></tr><tr><td>13S*</td><td><i>Lactobacillus coprophilus (77.0%)</i></td><td><i>Lactobacillus fermentum (68.4%)</i></td></tr><tr><td>1SB1</td><td><i>Lactobacillus coprophilus (97.0%)</i></td><td><i>unidentified</i></td></tr></table> |
9d37acdee2c965cf4e391817715e7bd3827b0e52e54cd2fea0a71940619b8a62.png | simple | <table><tr><td></td><td>Risk of T2D</td><td>Prediabetes</td><td>HOMA-IR</td></tr><tr><td>Highest ρ<sub>E</sub></td><td>Cer(d18:0/24:1),0.3177, <i>p</i> = 2.7 × 10<sup>−8</sup></td><td>PS(40:5),0.2917, <i>p</i> = 1.0000</td><td>Cer(d18:0/22:0), 0.4234, <i>p</i> = 2.3 × 10<sup>−24</sup></td></tr><tr><td>Lowest ρ<sub>E</sub></td><td>LPC(26:0),−0.3588 <i>p</i> = 0.0001</td><td>PC(39:6),−0.2076, <i>p</i> = 0.1501</td><td>PC(P-34:1),−0.2972, <i>p</i> = 7.8 × 10<sup>−17</sup></td></tr><tr><td>N (significant)</td><td>114</td><td>59</td><td>172</td></tr></table> |
24f495dfd9f66a3e3ac1faf563655a3487ee74a6e6a9c81781927c86737423a7.png | simple | <table><tr><td>Gene symbol</td><td>Forward primer (5′ to 3′)</td><td>Reverse primer (5′ to 3′)</td></tr><tr><td>Oct-4</td><td>CTTGGGCTACACAGGC</td><td>CTCAATACTCGTTCGCTTTC</td></tr><tr><td>Nanog</td><td>TTTGGAAGCTGCTGGGGAAG</td><td>GATGGGAGGAGGGGAGAGGA</td></tr><tr><td>CDX2</td><td>CCGAACAGGGACTTGTTTAGAG</td><td>CTCTGGCTTGGATGTTACACAG</td></tr><tr><td>TF</td><td>ACGCTCCTGCTCGGCTGGGT</td><td>CGTCTGCTTCACATCCTTCA</td></tr><tr><td>GAPDH</td><td>GGAGCCAAAAGGGTCATC</td><td>CCAGTGAGTTTCCCGTTC</td></tr></table> |
587e6057f192792b9886d621c5369dc90da9e709e70b7e8ecaf82df1b91e7474.png | simple | <table><tr><td></td><td>Mouse strain</td><td>Methods</td><td>PV cells with PNNs (%)</td></tr><tr><td>Visual cortex</td><td></td><td></td><td></td></tr><tr><td> Pizzo et al., 2016</td><td>C57BL/6J</td><td>PV: (1) monoclonal mouse α-PV (SWANT, 1:500); (2) polyclonal guinea pig α-PV PNN: biotin-conjugated WFA (Sigma, 1:200)</td><td><underline>All layers</underline> P18: ∼55% P35: ∼55%</td></tr><tr><td>Morishita et al., 2015</td><td>C57BL/6J</td><td>PV: monoclonal rabbit α-PV (SWANT, 1:500) PNN: biotin-conjugated WFA (Vector, 1:400)</td><td><underline>All layers</underline> P50: ∼72%</td></tr><tr><td>Lensjø et al., 2017</td><td>C57BL/6J</td><td>PV: polycolonal rabbit α-PV (SWANT, 1:2000) PNN: biotin-conjugated WFA (Sigma, 1:200)</td><td><underline>All layers</underline> 3–5 months:∼70%</td></tr><tr><td>Ueno et al., 2017c</td><td>C57BL/6J</td><td>PV: monoclonal mouse α-PV (Sigma, 1:1000) PNN: biotin-conjugated WFA (Vector, 1:200)</td><td><underline>All layers</underline> 2–6 months: ∼50-60%</td></tr><tr><td>Somatosensory cortex</td><td></td><td></td><td></td></tr><tr><td>Nowicka et al., 2009</td><td>Swiss albino mice</td><td>PV: (1) rabbit α-PV (1:1000); (2) monoclonal mouse α-PV (Sigma, 1:1000) PNN: biotin-conjugated WFA (Vector, 1:1000)</td><td><underline>Layer 1–3</underline> P20: <10% P30: ∼30% YA: ∼35% <underline>Layer 4</underline> P10: ∼40% P20: ∼50% P30: ∼50% YA: ∼80% <underline>Layer 5–6</underline> P10: ∼10% P30: ∼35% YA: ∼40%</td></tr><tr><td>Ueno et al., 2017b</td><td>C57BL/6J</td><td>PV: monoclonal mouse α-PV (Sigma, 1:1000) PNN: biotin-conjugated WFA (Vector, 1:200)</td><td><underline>Layer 2-3</underline> P14: ∼70%; P21, 28: ∼50% P56: ∼60% <underline>Layer 4</underline> P14, 21, 28: ∼75% P56: ∼90% <underline>Layer 5-6</underline> P14: ∼75% P21, 28: ∼40-50% P56: ∼60%</td></tr><tr><td>Karetko-Sysa et al., 2014</td><td>C57BL/6J</td><td>PV: polyclonal goat α-PV (Affinity BioReagents, 1:1000) PNN: biotin-conjugated WFA (Vector, 1:1000)</td><td><i><sup>∗</sup>Most PV cells colocalized with PNNs in layer 4</i><underline>Layer 4-6</underline> YA: 67%</td></tr><tr><td>Auditory cortex</td><td></td><td></td><td></td></tr><tr><td>Brewton et al., 2016</td><td>C57BL/6J CBA/CaJ</td><td>PV: rabbit α-PV (SWANT, 1:10,000) PNN: FITC-conjugated WFA (Vector, 1:750)</td><td><underline>All layers</underline> C57 YA: 35% CBA YA: 50%</td></tr><tr><td>Nguyen et al., 2017</td><td>CBA/CaJ</td><td>PV: rabbit α-PV (SWANT, 1:5000) PNN: FITC-conjugated WFA (Vector, 1:500)</td><td><underline>All layers</underline> P30-60: 46%</td></tr><tr><td>Wen et al., 2017</td><td>FVB WT</td><td>PV: (1) rabbit α-PV (SWANT, 1:5000), (2) mouse α-PV (Sigma, 1:1000) PNN: FITC-conjugated WFA (Vector, 1:500)</td><td><underline>Layer 2/3</underline> P14: ∼1% P21: ∼29% P30: ∼15% <underline>Layer 4</underline> P14: ∼18% P21: ∼38% P30: ∼38%</td></tr><tr><td>Ueno et al., 2017c</td><td>C57BL/6J</td><td>PV: monoclonal mouse α-PV (Sigma, 1:1000) PNN: biotin-conjugated WFA (Vector, 1:200)</td><td><underline>All layers</underline> YA: ∼60-70%</td></tr></table> |
8cc23150ba81a6a3d61e3abb5473bab415695e0ab4f810a45303f46106547d47.png | complex | <table><tr><td></td><td colspan="4">Normal weight mice</td><td colspan="4">DIO mice</td></tr><tr><td></td><td>PBS</td><td>NS1</td><td>Vaccine</td><td>Sig.</td><td>PBS</td><td>NS1</td><td>Vaccine</td><td>Sig.</td></tr><tr><td>Ghrelin (pg/ml)</td><td>114.1 ± 27.9</td><td>186.9 ± 14.8</td><td>361.3 ± 79.9</td><td>p=0.009</td><td>105.9 ± 27.8</td><td>147.3 ± 53.2</td><td>429.6 ± 179.3</td><td>NS</td></tr><tr><td>Leptin (ng/ml)</td><td>1.32 ± 0.23</td><td>0.98 ± 0.21</td><td>1.50 ± 0.61</td><td>NS</td><td>5.85 ± 0.93</td><td>5.15 ± 0.75</td><td>7.11 ± 0.39</td><td>NS</td></tr><tr><td>Insulin (ng/ml)</td><td>0.35 ± 0.08</td><td>1.08 ± 0.63</td><td>0.41 ± 0.07</td><td>NS</td><td>1.31 ± 0.09</td><td>1.01 ± 0.13</td><td>1.27 ± 0.11</td><td>NS</td></tr><tr><td>Growth hormone (ng/ml)</td><td>2.65 ± 0.69</td><td>5.50 ± 2.44</td><td>2.57 ± 0.41</td><td>NS</td><td>2.36 ± 0.74</td><td>5.28 ± 1.95</td><td>4.13 ± 1.31</td><td>NS</td></tr><tr><td>IGF-1 (ng/ml)</td><td>473.8 ± 68.6</td><td>561.7 ± 35.3</td><td>499.8 ± 62.1</td><td>NS</td><td>347.7 ± 17.9</td><td>387.4 ± 34.5</td><td>394.8 ± 21.1</td><td>NS</td></tr><tr><td>Glucose (mg/dl)</td><td>86.5 ± 6.3</td><td>82.3 ± 8.2</td><td>76.3 ± 2.9</td><td>NS</td><td>156.3 ± 31.8</td><td>128.2 ± 15.0</td><td>121.8 ± 11.3</td><td>NS</td></tr><tr><td>TNF-α</td><td>0.30 ± 0.30</td><td>8.42 ± 4.22</td><td>1.65 ± 1.31</td><td>NS</td><td>45.59 ± 24.72</td><td>5.76 ± 4.44</td><td>21.34 ± 15.29</td><td>NS</td></tr></table> |
a623929f4b6014f85456200c29a782f8f48a36ee9042c648fc1f593f9f048c44.png | simple | <table><tr><td>Authors</td><td>Novel prognostic marker</td><td>Conclusion</td></tr><tr><td>Li et al. 2015 [39]</td><td>The expression patterns of miR-15a/16-1</td><td>miR-15a seems to be linked with disease progression and prognosis while miR-16-1 acts as a valuable diagnostic marker</td></tr><tr><td> Wang et al. 2015 [40]</td><td>Immune checkpoint signaling</td><td>The overall response rate to treatment was higher in low sPD-L1 patients than in high sPD-L1 patients</td></tr><tr><td>Jung et al. 2016 [41]</td><td>Inverse platelet to lymphocyte ratio (iPLR)</td><td>Staging by iPLR group had predictive value for PFS and OS</td></tr><tr><td>Zhou et al. 2015 [42]</td><td>Dysregulated long noncoding RNAs (lncRNAs)</td><td>Four lncRNAs were identified to be significantly associated with OS</td></tr><tr><td>Lee et al. 2015 [43]</td><td>Bone marrow (BM) microvessel density (MVD)</td><td>PFS was significantly lower in the high MVD group than in the low MVD group</td></tr><tr><td>Ma et al. 2015 [44]</td><td>N-Cadherin</td><td>OS is worse with high expression of N-Cadherin which may be related to 1q21 amplification.</td></tr><tr><td> Lullo et al. 2015 [45]</td><td>Th22 cells</td><td>Increased frequency of IL-22(+)IL-17(−)IL-13(+) T cells correlates with poor prognosis</td></tr><tr><td>Li et al. 2015 [46]</td><td>Downregulated miR-33b</td><td>miR-33b low expression had significantly shortened PFS and OS</td></tr><tr><td>Bolomsky et al. 2015 [47]</td><td>Insulin-like growth factor binding protein 7 (IGFBP7) expression</td><td>IGFBP7 expression is linked to translocation t(4;14) showing clinical features of adverse prognosis</td></tr><tr><td>Jung et al. 2015 [48]</td><td>Autophagic markers beclin 1 and LC3</td><td>Higher immunoreactivity for autophagic markers in MM is associated with superior patient survival</td></tr><tr><td>Trotter et al. 2015 [49]</td><td>Myeloma cell-derived Runx2</td><td>Runx2 expression is a major regulator of MM progression in bone and myeloma bone disease</td></tr></table> |
813ecd0b048483ce7b2ef2b7cf733d0d5dea603a67c37543640bafc7ee95421f.png | simple | <table><tr><td>SYMBOL</td><td>RefSeq</td><td>logFC</td><td>adj.P.Val</td><td>Sens.</td><td>Spec.</td><td>KEGGID</td></tr><tr><td>SERPINA1</td><td>NM_000295, NM_001002235, NM_001002236</td><td>3.30</td><td>7.81e-39</td><td>0.98</td><td>1.00</td><td>04610</td></tr><tr><td>PROS1</td><td>NM_000313</td><td>2.12</td><td>8.89e-34</td><td>0.98</td><td>1.00</td><td>04610</td></tr><tr><td>LRP4</td><td>NM_002334</td><td>2.80</td><td>8.89e-34</td><td>1.00</td><td>0.96</td><td>NA</td></tr><tr><td>NPC2</td><td>NM_006432</td><td>1.29</td><td>5.83e-33</td><td>1.00</td><td>0.94</td><td>04142</td></tr><tr><td>LAMB3</td><td>NM_000228, NM_001017402</td><td>2.46</td><td>5.11e-31</td><td>0.96</td><td>1.00</td><td>04510, 04512, 05200, 05222</td></tr><tr><td>DPP4</td><td>NM_001935</td><td>2.86</td><td>6.96e-31</td><td>0.98</td><td>0.98</td><td>NA</td></tr><tr><td>SDC4</td><td>NM_002999</td><td>1.68</td><td>5.50e-30</td><td>0.96</td><td>0.96</td><td>04512, 04514</td></tr><tr><td>IPCEF1</td><td>NM_015553</td><td>-2.10</td><td>2.88e-29</td><td>1.00</td><td>0.00</td><td>NA</td></tr><tr><td>QPCT</td><td>NM_012413</td><td>2.09</td><td>3.00e-29</td><td>0.98</td><td>1.00</td><td>NA</td></tr><tr><td>MPPED2</td><td>NM_001584</td><td>-2.28</td><td>7.73e-29</td><td>1.00</td><td>0.00</td><td>NA</td></tr><tr><td>TIMP1</td><td>NM_003254</td><td>1.85</td><td>1.48e-27</td><td>0.96</td><td>0.94</td><td>NA</td></tr><tr><td>TFF3</td><td>NM_003226</td><td>-3.42</td><td>2.07e-27</td><td>1.00</td><td>0.00</td><td>NA</td></tr><tr><td>PRSS23</td><td>NM_007173</td><td>1.48</td><td>2.32e-27</td><td>0.98</td><td>0.98</td><td>NA</td></tr><tr><td>MET</td><td>NM_000245</td><td>1.64</td><td>2.37e-27</td><td>0.94</td><td>0.98</td><td>04060, 04144, 04360, 04510, 04520, 05120, 05200, 05210, 05211, 05218</td></tr><tr><td>CDH3</td><td>NM_001793</td><td>2.72</td><td>3.45e-27</td><td>0.96</td><td>0.94</td><td>04514</td></tr><tr><td>GGCT</td><td>NM_024051</td><td>1.21</td><td>2.74e-26</td><td>0.98</td><td>0.92</td><td>00480</td></tr><tr><td>PDLIM4</td><td>NM_003687</td><td>2.21</td><td>3.37e-26</td><td>0.96</td><td>0.98</td><td>NA</td></tr><tr><td>KRT19</td><td>NM_002276</td><td>2.33</td><td>3.40e-25</td><td>0.98</td><td>0.98</td><td>NA</td></tr><tr><td>CITED1</td><td>NM_004143</td><td>3.17</td><td>4.42e-25</td><td>0.94</td><td>0.96</td><td>NA</td></tr><tr><td>CHI3L1</td><td>NM_001276</td><td>3.50</td><td>4.42e-25</td><td>0.96</td><td>0.90</td><td>NA</td></tr></table> |
e71bdc256e7b416f442f5e5256988e1739ef72e93e6b9d8ce4e9b87bd6868ce0.png | complex | <table><tr><td></td><td colspan="2">Subjects</td></tr><tr><td></td><td><i>Number</i></td><td><i>Percentage</i></td></tr><tr><td>Supplements use</td><td></td><td></td></tr><tr><td>No</td><td>145</td><td>69.9%</td></tr><tr><td>Yes</td><td>62</td><td>30.1%</td></tr><tr><td>Users of supplement by gender</td><td></td><td></td></tr><tr><td>Male</td><td>43</td><td>34.1%</td></tr><tr><td>Female</td><td>19</td><td>23.8%</td></tr><tr><td>Frequency of use</td><td></td><td></td></tr><tr><td>1 time per wk</td><td>8</td><td>12.9%</td></tr><tr><td>2 times per wk</td><td>5</td><td>8.1%</td></tr><tr><td>3 times per wk</td><td>13</td><td>21.0%</td></tr><tr><td>4 times per wk</td><td>11</td><td>17.7%</td></tr><tr><td>5 times per wk</td><td>9</td><td>14.5%</td></tr><tr><td>6 times per wk</td><td>1</td><td>1.6%</td></tr><tr><td>7 times per wk</td><td>15</td><td>24.2%</td></tr><tr><td>Protein supplements</td><td></td><td></td></tr><tr><td>Whey protein shakes</td><td>31</td><td>50.0%</td></tr><tr><td>Egg protein shakes</td><td>15</td><td>24.1%</td></tr><tr><td>Protein bars</td><td>12</td><td>19.3%</td></tr><tr><td>Protein Gel</td><td>1</td><td>1.6%</td></tr><tr><td>Protein shake blends</td><td>3</td><td>4.8%</td></tr><tr><td>Other supplements*</td><td></td><td></td></tr><tr><td>Multivitamin/mineral</td><td>3</td><td>4.8%</td></tr><tr><td>Creatine - Amino acids</td><td>30</td><td>48.3%</td></tr><tr><td>Amino acids</td><td>16</td><td>25.9%</td></tr><tr><td>Multivitamin/mineral - Creatine - Amino acids</td><td>8</td><td>12.9%</td></tr><tr><td>Multivitamin/mineral - Amino acids</td><td>1</td><td>1.6%</td></tr><tr><td>Creatine</td><td>4</td><td>6.4%</td></tr></table> |
fe28d146b4b64255f7ab86669ac9e62224b1fe4825ef9d7cc498b28ae44a8d92.png | simple | <table><tr><td>Characteristic</td><td>Number</td><td>Percent</td></tr><tr><td>Age (in years)</td><td> </td><td> </td></tr><tr><td>15–24</td><td>5</td><td>33.3</td></tr><tr><td>25–34</td><td>6</td><td>40</td></tr><tr><td>35 or above</td><td>4</td><td>26.7</td></tr><tr><td>Education</td><td> </td><td> </td></tr><tr><td>Elementary & secondary school</td><td>2</td><td>13.3</td></tr><tr><td>Diploma</td><td>4</td><td>26.7</td></tr><tr><td>University</td><td>9</td><td>60</td></tr><tr><td>Marital status</td><td> </td><td> </td></tr><tr><td>Single</td><td>10</td><td>66.7</td></tr><tr><td>Married</td><td>5</td><td>33.3</td></tr><tr><td>Occupation</td><td> </td><td> </td></tr><tr><td>Housewife</td><td>6</td><td>40</td></tr><tr><td>Employed</td><td>4</td><td>26.7</td></tr><tr><td>Student</td><td>5</td><td>33.3</td></tr><tr><td>Total</td><td>15</td><td>100</td></tr></table> |
b028307bb619d65c2141e7dcdcacfde4dfdb4947ccbc8f409ac9883e98609386.png | complex | <table><tr><td rowspan="2"></td><td rowspan="2" colspan="2">First yearTotalN = 298n (%)</td><td rowspan="2" colspan="2">Last yearTotalN = 209n (%)</td><td rowspan="2">P value</td><td colspan="4">Men</td><td rowspan="2">P value</td><td colspan="4">Women</td><td rowspan="2">P value</td></tr><tr><td colspan="2">First yearN = 125n (%)</td><td colspan="2">Last yearN = 77n (%)</td><td colspan="2">First yearN = 173n (%)</td><td colspan="2">Last yearN = 132n (%)</td></tr><tr><td>Work</td><td>290</td><td>(97)</td><td>195</td><td>(93)</td><td>< .05</td><td>122</td><td>(98)</td><td>65</td><td>(84)</td><td>< .001</td><td>168</td><td>(97)</td><td>130</td><td>(98)</td><td>NS</td></tr><tr><td>I like my job*</td><td>158</td><td>(53)</td><td>89</td><td>(43)</td><td>< .05</td><td>55</td><td>(44)</td><td>26</td><td>(34)</td><td>NS</td><td>103</td><td>(60)</td><td>63</td><td>(48)</td><td>< .05</td></tr><tr><td>I know whatI want to be</td><td>70</td><td>(23)</td><td>82</td><td>(39)</td><td>< .001</td><td>28</td><td>(22)</td><td>26</td><td>(34)</td><td>NS</td><td>42</td><td>(24)</td><td>56</td><td>(42)</td><td>< .01</td></tr><tr><td>The world is my workplace</td><td>56</td><td>(19)</td><td>13</td><td>(6)</td><td>< .001</td><td>21</td><td>(17)</td><td>3</td><td>(4)</td><td>< .01</td><td>35</td><td>(20)</td><td>10</td><td>(8)</td><td>< .01</td></tr><tr><td>I am a good doctor</td><td>30</td><td>(10)</td><td>32</td><td>(15)</td><td>NS</td><td>12</td><td>(10)</td><td>8</td><td>(10)</td><td>NS</td><td>18</td><td>(10)</td><td>24</td><td>(18)</td><td>NS</td></tr><tr><td>Full-time or more</td><td>27</td><td>(9)</td><td>15</td><td>(7)</td><td>NS</td><td>9</td><td>(7)</td><td>3</td><td>(4)</td><td>NS</td><td>18</td><td>(10)</td><td>12</td><td>(9)</td><td>NS</td></tr><tr><td>Part-time</td><td>11</td><td>(4)</td><td>28</td><td>(13)</td><td>< .001</td><td>2</td><td>(2)</td><td>12</td><td>(16)</td><td>< .001</td><td>9</td><td>(5)</td><td>16</td><td>(12)</td><td>< .05</td></tr><tr><td>Work– not specified*</td><td>42</td><td>(14)</td><td>28</td><td>(13)</td><td>NS</td><td>25</td><td>(20)</td><td>11</td><td>(14)</td><td>NS</td><td>17</td><td>(10)</td><td>17</td><td>(13)</td><td>NS</td></tr><tr><td>Family</td><td>228</td><td>(77)</td><td>160</td><td>(77)</td><td>NS</td><td>89</td><td>(71)</td><td>53</td><td>(69)</td><td>NS</td><td>139</td><td>(80)</td><td>107</td><td>(81)</td><td>NS</td></tr><tr><td>Children*</td><td>136</td><td>(46)</td><td>119</td><td>(57)</td><td>< .05</td><td>51</td><td>(41)</td><td>35</td><td>(45)</td><td>NS</td><td>85</td><td>(49)</td><td>84</td><td>(64)</td><td>< .05</td></tr><tr><td>Partner</td><td>107</td><td>(36)</td><td>100</td><td>(48)</td><td>< .01</td><td>49</td><td>(39)</td><td>33</td><td>(43)</td><td>NS</td><td>58</td><td>(34)</td><td>67</td><td>(51)</td><td>< .01</td></tr><tr><td>Family– not specified</td><td>72</td><td>(24)</td><td>28</td><td>(13)</td><td>< .01</td><td>27</td><td>(22)</td><td>10</td><td>(13)</td><td>NS</td><td>45</td><td>(26)</td><td>18</td><td>(14)</td><td>< .01</td></tr><tr><td>Leisure</td><td>93</td><td>(31)</td><td>98</td><td>(47)</td><td>< .001</td><td>36</td><td>(29)</td><td>33</td><td>(43)</td><td>< .05</td><td>57</td><td>(33)</td><td>65</td><td>(49)</td><td>< .01</td></tr><tr><td>Travel and hobbies*</td><td>37</td><td>(12)</td><td>50</td><td>(24)</td><td>< .01</td><td>14</td><td>(11)</td><td>11</td><td>(14)</td><td>NS</td><td>23</td><td>(13)</td><td>39</td><td>(30)</td><td>< .001</td></tr><tr><td>Friends and relatives</td><td>35</td><td>(12)</td><td>42</td><td>(20)</td><td>< .05</td><td>8</td><td>(6)</td><td>18</td><td>(23)</td><td>< .001</td><td>27</td><td>(16)</td><td>24</td><td>(18)</td><td>NS</td></tr><tr><td>Physical activity</td><td>20</td><td>(7)</td><td>26</td><td>(12)</td><td>< .05</td><td>6</td><td>(8)</td><td>9</td><td>(12)</td><td>NS</td><td>12</td><td>(7)</td><td>17</td><td>(13)</td><td>NS</td></tr><tr><td>Leisure– not specified</td><td>17</td><td>(6)</td><td>16</td><td>(8)</td><td>NS</td><td>9</td><td>(7)</td><td>4</td><td>(5)</td><td>NS</td><td>8</td><td>(5)</td><td>12</td><td>(9)</td><td>NS</td></tr><tr><td>Quality ofpersonal life</td><td>131</td><td>(44)</td><td>127</td><td>(61)</td><td>< .001</td><td>48</td><td>(38)</td><td>51</td><td>(66)</td><td>< .001</td><td>83</td><td>(48)</td><td>76</td><td>(58)</td><td>NS</td></tr><tr><td>Work-life balance</td><td>81</td><td>(27)</td><td>67</td><td>(32)</td><td>NS</td><td>24</td><td>(19)</td><td>26</td><td>(34)</td><td>< .05</td><td>57</td><td>(33)</td><td>41</td><td>(31)</td><td>NS</td></tr><tr><td>Happiness</td><td>31</td><td>(10)</td><td>50</td><td>(24)</td><td>< .001</td><td>13</td><td>(10)</td><td>21</td><td>(27)</td><td>< .01</td><td>18</td><td>(10)</td><td>29</td><td>(22)</td><td>< .01</td></tr><tr><td>Health</td><td>15</td><td>(5)</td><td>20</td><td>(10)</td><td>< .05</td><td>3</td><td>(2)</td><td>9</td><td>(12)</td><td>< .01</td><td>12</td><td>(7)</td><td>11</td><td>(8)</td><td>NS</td></tr><tr><td>Wealth</td><td>39</td><td>(13)</td><td>39</td><td>(19)</td><td>NS</td><td>20</td><td>(16)</td><td>15</td><td>(19)</td><td>NS</td><td>19</td><td>(11)</td><td>24</td><td>(18)</td><td>NS</td></tr></table> |
df79b14003e306d4278dd63c9f3ae5f352246f1f8ee9aaa2e4411513cee610d9.png | simple | <table><tr><td></td><td></td><td>VT IPD</td><td>NVT IPD</td><td>Total</td></tr><tr><td>Baseline</td><td></td><td>0</td><td>3765</td><td>3765</td></tr><tr><td>V, vaccine coverage</td><td>0.89</td><td></td><td></td><td></td></tr><tr><td></td><td>0.5</td><td>757</td><td>3594</td><td>4351</td></tr><tr><td></td><td>0.95</td><td>0</td><td>3765</td><td>3765</td></tr><tr><td>1/w, Duration of vaccine protection</td><td>8.3 years</td><td></td><td></td><td></td></tr><tr><td></td><td>5 Years</td><td>788</td><td>3570</td><td>4358</td></tr><tr><td></td><td>20 Years</td><td>0</td><td>3765</td><td>3765</td></tr><tr><td>Degree</td><td>0.76</td><td></td><td></td><td></td></tr><tr><td></td><td>0.3</td><td>1599</td><td>3338</td><td>4937</td></tr><tr><td></td><td>0.9</td><td>0</td><td>3765</td><td>3765</td></tr><tr><td>c<sub>V</sub></td><td>0.5</td><td></td><td></td><td></td></tr><tr><td></td><td>0</td><td>0</td><td>3836</td><td>3836</td></tr><tr><td></td><td>1</td><td>2</td><td>3710</td><td>3712</td></tr><tr><td>c<sub>N</sub></td><td>0.85</td><td></td><td></td><td></td></tr><tr><td></td><td>0</td><td>0</td><td>9533</td><td>9533</td></tr><tr><td></td><td>1</td><td>0</td><td>2921</td><td>2921</td></tr><tr><td>ε</td><td>0.88</td><td></td><td></td><td></td></tr><tr><td></td><td>0</td><td>0</td><td>3765</td><td>3765</td></tr><tr><td></td><td>0.95</td><td>438</td><td>3702</td><td>4140</td></tr></table> |
00d5d2f9c4bbcd914bdf476737442fc3888d24c3371f7219620ae6f3a658e1e9.png | simple | <table><tr><td>Pathway</td><td>Number of Proteins in Pathway</td><td>Proteins from Gene List</td><td><i>P</i>-value</td><td>FDR</td><td>Genes</td></tr><tr><td>Pathways in cancer (K)</td><td>327</td><td>7</td><td>0.0004</td><td>1.40E-02</td><td>E2F1,PTEN,AKT2,MSH6,HSP90AA1,JUN,VEGFA</td></tr><tr><td>Direct p53 effectors (N)</td><td>133</td><td>5</td><td>0.0002</td><td>1.40E-02</td><td>E2F1,PTEN,SP1,JUN,SMARCA4</td></tr><tr><td>Hepatitis B (K)</td><td>146</td><td>5</td><td>0.0004</td><td>1.38E-02</td><td>E2F1,PTEN,AKT2,JUN,YWHAQ</td></tr><tr><td>Nonsense-mediated decay (R)</td><td>106</td><td>5</td><td>0.0001</td><td>1.55E-02</td><td>RPL30,UPF1,SMG7,RNPS1,RPL18A</td></tr><tr><td>RNA transport (K)</td><td>164</td><td>5</td><td>0.0006</td><td>1.50E-02</td><td>EEF1A1,UPF1,RNPS1,EIF4G2,NUP205</td></tr><tr><td>E2F transcription factor network (N)</td><td>68</td><td>4</td><td>0.0002</td><td>1.44E-02</td><td>E2F1,KAT2B,SP1,RRM2</td></tr><tr><td>Estrogen signaling pathway (K)</td><td>100</td><td>4</td><td>0.0009</td><td>1.69E-02</td><td>AKT2,HSP90AA1,SP1,JUN</td></tr><tr><td>Glucocorticoid receptor regulatory network (N)</td><td>77</td><td>4</td><td>0.0003</td><td>1.34E-02</td><td>SMARCD1,HSP90AA1,JUN,SMARCA4</td></tr><tr><td>HIF-1-alpha transcription factor network (N)</td><td>66</td><td>4</td><td>0.0002</td><td>2.03E-02</td><td>NPM1,SP1,JUN,VEGFA</td></tr><tr><td>Huntington disease (P)</td><td>121</td><td>4</td><td>0.0017</td><td>2.79E-02</td><td>GAPDH,AKT2,AP2A2,JUN</td></tr><tr><td>Processing of capped intron-containing pre-mRNA (R)</td><td>138</td><td>4</td><td>0.0028</td><td>3.33E-02</td><td>DDX23,PCBP1,RNPS1,NUP205</td></tr><tr><td>Prostate cancer (K)</td><td>89</td><td>4</td><td>0.0006</td><td>1.56E-02</td><td>E2F1,PTEN,AKT2,HSP90AA1</td></tr><tr><td>Regulation of androgen receptor activity (N)</td><td>49</td><td>4</td><td>0.0001</td><td>1.70E-02</td><td>KAT7,HSP90AA1,KAT2B,JUN</td></tr><tr><td>Regulation of telomerase (N)</td><td>68</td><td>4</td><td>0.0002</td><td>1.44E-02</td><td>E2F1,HSP90AA1,SP1,JUN</td></tr></table> |
9852f16d5b874bc348f22de7384a6e30f7dffb0e91a60b9d75930c2a7dd01f70.png | complex | <table><tr><td> </td><td> </td><td>Mean difference</td><td>SD (±)</td><td><i>P </i></td></tr><tr><td rowspan="3">Flat SimK (D)</td><td>IOL Master-Galilei</td><td>0.155</td><td>0.156</td><td><0.001</td></tr><tr><td>IOL Master-WAM 5500</td><td>0.007</td><td>0.187</td><td>0.302</td></tr><tr><td>Galilei-WAM 5500</td><td>−0.148</td><td>0.195</td><td><0.001</td></tr><tr><td rowspan="3">Steep SimK (D)</td><td>IOL Master-Galilei</td><td>0.171</td><td>0.168</td><td><0.001</td></tr><tr><td>IOL Master-WAM 5500</td><td>−0.055</td><td>0.227</td><td>0.172</td></tr><tr><td>Galilei-WAM 5500</td><td>−0.226</td><td>0.236</td><td><0.001</td></tr><tr><td rowspan="3">Corneal astigmatism (D)</td><td>IOL Master-Galilei</td><td>0.016</td><td>0.249</td><td>0.662</td></tr><tr><td>IOL Master-WAM 5500</td><td>−0.061</td><td>0.265</td><td>0.055</td></tr><tr><td>Galilei-WAM 5500</td><td>−0.078</td><td>0.292</td><td>0.022</td></tr><tr><td>ACD (mm)</td><td>IOL Master-Galilei</td><td>−0.269</td><td>0.158</td><td><0.001</td></tr><tr><td>WTW (mm)</td><td>IOL Master-Galilei</td><td>−0.080</td><td>0.274</td><td>0.009</td></tr></table> |
11ae47b91f58df91963ee4627e0a721e7054ff4ece1438c1c543cbe79ff2f550.png | simple | <table><tr><td>Programs</td><td>Species</td><td>Algorithms</td><td>Advantages</td><td>Disadvantages</td></tr><tr><td>Diana-microT</td><td>Human</td><td>Seed match, thermodynamics</td><td>Prefers target structure before seed pairing.</td><td>Absence of cooperativity and multiplicity of miRNAbinding sites.Conservation filter.</td></tr><tr><td>miRDB</td><td>Human, mouse, rat, dog, chicken</td><td>SVM classifier</td><td>Editable Wikipedia based interface for functionalannotation.</td><td>Feature selection procedure ismissing.</td></tr><tr><td>miRWalk</td><td>Human, mouse, rat</td><td>Seed match, statistical model</td><td>Provides binding sites within promoter, 5’-UTR, CDS,and 3’-UTR regions.Amalgamates 10 prediction datasets and other uniquefeatures such as validated information on miRNAs associated with genes,diseases, cell lines, pathways, etc.</td><td>Free energy of the duplex is missing,however; it integrates other algorithms which consider free energy.</td></tr><tr><td>miRanda</td><td>Human, mouse, rat, fly, worm</td><td>Complementarity, free energy, conservation</td><td>Offers tissue-based miRNA expression profile.</td><td>Low precision.Conservation filter.</td></tr><tr><td>miTarget</td><td>Any</td><td>Seed match, free energy, SVM classifier</td><td>Validated miRNA targets information collected fromliterature search is used as training dataset.</td><td>A simple filtering for feature selection method.</td></tr><tr><td>PicTar</td><td>Vertebrates, flies, worms</td><td>Seed match, free energy, conservation, HMM</td><td>Considers cross-species conservation to reduce falsepositives.</td><td>Non-conservative sites prediction.</td></tr><tr><td>PITA</td><td>Human, mouse, fly, worm</td><td>Seed match, free energy</td><td>Considers secondary structure for prediction.</td><td>Low efficiency to existing algorithms.</td></tr><tr><td>RNA22</td><td>Human, mouse, fly, worm</td><td>Pattern recognition</td><td>Serves interactive exploration.It does not consider cross-species conservationfilter.</td><td>Low efficiency to existing algorithms.</td></tr><tr><td>RNAhybrid</td><td>Any</td><td>Seed match, free energy, statistical model</td><td>Extension of classical RNA secondary structureprograms.</td><td>Unable to distinguish functional and non-functionalsites.</td></tr><tr><td>TargetScan</td><td>Mammals, flies, worms, fish</td><td>Seed match, free energy, conservation</td><td>Broadly scans for conserved 8nt and 7nt sites.</td><td>Restricts to seed matching and conservation.</td></tr></table> |
9927c9a53ce7a3bc12b4c750dd2015c0600743a5a8ccac0681233dfc2f611399.png | complex | <table><tr><td rowspan="2"></td><td></td><td></td><td>Non-surgical <i>n</i> = 261</td><td>Bariatric surgery <i>n</i> = 301</td><td>Adjusted for gender/ age/BMI</td><td></td><td></td></tr><tr><td>Range</td><td>α</td><td>Mean (SD)</td><td>Mean (SD)</td><td>F</td><td><i>p</i></td><td>ηp<sup>2</sup></td></tr><tr><td>Self-esteem</td><td>1–4</td><td>0.81</td><td>2.7 (0.7)</td><td>2.7 (0.7)</td><td>0.54</td><td>0.46</td><td></td></tr><tr><td>Body satisfaction</td><td>1–5</td><td>0.74</td><td>2.4 (0.5)</td><td>2.6 (0.5)</td><td>1.76</td><td>0.18</td><td></td></tr><tr><td>Appearance importance</td><td>1–5</td><td>0.82</td><td>3.4 (0.7)</td><td>3.4 (0.8)</td><td>2.68</td><td>0.10</td><td></td></tr><tr><td colspan="8">Mental health</td></tr><tr><td> - Anxiety</td><td>0–20</td><td></td><td>7.2 (4.1)</td><td>7.0 (4.2)</td><td>0.78</td><td>0.38</td><td></td></tr><tr><td> - Depression</td><td>0–20</td><td></td><td>4.8 (3.2)</td><td>5.4 (3.8)</td><td>4.45</td><td><0.05</td><td>0.008</td></tr><tr><td>Binge eating</td><td>1–3</td><td></td><td>1.8 (0.9)</td><td>1.7 (0.8)</td><td>7.69</td><td><0.01</td><td>0.015</td></tr><tr><td colspan="8">Stressful life events</td></tr><tr><td> -frequency</td><td>0–13</td><td></td><td>3.3 (2.2)</td><td>3.8 (2.8)</td><td>3.25</td><td>0.07</td><td></td></tr><tr><td> -impact</td><td>1–4</td><td></td><td>3.2 (0.7)</td><td>3.3 (0.7)</td><td>0.59</td><td>0.44</td><td></td></tr><tr><td> -coping</td><td>1–3</td><td></td><td>1.9 (0.6)</td><td>2.0 (0.6)</td><td>1.41</td><td>0.24</td><td></td></tr><tr><td colspan="8">Emotion regulation</td></tr><tr><td> - reappraisal</td><td>1–7</td><td>0.77</td><td>4.1 (0.9)</td><td>4.0 (0.9)</td><td>1.48</td><td>0.22</td><td></td></tr><tr><td> - suppression</td><td>1–7</td><td>79</td><td>3.8 (1.1)</td><td>3.8 (1.1)</td><td>0.34</td><td>0.56</td><td></td></tr><tr><td colspan="8">Resilience factors</td></tr><tr><td> - Total</td><td>1–5</td><td>0.91</td><td>3.6 (0.6)</td><td>3.7 (0.6)</td><td>3.00</td><td>0.08</td><td></td></tr><tr><td> - Personal strength</td><td>1–5</td><td>0.87</td><td>3.4 (0.8)</td><td>3.5 (0.8)</td><td>8.40</td><td><0.01</td><td>0.015</td></tr><tr><td> - Structural style</td><td>1–5</td><td>0.49</td><td>3.2 (0.8)</td><td>3.4 (0.8)</td><td>10.45</td><td><0.001</td><td>0.019</td></tr><tr><td> - Social competence</td><td>1–5</td><td>0.74</td><td>3.6 (0.7)</td><td>3.7 (0.8)</td><td>0.99</td><td>0.32</td><td></td></tr><tr><td> - Family cohesion</td><td>1–5</td><td>0.84</td><td>3.7 (0.8)</td><td>3.6 (1.0)</td><td>0.18</td><td>0.67</td><td></td></tr><tr><td> - Social resources</td><td>1–5</td><td>0.80</td><td>4.1 (0.7)</td><td>4.1 (0.8)</td><td>0.01</td><td>0.95</td><td></td></tr><tr><td>Relationship satisfaction<sup>a</sup></td><td>1–7</td><td>0.85</td><td>5.6 (1.1)</td><td>5.6 (1.1)</td><td>0.07</td><td>0.79</td><td></td></tr></table> |
50fc028b71253a921de3957b0746bc6b25895b1f2cbf252812e8b79dfc9820aa.png | simple | <table><tr><td>Parameter</td><td>Description</td></tr><tr><td>L</td><td>ORF length in codons</td></tr><tr><td>x</td><td>average number of transcripts per cell</td></tr><tr><td>g</td><td>ribosome density in number of ribosomes per 100 codons</td></tr><tr><td>w</td><td>number of ribosomes attached to a single transcript</td></tr><tr><td>m</td><td>transcript mean lifetime</td></tr><tr><td>I</td><td>mean translation initiation time</td></tr><tr><td>E</td><td>mean translation elongation time</td></tr><tr><td>e</td><td>mean time required for elongation of one codon of a transcript</td></tr><tr><td>b</td><td>number of proteins produced from a single transcript during its lifespan</td></tr><tr><td>B</td><td>total number of protein molecules produced from all transcripts of a gene</td></tr><tr><td>A</td><td>number of protein molecules per cell taken from high-throughput studies</td></tr><tr><td>R</td><td>average number of proteins produced from a gene per second</td></tr></table> |
d35b21c18664753a1482f56ab35220663f313a34ef5f5a258defe287e2bee279.png | simple | <table><tr><td>Tissue/Organ</td><td>Weighting factor</td></tr><tr><td>Breast, colon, lungs, red marrow, remainder, stomach</td><td>0.12</td></tr><tr><td>Gonads</td><td>0.08</td></tr><tr><td>Bladder, liver, esophagus, thyroid</td><td>0.04</td></tr><tr><td>Bone surfaces, brain, salivary glands, skin</td><td>0.01</td></tr></table> |
e54c93be8956e702bf9860fa8e704d409d23324ed5cf3cd9af2e57b4aa00106a.png | complex | <table><tr><td rowspan="2">Criteria</td><td>O157</td><td>O26</td><td>O103</td><td>O111</td><td>O145</td><td>O45</td><td>O91</td><td>O113</td><td>O121</td><td>O128</td></tr><tr><td>(6)</td><td>(27)</td><td>(8)</td><td>(17)</td><td>(8)</td><td>(8)</td><td>(12)</td><td>(4)</td><td>(11)</td><td>(6)</td></tr><tr><td>Spring (32)</td><td>-</td><td>9</td><td>-</td><td>3</td><td>5</td><td>6</td><td>2</td><td>-</td><td>5</td><td>2</td></tr><tr><td>Summer (40)</td><td>4</td><td>10</td><td>3</td><td>5</td><td>2</td><td>1</td><td>7</td><td>2</td><td>3</td><td>3</td></tr><tr><td>(Autumn) (17)</td><td>-</td><td>2</td><td>3</td><td>9</td><td>-</td><td>1</td><td>-</td><td>-</td><td>1</td><td>1</td></tr><tr><td>Winter (18)</td><td>2</td><td>6</td><td>2</td><td>-</td><td>1</td><td>-</td><td>3</td><td>2</td><td>2</td><td>-</td></tr><tr><td>Nausea (42)</td><td>-</td><td>7</td><td>1</td><td>6</td><td>5</td><td>5</td><td>5</td><td>3</td><td>7</td><td>3</td></tr><tr><td>Fever (34)</td><td>2</td><td>17</td><td>1</td><td>8</td><td>-</td><td>1</td><td>3</td><td>1</td><td>1</td><td>-</td></tr><tr><td>Dysentery (14)</td><td>4</td><td>3</td><td>1</td><td>-</td><td>2</td><td>-</td><td>2</td><td>-</td><td>1</td><td>1</td></tr><tr><td>Other clinical signs (17)</td><td>-</td><td>-</td><td>5</td><td>3</td><td>1</td><td>2</td><td>2</td><td>-</td><td>2</td><td>2</td></tr></table> |
acd630d07a72900833ee14629f2e33201406c522f2958394283524d464ca1a31.png | simple | <table><tr><td>Load Cases</td><td>No. of Locations</td><td>Load Cases</td><td>No. of Locations</td></tr><tr><td>Load Case 3-1</td><td>3</td><td>Load Case 3-7</td><td>4</td></tr><tr><td>Load Case 3-2</td><td>5</td><td>Load Case 3-8</td><td>6</td></tr><tr><td>Load Case 3-3</td><td>7</td><td>Load Case 3-9</td><td>8</td></tr><tr><td>Load Case 3-4</td><td>9</td><td>Load Case 3-10</td><td>10</td></tr><tr><td>Load Case 3-5</td><td>11</td><td>Load Case 3-11</td><td>12</td></tr><tr><td>Load Case 3-6</td><td>2</td><td>Load Case 3-12</td><td>13</td></tr></table> |
de86b55e585661f30c55804790f5f3b6ae6b287e32c710ad26b44d6be8d1f3fe.png | simple | <table><tr><td></td><td>Bipolar I disorder (<i>N</i> = 14) <i>N</i> (%)</td><td>Bipolar spectrum disorder (<i>N</i> = 26) <i>N</i> (%)</td><td>Bipolar disorder total (<i>N</i> = 40) <i>N</i> (%)</td><td>Significance Fisher exact test</td></tr><tr><td>Recognized past depressive episodes</td><td>11 (78.6)</td><td>22 (84.6)</td><td>33 (82.5)</td><td>ns</td></tr><tr><td>Recognized past (hypo)manic episodes</td><td>3 (21.4)</td><td>6 (23.1)</td><td>9 (22.5)</td><td>ns</td></tr><tr><td>Consulted health professional for depressive episodes</td><td>11 (78.6)</td><td>19 (73.1)</td><td>30 (75.0)</td><td>ns</td></tr><tr><td>Consulted health professional for (hypo)manic episodes</td><td>5 (35.7)</td><td>2 (7.7)</td><td>7 (17.5)</td><td><i>P</i> = 0.039</td></tr><tr><td>Hospitalization for a manic episode</td><td>7 (50)</td><td>0 (0)</td><td>7 (17.5)</td><td><i>P</i> = 0.000</td></tr><tr><td>Indicated a past diagnosis of bipolar disorder</td><td>4 (28.6)</td><td>1 (3.8)</td><td>5 (12.5)</td><td><i>P</i> = 0.043</td></tr><tr><td>Treatment for bipolar disorder</td><td>4 (28.6)</td><td>1 (3.8)</td><td>5 (12.5)</td><td><i>P</i> = 0.043</td></tr></table> |
5410f12f03ab3ed6f28531e0f316aedf7688591fecd4782d64e31e7bf67a4020.png | complex | <table><tr><td>Ethnicity</td><td colspan="2">MKT</td><td colspan="2">WPA</td><td colspan="2">MLA</td><td colspan="2">Total</td></tr><tr><td>Sgaw Karen</td><td>1,081</td><td>26.3%</td><td>1,470</td><td>32.0%</td><td>3,443</td><td>71.3%</td><td>5,994</td><td>44.3%</td></tr><tr><td>Poe Karen</td><td>456</td><td>11.1%</td><td>774</td><td>16.9%</td><td>441</td><td>9.1%</td><td>1,671</td><td>12.4%</td></tr><tr><td>Burman</td><td>1,954</td><td>47.6%</td><td>1,822</td><td>39.7%</td><td>77</td><td>1.6%</td><td>3,853</td><td>28.5%</td></tr><tr><td>“Muslim”</td><td>15</td><td>0.4%</td><td>11</td><td>0.2%</td><td>573</td><td>11.9%</td><td>599</td><td>4.4%</td></tr><tr><td>Mon</td><td>72</td><td>1.8%</td><td>56</td><td>1.2%</td><td>14</td><td>0.3%</td><td>142</td><td>1.1%</td></tr><tr><td>Kachin</td><td>2</td><td>0.0%</td><td>0</td><td>0.0%</td><td>12</td><td>0.2%</td><td>14</td><td>0.1%</td></tr><tr><td>Pa Oh</td><td>46</td><td>1.1%</td><td>501</td><td>1.1%</td><td>10</td><td>0.2%</td><td>106</td><td>0.8%</td></tr><tr><td>Rakhine</td><td>55</td><td>1.3%</td><td>14</td><td>0.3%</td><td>1</td><td>0.0%</td><td>70</td><td>0.5%</td></tr><tr><td>Shan</td><td>9</td><td>0.2%</td><td>10</td><td>0.2%</td><td>6</td><td>0.1%</td><td>25</td><td>0.2%</td></tr><tr><td>“Mixed”</td><td>348</td><td>8.5%</td><td>334</td><td>7.3%</td><td>234</td><td>4.8%</td><td>916</td><td>6.8%</td></tr><tr><td>Other</td><td>66</td><td>1.6%</td><td>48</td><td>1.0%</td><td>16</td><td>0.3%</td><td>130</td><td>1.0%</td></tr><tr><td>Total</td><td>4,104</td><td>100.0%</td><td>4,585</td><td>100.0%</td><td>4,827</td><td>100.0%</td><td>13,520</td><td>100.0%</td></tr></table> |
678786ad7157bc41300858b40a80fcf3483b290a4fe91bbbd38c00ff1478b6c7.png | simple | <table><tr><td></td><td>Y</td><td>J</td><td>P</td><td>I</td></tr><tr><td>ABNER(B)</td><td>54.2</td><td>60.8</td><td>62.0</td><td>54.0</td></tr><tr><td>BANNER</td><td>62.0</td><td>61.0</td><td>68.7</td><td>53.9</td></tr></table> |
0a66e0ba80beb546c064673a3ead28af6f992e5e064c7cc71038278839ba27e7.png | simple | <table><tr><td><i>Extend_thres</i></td><td>P</td><td>R</td><td>F</td><td>Sn</td><td>PPV</td><td>Acc</td></tr><tr><td>0.05</td><td>0.506</td><td>0.314</td><td>0.387</td><td>0.569</td><td>0.389</td><td>0.471</td></tr><tr><td>0.1</td><td>0.589</td><td>0.36</td><td>0.447</td><td>0.521</td><td>0.541</td><td>0.531</td></tr><tr><td>0.2</td><td>0.55</td><td>0.341</td><td>0.421</td><td>0.451</td><td>0.611</td><td>0.525</td></tr><tr><td>0.3</td><td>0.524</td><td>0.321</td><td>0.398</td><td>0.39</td><td>0.653</td><td>0.505</td></tr><tr><td>0.4</td><td>0.515</td><td>0.311</td><td>0.388</td><td>0.349</td><td>0.677</td><td>0.486</td></tr><tr><td>0.5</td><td>0.506</td><td>0.314</td><td>0.387</td><td>0.332</td><td>0.699</td><td>0.482</td></tr><tr><td>0.6</td><td>0.502</td><td>0.314</td><td>0.386</td><td>0.331</td><td>0.701</td><td>0.482</td></tr><tr><td>0.7</td><td>0.502</td><td>0.314</td><td>0.386</td><td>0.331</td><td>0.701</td><td>0.482</td></tr><tr><td>0.8</td><td>0.502</td><td>0.314</td><td>0.386</td><td>0.331</td><td>0.701</td><td>0.482</td></tr><tr><td>0.9</td><td>0.502</td><td>0.314</td><td>0.386</td><td>0.331</td><td>0.701</td><td>0.482</td></tr><tr><td>1.0</td><td>0.502</td><td>0.314</td><td>0.386</td><td>0.331</td><td>0.701</td><td>0.482</td></tr></table> |
97320fa28c7889396ac5117d02a1889bc9ac98988099b87291d6933fd831e6bd.png | simple | <table><tr><td>Control</td><td>PaDRw-25 (t48)</td><td>PaDRw-25 (t72)</td></tr><tr><td>Peak (cm<sup>−1</sup>)</td><td>Peak (cm<sup>−1</sup>)</td><td>Peak (cm<sup>−1</sup>)</td></tr><tr><td>3306 (p, c)</td><td>3308 (+2)</td><td>3308 (+2)</td></tr><tr><td>2957 (p, l)</td><td>2958 (+1)</td><td>2958 (+1)</td></tr><tr><td>2922 (l)</td><td>2921 (−1)</td><td>2922</td></tr><tr><td>2869 (p, l)</td><td>2874 (+5)</td><td>2875 (+6)</td></tr><tr><td>2850 (l)</td><td>2850</td><td>2851 (+1)</td></tr><tr><td>1651 (p)</td><td>1646 (−5)</td><td>1648 (−3)</td></tr><tr><td>1544 (p)</td><td>1538 (−6)</td><td>1538 (−6)</td></tr><tr><td>1453 (p, l)</td><td>1450 (−3)</td><td>1449 (−4)</td></tr><tr><td>1393 (p, l)</td><td>1399 (+6)</td><td>1398 (+5)</td></tr><tr><td>1296 (p)</td><td>1305 (+9)</td><td>1304 (+8)</td></tr><tr><td>1248 (DNA)</td><td>1231 (+17)</td><td>1230 (+18)</td></tr><tr><td>1146 (DNA, c)</td><td>1150 (+4)</td><td>-</td></tr><tr><td>1082 (DNA)</td><td>1084 (+2)</td><td>1096 (+14)</td></tr><tr><td>1037 (DNA, c)</td><td>1057 (+20)</td><td>1067 (+30)</td></tr></table> |
b8ef6bf0b412f61b5d3530186468e521646c8f15e5b45a538e93b7a4b11c62e6.png | simple | <table><tr><td> </td><td>XX18</td><td>YY18</td><td>XY18</td><td>1818</td><td>Total Disomy</td></tr><tr><td>3PBA</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>≤LOD (n = 33)</td><td>1.00</td><td>1.00</td><td>1.00</td><td>1.00</td><td>1.00</td></tr><tr><td>>LOD (n = 42)</td><td>1.00 (0.90, 1.10)</td><td>1.28 (1.15, 1.42)</td><td>0.82 (0.77, 0.87)</td><td>0.89 (0.65, 1.23)</td><td>0.93 (0.87, 0.97)</td></tr><tr><td>CDCCA</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>≤LOD (n = 53)</td><td>1.00</td><td>1.00</td><td>1.00</td><td>1.00</td><td>1.00</td></tr><tr><td>>LOD (n = 22)</td><td>1.22 (1.09, 1.36)</td><td>1.18 (1.05, 1.31)</td><td>1.07 (1.00, 1.14)</td><td>0.89 (0.65, 1.21)</td><td>1.12 (1.06, 1.17)</td></tr><tr><td>TDCCA</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>≤LOD (n = 56)</td><td>1.00</td><td>1.00</td><td>1.00</td><td>1.00</td><td>1.00</td></tr><tr><td>>LOD (n = 19)</td><td>1.30 (1.17, 1.46)</td><td>1.19 (1.06, 1.34)</td><td>1.01 (0.93, 1.08)</td><td>1.10 (0.84, 1.44)</td><td>1.09 (1.04, 1.15)</td></tr></table> |
c0ed39d03f0f1497682b7ae2b6b6d7c184b8c5a2c25b91746e227014fdd8e752.png | complex | <table><tr><td colspan="2">Genetic model</td><td>OR (95% CI)</td><td><i>P</i> heterogeneity</td></tr><tr><td>Co-dominant model</td><td>CC</td><td>1</td><td></td></tr><tr><td></td><td>CT</td><td>1.072 (0.843, 1.362)<sup>b</sup></td><td>0.025</td></tr><tr><td></td><td>TT</td><td>1.666 (1.127, 2.461)<sup>a</sup></td><td>0.991</td></tr><tr><td>Dominant model</td><td>CT+TT vs. CC</td><td>1.119 (0.899, 1.392)<sup>b</sup></td><td>0.050</td></tr><tr><td>Recessive model</td><td>CC+CT vs. TT</td><td>1.663 (1.148, 2.408)<sup>a</sup></td><td>0.967</td></tr><tr><td>Allele</td><td>C vs. T</td><td>1.150 (1.014, 1.304)<sup>a</sup></td><td>0.231</td></tr></table> |
65ebc13e1090e4a179651eb945134b576a72904cd4854a9db280858c0da1641f.png | simple | <table><tr><td>Chromosome</td><td>Start</td><td>End</td><td>Length</td><td>Score</td></tr><tr><td>1</td><td>82955709</td><td>82956371</td><td>663</td><td>306.0</td></tr><tr><td>7</td><td>1194442</td><td>1195252</td><td>811</td><td>286.97</td></tr><tr><td>1</td><td>76438827</td><td>76439515</td><td>689</td><td>251.83</td></tr><tr><td>5</td><td>4911834</td><td>4912728</td><td>895</td><td>236.06</td></tr><tr><td>5</td><td>4907997</td><td>4908831</td><td>835</td><td>235.12</td></tr><tr><td>9</td><td>4315702</td><td>4316286</td><td>585</td><td>230.55</td></tr><tr><td>1</td><td>89187456</td><td>89187990</td><td>535</td><td>214.65</td></tr><tr><td>8</td><td>61869092</td><td>61869619</td><td>528</td><td>201.54</td></tr><tr><td>3</td><td>59054967</td><td>59055546</td><td>580</td><td>188.78</td></tr><tr><td>9</td><td>58915814</td><td>58916418</td><td>605</td><td>184.69</td></tr><tr><td>6</td><td>41195995</td><td>41196596</td><td>602</td><td>173.86</td></tr><tr><td>2</td><td>46987902</td><td>46988604</td><td>703</td><td>173.8</td></tr><tr><td>2</td><td>48205156</td><td>48205766</td><td>611</td><td>173.8</td></tr><tr><td>12</td><td>6609432</td><td>6610083</td><td>652</td><td>173.8</td></tr><tr><td>12</td><td>64009107</td><td>64009667</td><td>561</td><td>173.51</td></tr></table> |
9263c6d9e984570eb9cf0ec5816e8da3dbaf5abfce669b7216bbd8c28146b0f9.png | simple | <table><tr><td>Number of SNPs</td><td>Haplotype combination</td><td>Chromosomal position</td><td><i>P</i>value</td><td>FWER corrected <i>P</i>value</td></tr><tr><td>2</td><td>rs2268493-rs2254298</td><td>8800840-8802228</td><td>0.00086</td><td>0.00468</td></tr><tr><td>3</td><td>rs2268490-rs2268493-rs2254298</td><td>8797085-8802228</td><td>0.000365</td><td>0.0018</td></tr><tr><td>3</td><td>rs2268493-rs2254298-rs53576</td><td>8800840-8804371</td><td>0.00208</td><td>0.01268</td></tr><tr><td>4</td><td>rs237885-rs2268490-rs2268493-rs2254298</td><td>8795543-8802228</td><td>0.0012</td><td>0.00712</td></tr><tr><td>4</td><td>rs2268490- rs2268493-rs2254298-rs53576</td><td>8797085-8804371</td><td>0.00132</td><td>0.0079</td></tr></table> |
877a712b8732914055f462e97b781d2621435fbaaff5a176ecbbe7deb0a200e2.png | simple | <table><tr><td>Gene</td><td>Wt</td><td>Het</td><td>Null</td></tr><tr><td>IL-17A</td><td>7.62 ± 4.70∗</td><td>1.10 ± 0.32<sup>‡</sup></td><td>0.31 ± 0.01<sup>‡</sup></td></tr><tr><td>IL-17F</td><td>12.95 ± 3.71∗</td><td>5.46 ± 1.07<sup>‡</sup></td><td>4.19 ± 0.98<sup>‡</sup></td></tr><tr><td>IL-21</td><td>1.53 ± 0.80</td><td>0.70 ± 0.18</td><td>0.47 ± 0.14</td></tr><tr><td>IL-22</td><td>1.48 ± 1.05</td><td> 0.44 ± 0.33</td><td>0.10 ± 0.10</td></tr><tr><td>IL-23</td><td>3.88 ± 0.43∗</td><td> 3.58 ± 0.57<sup>∗‡</sup></td><td>2.19 ± 0.39<sup>‡</sup></td></tr><tr><td>IL-23R</td><td>0.73 ± 0.16</td><td>0.40 ± 0.05</td><td>0.65 ± 0.21</td></tr><tr><td>IL-27</td><td>2.75 ± 0.67</td><td>1.86 ± 0.42</td><td>1.80 ± 0.46</td></tr><tr><td>CCL20</td><td>1.42 ± 0.49</td><td>1.36 ± 0.57</td><td>1.13 ± 0.30</td></tr><tr><td>CCR6</td><td>1.22 ± 0.38</td><td>0.82 ± 0.24</td><td>0.91 ± 0.44</td></tr><tr><td>ROR<i>γτ</i></td><td>11.07 ± 2.04∗</td><td>8.75 ± 1.34∗</td><td>5.28 ± 0.17<sup>‡</sup></td></tr><tr><td>Tbet</td><td>8.35 ± 1.32∗</td><td>3.30 ± 0.66<sup>‡</sup></td><td>4.12 ± 0.69<sup>‡</sup></td></tr><tr><td>Foxp3</td><td> 2.95 ± 0.65</td><td>2.52 ± 0.23</td><td>1.81 ± 0.27</td></tr><tr><td>IL-10</td><td>13.57 ± 3.91∗</td><td>9.08 ± 2.77∗</td><td>3.95 ± 1.38<sup>‡</sup></td></tr><tr><td>TGF<i>β</i>1</td><td>1.80 ± 0.27</td><td>1.68 ± 0.26</td><td>1.31 ± 0.13</td></tr><tr><td>MCP-1</td><td>25.57 ± 8.37∗</td><td>32.41 ± 14.00∗</td><td> 8.86 ± 3.49<sup>‡</sup></td></tr><tr><td>IL-1<i>β</i></td><td>44.13 ± 12.57</td><td>31.30 ± 13.19</td><td>24.51 ± 12.95</td></tr><tr><td>TNF<i>α</i></td><td>9.85 ± 1.81</td><td>9.89 ± 3.82</td><td>5.65 ± 1.72</td></tr><tr><td>IL-6</td><td>11.54 ± 4.07∗</td><td>7.11 ± 3.34<sup>∗‡</sup></td><td>2.10 ± 0.73<sup>‡</sup></td></tr><tr><td>IFN<i>γ</i></td><td>1.89 ± 1.01</td><td>0.52 ± 0.16</td><td>0.62 ± 0.21</td></tr><tr><td>IL-4</td><td>0.64 ± 0.36</td><td>nd</td><td>0.38 ± 0.73</td></tr></table> |
1e07957cf6fbf868f1457956cd1423878d1612eae03ce64bd1eea6a6b4ead10b.png | complex | <table><tr><td>Efficacy measures</td><td>Baseline</td><td>Week 12</td><td>Week 24</td></tr><tr><td colspan="4">6MWD, meters (LOCF)</td></tr><tr><td> <i>N</i></td><td>133</td><td>133</td><td>133</td></tr><tr><td> Mean (SD)</td><td>377.1 (61.30)</td><td>+53.6 (64.50)</td><td>+64.4 (91.17)</td></tr><tr><td> *<i>P</i> value (95 % CI)</td><td></td><td><0.001 (42.5; 64.7)</td><td><0.001 (48.7; 80.0)</td></tr><tr><td colspan="4">BDI scores (LOCF)</td></tr><tr><td> <i>N</i></td><td>133</td><td>133</td><td>133</td></tr><tr><td> Mean (SD)</td><td>2.5 (1.37)</td><td>−0.3 (1.52)</td><td>−0.2 (1.95)</td></tr><tr><td> <i>P</i> value (95 % CI)</td><td></td><td><0.001</td><td>0.003</td></tr><tr><td colspan="4">WHO functional classification, <i>n</i> (%) (LOCF)</td></tr><tr><td> <i>N</i></td><td>-</td><td>133</td><td>133</td></tr><tr><td> Improved by class 1/2</td><td></td><td>44 (33.1)/0</td><td>51 (38.3)/0</td></tr><tr><td> No change</td><td></td><td>84 (63.2)</td><td>77 (57.9)</td></tr><tr><td> Worsened by class 1/2</td><td></td><td>4 (3.0)/1 (0.8)</td><td>3 (2.3)/2 (1.5)</td></tr><tr><td colspan="4">NT-proBNP levels, ng/L (Observed data)</td></tr><tr><td> <i>N</i></td><td>132</td><td>123</td><td>122</td></tr><tr><td> Mean (SD)</td><td>1600.7 (1832.84)</td><td>−861.4 (1452.96)</td><td>−806.0 (1384.00)</td></tr><tr><td> <i>P</i> values (95 % CI)</td><td></td><td><i>P</i> < 0.001</td><td><i>P</i> < 0.001</td></tr></table> |
3ae7d8e0c931c0f8ec5d0eaa14b9c3707f7e7f16a3c82817b31df6d3bcddf6a2.png | simple | <table><tr><td>Direction of the Acceleration Loaded</td><td>Maximum Differential Stress of <i>x</i>-Component (MPa)</td><td>Maximum Differential Stress of <i>y</i>-Component (MPa)</td><td>Maximum Differential Stress of <i>z</i>-Component (MPa)</td></tr><tr><td><i>x</i>-axis</td><td>0.00048</td><td>14.7</td><td>0.00036</td></tr><tr><td><i>y</i>-axis</td><td>0.0009</td><td>0.00025</td><td>0.00065</td></tr><tr><td><i>z</i>-axis</td><td>0.00014</td><td>0.000172</td><td>0.000354</td></tr></table> |
b5c79dd08ed3d40f25a992ae35aee616465a9bbf26028de06ccfa6c721f2880c.png | simple | <table><tr><td>Participant</td><td>No motor constant load VOL</td><td>No motor constant load FES</td><td>No motor incremental load VOL</td><td>No motor incremental load FES</td><td>Motor constant load VOL</td><td>Motor constant load FES</td><td>Motor incremental load VOL</td><td>Other cycling trials completed</td></tr><tr><td>1</td><td></td><td></td><td>×</td><td>× </td><td></td><td></td><td></td><td>No motor constant load with FES alternating on:off in 1 minute increments </td></tr><tr><td>2</td><td>×</td><td>×</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>3</td><td>×</td><td></td><td></td><td></td><td>×</td><td>×</td><td></td><td></td></tr><tr><td>4</td><td></td><td></td><td></td><td></td><td>×</td><td>×</td><td>×</td><td>No motor-Brief trial without FES assistance</td></tr></table> |
ecd2225376c392442d19b3e8e239d9f0faec2fd1bd20ee70f40ea3c1d9773561.png | simple | <table><tr><td>Event sequence</td><td>WBC (×10<sup>9</sup>)</td><td>Eosinophils in PB (%, AEC)</td><td>Eosinophils in BM (%)</td><td>Blasts in BM (%)</td><td>Diagnosis</td><td>Intervention</td><td>Disease status</td></tr><tr><td>Initial presentation</td><td>44.6</td><td>1, 0.45</td><td>1</td><td>7</td><td>CMML-1</td><td>SGI-110</td><td>Refractory</td></tr><tr><td>After 2 months</td><td>65.1</td><td>9, 5.8</td><td>5</td><td>4</td><td>CMML-1</td><td>SGI-110</td><td>Progression</td></tr><tr><td>After 1 month</td><td>126</td><td>11, 13.8</td><td>16</td><td>12</td><td>Myelodysplastic/myeloproliferative neoplasm with eosinophilia, and <i>PDGFRA</i> rearrangement</td><td>Fludarabine + Cytarabine</td><td>Progression</td></tr><tr><td>After 1 month</td><td>6.4</td><td>1, 0.06</td><td>1</td><td>26</td><td>AML with <i>PDGFRA</i> rearrangement</td><td>Imatinib (with Idarubicin + Cutarabine)</td><td>Remission</td></tr></table> |
e2f0cdac9fb321da2ba3e0d757588c8fe0641eb3a7e535859b2615a87a1a4454.png | simple | <table><tr><td>Gene name</td><td>Forward primer</td><td>Reverse primer</td></tr><tr><td><i>IL-6</i></td><td>5′-ATCTGCCCTTCAGGAACAGC-3′</td><td>5′-AGCCTCCGACTTGTGAAGTG-3′</td></tr><tr><td><i>STAT3</i></td><td>5′-CAAAGAAAACATGGCCGGCA-3′</td><td>5′-GGGGGCTTTGTGCTTAGGAT-3′</td></tr><tr><td><i>JAK-1</i></td><td>5′-ATGGAGTTTCTGCCTTCGGG-3′</td><td>5′-TTCTTGCTGCTAAGTCCCGG-3′</td></tr><tr><td><i>MEK5</i></td><td>5′-TCGTGCCATGGAGAACCA-3′</td><td>5′-CGCGCCACTATTTGGAATCT-3′</td></tr><tr><td><i>FADD</i></td><td>5′-CCAAACAAGTGCAAGAGCCC-3′</td><td>5′-AGGATTGCAGAGTGAGCCAC-3′</td></tr><tr><td><i>Bcl2</i></td><td>5′-CTTCTCTCGTCGCTACCGTC-3′</td><td>5′-CATGACCCCACCGAACTCAA-3′</td></tr><tr><td><i>BCL-XL</i></td><td>5′-CTTCTCTCGTCGCTACCGTC-3′</td><td>5′-GTGAGGTGGAAGGGACCATG-3′</td></tr><tr><td><i>EGF</i></td><td>5′-TGTGGGCTGAGAAGAAGCTG-3′</td><td>5′-GAGTACCAGATCTGCCGCTC-3′</td></tr><tr><td><i>GAPDH</i></td><td>5′-AACTCCCATTCCTCCACCTT-3′</td><td>5′-GAGGGCCTCTCTCTTGCTCT-3′</td></tr></table> |
23feeb58bab99f0ffc74c36e5ca427842a29d1da364adabfe5147e43a21a9d83.png | simple | <table><tr><td></td><td>Total</td><td>FOBT</td><td>Colonoscopy/sigmoidoscopy</td></tr><tr><td>% Ordered</td><td>48</td><td>33</td><td>26</td></tr><tr><td>% Completed</td><td>43</td><td>23</td><td>26</td></tr></table> |
37881e4d40b3ac0884ef98947d86bb9b6981e9fd13b34e45f3d1ad39f6c2a55f.png | complex | <table><tr><td colspan="2">Method</td><td>FPS</td></tr><tr><td rowspan="7">Ours</td><td>K-SVD & Lasso</td><td>482</td></tr><tr><td>K-SVD & Ridge</td><td>34</td></tr><tr><td>K-SVD & Elastic Net</td><td>27</td></tr><tr><td>DMM & SVM</td><td>87</td></tr><tr><td>DMM & RF</td><td>215</td></tr><tr><td>LBP & SVM</td><td>62</td></tr><tr><td>LBP & RF</td><td>159</td></tr><tr><td rowspan="3"></td><td>MEMM [12]</td><td>10</td></tr><tr><td>Orderlet [24]</td><td>25</td></tr><tr><td>DNBC [36]</td><td>7</td></tr></table> |
94b3af86795610f5df9afd444cacc5c0886962e080427dc2f485ef56a832a2cb.png | complex | <table><tr><td>Lymphoma type</td><td colspan="4">Mean MFI relative to normal B cells (SEM)</td></tr><tr><td> </td><td>IgM</td><td>IgG</td><td>CD79a</td><td>CD79b</td></tr><tr><td>MZL</td><td>0.23 (0.62)</td><td>−0.21 (0.28)</td><td>0.19 (0.33)</td><td>−1.29 (0.43)</td></tr><tr><td>SLL/CLL</td><td>−1.38 (0.38)</td><td>−0.38 (0.24)</td><td>−0.15 (0.18)</td><td>−2.04 (0.32)</td></tr></table> |
421f95b2b1f1deb96638770cab12c283fde49944f956b6b09948829b2607ab38.png | simple | <table><tr><td>GOJ subtypes</td><td>Type I (Adenocarcinoma of distal oesophagus)</td><td>Type II (True cardia carcinoma)</td><td>Type III (Sub-cardial carcinoma)</td></tr><tr><td>Endoscopic criteria</td><td>Tumour mass arises 1 to 5 cm above the endoscopic cardia</td><td>Tumour mass arises 1 cm above to 2 cm below the endoscopic cardia</td><td>Tumour mass arises 2 to 5 cm below the area of the endoscopic cardia</td></tr><tr><td>Differing Characteristics</td><td>• Male predominance• Arise in association with Barrett's oesophagus (80%)• More likely to have hiatus hernia or history of GORD</td><td>• More similarities to Type III tumours than Type I• Barrett's mucosa identified in 10%</td><td>• Barrett's mucosa identified in only 2%• 60% have a diffuse growth pattern and 70% undifferentiated</td></tr><tr><td>Lymph node metastases</td><td>To mediastinal and abdominal lymph node stations</td><td>Mainly to abdominal lymph node stations</td><td>Mainly to abdominal lymph node stations</td></tr><tr><td>Precursor lesions</td><td>Barrett's oesophagus</td><td>Possible short segment Barrett's oesophagus or IM at the gastric cardia</td><td>Helicobacter pylori and IM of the subcardia region</td></tr><tr><td>Optimal surgical treatment</td><td>Transthoracic or transhiatal oesophagectomy</td><td>Controversial; may include either extended total gastrectomy or transthoracic or transhiatal oesophagogastrectomy</td><td>Extended total gastrectomy</td></tr></table> |
e28ccab4b8c2e7541651bb550e3a0795b718554501601858985c49d2904946de.png | simple | <table><tr><td></td><td>Adherence to ≥ 4 recommendation items(<i>n</i> = 385)</td><td>Adherence to < 4 recommendation items(<i>n</i> = 325)</td><td><i>p value</i></td><td>Overall cohort (<i>n</i> = 710)</td></tr><tr><td>Age, years, mean, (SD)</td><td>57.9 (8.77)</td><td>57.2 (9.64)</td><td><i>0.268</i></td><td>57.6 (9.18)</td></tr><tr><td>Males, <i>n</i> (%)</td><td>306 (79)</td><td>276 (85)</td><td><i>0.060</i></td><td>582 (82)</td></tr><tr><td>Education, years, mean (SD)</td><td>11.8 (3.64)</td><td>10.8 (3.19)</td><td><i>< 0.001</i></td><td>11.4 (3.48)</td></tr><tr><td>Ethnicity, <i>n</i> (%)</td><td></td><td></td><td><i>0.100</i></td><td></td></tr><tr><td> European</td><td>241 (63)</td><td>232 (71)</td><td></td><td>473 (67)</td></tr><tr><td> South Asian</td><td>49 (13)</td><td>27 (8)</td><td></td><td>76 (11)</td></tr><tr><td> Other Asian</td><td>44 (11)</td><td>28 (9)</td><td></td><td>72 (10)</td></tr><tr><td> Middle Eastern</td><td>39 (10)</td><td>32 (10)</td><td></td><td>71 (10)</td></tr><tr><td> Other</td><td>12 (3)</td><td>6 (2)</td><td></td><td>18 (3)</td></tr><tr><td>Hypertension, <i>n</i> (%)</td><td>242 (63)</td><td>198 (61)</td><td><i>0.597</i></td><td>440 (62)</td></tr><tr><td>Diabetes, <i>n</i> (%)</td><td>124 (32)</td><td>105 (32)</td><td><i>0.977</i></td><td>229 (32)</td></tr><tr><td>Depression, <i>n</i> (%)</td><td>57 (15)</td><td>52 (16)</td><td><i>0.660</i></td><td>109 (15)</td></tr><tr><td>Current smoker, <i>n</i> (%)</td><td>174 (45)</td><td>203 (62)</td><td><i>< 0.001</i></td><td>377 (53)</td></tr><tr><td>BMI, mean (SD)</td><td>29.2 (5.52)</td><td>30.1 (6.37)</td><td><i>0.044</i></td><td>29.7 (5.93)</td></tr><tr><td>Cardiac rehabilitation attendance, <i>n</i> (%)</td><td>162 (43)</td><td>132 (42)</td><td><i>0.683</i></td><td>294 (43)</td></tr></table> |
900d9a858d3c3bd101041e0bb14c78bedaaac5b2b7afdacfb99fe8e14c1f5e5e.png | complex | <table><tr><td>CAM preparation</td><td>% (n)</td></tr><tr><td colspan="2">Homeopathy</td></tr><tr><td> Schuessler Salts</td><td>3.1 (11)</td></tr><tr><td colspan="2">Dietary supplements</td></tr><tr><td> Minerals</td><td> </td></tr><tr><td>Magnesium</td><td>13.5 (48)</td></tr><tr><td>Calcium</td><td>9.0 (32)</td></tr><tr><td>Zinc</td><td>2.5 (9)</td></tr><tr><td>Iron</td><td>2.0 (7)</td></tr><tr><td> Single vitamins</td><td> </td></tr><tr><td>Vitamin C</td><td>2.3 (8)</td></tr><tr><td>Vitamin B</td><td>1.4 (5)</td></tr><tr><td>Vitamin D</td><td>0.8 (3)</td></tr><tr><td> Combination (mineral/vitamin/other)</td><td>4.5 (16)</td></tr><tr><td colspan="2">Herbs</td></tr><tr><td colspan="2"> Without specific indication</td></tr><tr><td>Chamomile (Matricaria recutita) tea</td><td>6.5 (23)</td></tr><tr><td>Unspecified “herbal” tea</td><td>5.1 (18)</td></tr><tr><td>Fennel, anise, caraway (Foeniculum vulgare, Pimpinella anisum, Carum carvi) tea</td><td>4.8 (17)</td></tr><tr><td>Peppermint (Mentha piperita) tea</td><td>3.7 (13)</td></tr><tr><td> Medicinal formulation</td><td> </td></tr><tr><td>Bronchial tea</td><td>2.8 (10)</td></tr><tr><td>Kidney-Bladder tea</td><td>2.5 (9)</td></tr><tr><td>Gastrointestinal tea</td><td>2.3 (8)</td></tr><tr><td> Ginkgo (Ginkgo biloba)</td><td>3.9 (14)</td></tr><tr><td> Valerian (Valeriana officinalis)</td><td>2.8 (10)</td></tr><tr><td> St. John’s wort (Hypericum perforatum)</td><td>1.4 (5)</td></tr><tr><td colspan="2">External applications</td></tr><tr><td> Ointments</td><td> </td></tr><tr><td> Arnica (Arnica montana)</td><td>5.6 (20)</td></tr><tr><td> Calendula (Calendula officinalis)</td><td>3.1 (11)</td></tr><tr><td> Mountain pine (Pinus Montana) foot cream/balm/footbath</td><td>3.1 (11)</td></tr><tr><td> Rubbing alcohol</td><td>3.1 (11)</td></tr><tr><td colspan="2">Juices</td></tr><tr><td> Unspecified “vegetable” juice</td><td>0.6 (2)</td></tr><tr><td> Grapefruit (Citrus paradisi) juice</td><td>0.3 (1)</td></tr></table> |
fcf61df9c2e19ce2a0a971ca95848cbb69c25060faadd1124ca4709ec9173acd.png | simple | <table><tr><td>Target gene<sup>a</sup></td><td>Forward primer, reverse primer and probe sequences (5'-3')</td><td>Location within sequences</td><td>Gene Bank accession no.</td></tr><tr><td><i>nleG6-2 </i>(Z2150)</td><td>ATATGCTCTCTATATGATAAGGATG</td><td>1928877-1928901</td><td>AE005174</td></tr><tr><td></td><td>AAAGTGACATTCGTCTTTTCTCATA</td><td>1928996-1928872</td><td></td></tr><tr><td></td><td>[6FAM]CGTTAGTGCAACTTGTTGAAACTGGTGGAA[BHQ1]</td><td>1928902-1928931</td><td></td></tr><tr><td><i>nleG5-2 </i>(Z2151)</td><td>AGACTATTCGTGGAGAAGCTCAAG</td><td>1929199-1929222</td><td>AE005174</td></tr><tr><td></td><td>TATTGAAGGCCAATCTGGATG</td><td>1929337-1929317</td><td></td></tr><tr><td></td><td>[6FAM]TGGATATTTTATGGGAAGTCTTAACCAGGATGG[BHQ1]</td><td>1929269-1929301</td><td></td></tr><tr><td><i>espK</i></td><td>ATTGTAACTGATGTTATTTCGTTTGG</td><td>1673295-1673320</td><td>AE005174</td></tr><tr><td></td><td>GRCATCAAAAGCGAAATCACACC</td><td>1673419-1673397</td><td></td></tr><tr><td></td><td>[6FAM]CAGATACTCAATATCACAATCTTTGATATATAAACGACC[BHQ1]</td><td>1673330-1673368</td><td></td></tr><tr><td><i>bfpA</i></td><td>CCAGTCTGCGTCTGATTCCA</td><td>2756-2775</td><td>FM180569</td></tr><tr><td></td><td>CGTTGCGCTCATTACTTCTGAA</td><td>2816-2795</td><td></td></tr><tr><td></td><td>TAAGTCGCAGAATGC-MGB</td><td>2777-2791</td><td></td></tr></table> |
bafce8a9db7386c7bf4915d24b08ead18bf8f7491b5284ca7a6bb4c231691494.png | simple | <table><tr><td></td><td>Capital cost ($MM)</td><td>Additional chemical cost ($MM/year)</td><td>Description</td></tr><tr><td>Preprocessing unit</td><td>$10.17</td><td>$1.90</td><td>Preprocessing unit includes tanks for preprocessing and belt transfer conveyors, where the preprocessed biomass may be additionally washed</td></tr><tr><td>Wastewater treatment unit<sup>a</sup></td><td>$21.70</td><td>$3.00</td><td>Additional cost account for the increase of the wastewater treatment capacity and treatment chemicals</td></tr></table> |
6370ab9cb05a7b6c57b5eb543fb601c4d3f69ae70d7fbedfdad4c4709d505fc7.png | simple | <table><tr><td>Parameters</td><td>B</td><td>Wald</td><td>Sig.</td><td>Exp (B)</td><td>95% CI</td></tr><tr><td>Age (≥60y)</td><td>0.913</td><td>0.996</td><td>0.318</td><td>2.491</td><td>0.415-14.957</td></tr><tr><td>Histological type</td><td>0.457</td><td>0.110</td><td>0.740</td><td>1.579</td><td>0.107-23.390</td></tr><tr><td>Grade</td><td>-1.369</td><td>3.599</td><td>0.058</td><td>0.254</td><td>0.062-1.046</td></tr><tr><td>Stage</td><td>-0.234</td><td>0.051</td><td>0.821</td><td>0.791</td><td>0.103-6.051</td></tr><tr><td>Tumor size</td><td>1.006</td><td>0.996</td><td>0.318</td><td>2.734</td><td>0.379-19.708</td></tr><tr><td>LN metastasis (+)</td><td>-0.061</td><td>0.004</td><td>0.948</td><td>0.941</td><td>0.154-5.735</td></tr><tr><td>Family history (+)</td><td>0.656</td><td>0.957</td><td>0.328</td><td>1.927</td><td>0.518-7.177</td></tr><tr><td>Menopause (+)</td><td>0.248</td><td>0.137</td><td>0.712</td><td>1.282</td><td>0.344-4.778</td></tr><tr><td>Her2 (+)</td><td>0.364</td><td>0.364</td><td>0.546</td><td>1.438</td><td>0.442-4.685</td></tr><tr><td>PR (+)</td><td>-0.17</td><td>0.000</td><td>0.984</td><td>0.983</td><td>0.185-5.220</td></tr><tr><td>ER (+)</td><td>0.024</td><td>0.001</td><td>0.978</td><td>1.024</td><td>0.188-5.578</td></tr><tr><td>Ki-67 (≥ 14%)</td><td>1.673</td><td>7.992</td><td>0.005</td><td>5.326</td><td>1.670-16.983</td></tr><tr><td>Jab1/COPS5</td><td>0.036</td><td>5.181</td><td>0.023</td><td>1.037</td><td>1.005-1.069</td></tr></table> |
e79ba17f769878ac9ad1559198833d9f84b8093f89a04c7538ea7cea5ea81542.png | simple | <table><tr><td>Antibiotics</td><td><i>S. aureus</i> (n = 30)Resistant frequency (%)</td><td>MRSA (n = 8)Resistant frequency (%)</td></tr><tr><td>Penicillin G</td><td>22 (73)</td><td>8 (100)</td></tr><tr><td>Ciprofloxacin</td><td>11 (36.7)</td><td>6 (75.0)</td></tr><tr><td>Gentamicin</td><td>10 (33.3)</td><td>5 (62.5)</td></tr><tr><td>Amikacin</td><td>3 (10)</td><td>1 (12.5)</td></tr><tr><td>Erythromycin</td><td>10 (33.3)</td><td>5 (62.5)</td></tr><tr><td>Cotrimoxazole</td><td>6 (20)</td><td>4 (50.0)</td></tr><tr><td>Tetracycline</td><td>6 (20)</td><td>3 (37.5)</td></tr><tr><td>Rifampicin</td><td>6 (20)</td><td>3 (37.5)</td></tr><tr><td>Vancomycin</td><td>0</td><td>0</td></tr><tr><td>Teicoplanin</td><td>0</td><td>0</td></tr><tr><td>Cefoxitin</td><td>8 (26.7)</td><td>8 (100)</td></tr><tr><td>Oxacillin</td><td>8 (26.7)</td><td>8 (100)</td></tr><tr><td>Clindamycin</td><td>8 (26.7)</td><td>3 (37.5)</td></tr></table> |
f7a84a20b3d0184b59fc7900f96d4275110f9361199a482ece6f18921708d305.png | complex | <table><tr><td rowspan="2">Index</td><td rowspan="2">Target group</td><td colspan="3">Number of drugs</td></tr><tr><td>Training dataset</td><td>Test dataset</td><td>Total</td></tr><tr><td>1</td><td>G Protein-coupled Receptors</td><td>272</td><td>35</td><td>307</td></tr><tr><td>2</td><td>Nuclear Receptors</td><td>82</td><td>13</td><td>95</td></tr><tr><td>3</td><td>Ion Channels</td><td>109</td><td>9</td><td>118</td></tr><tr><td>4</td><td>Enzymes</td><td>325</td><td>31</td><td>356</td></tr><tr><td>—</td><td>Total</td><td>788</td><td>88</td><td>876</td></tr></table> |
8f0c5d6b98f040a02ac7e1b66378809fcafbb8ebcca29cc13e7a9a9c02b2a12a.png | simple | <table><tr><td>Variable</td><td>CAP due to other definite bacterial pathogensn = 621</td><td>p<sup>1</sup></td><td>MPP n = 307</td><td>p<sup>2</sup></td><td>CAP with no known bacterial etiology n = 3604</td></tr><tr><td>Age (∅ ± SD)</td><td>61 ± 17 years</td><td>.000</td><td>41 ± 16 years</td><td>.000</td><td>61 ± 18 years</td></tr><tr><td>Male gender</td><td>58%</td><td>.000</td><td>41%</td><td>.000</td><td>56%</td></tr><tr><td>Outpatient/hospitalized</td><td>22%/78%</td><td>.000</td><td>56%/44%</td><td>.000</td><td>36%/64%</td></tr><tr><td>CRB 65 Score0-1-2-3-4 (%)</td><td>33-46-16-4-1</td><td>.000</td><td>72-25-3-0.4-0</td><td>.000</td><td>39-43-15-2-0.4</td></tr><tr><td>Packyears(∅ ± SD)</td><td>32 ± 25</td><td>.000</td><td>15 ± 14</td><td>.000</td><td>29 ± 23</td></tr><tr><td>Pleural effusion</td><td>17%</td><td>.000</td><td>6%</td><td>.001</td><td>13%</td></tr><tr><td>Dyspnoea</td><td>80%</td><td>.000</td><td>69%</td><td>ns</td><td>72%</td></tr><tr><td>Pleural pain</td><td>47%</td><td>.000</td><td>34%</td><td>ns</td><td>42%</td></tr><tr><td>Confusion</td><td>11%</td><td>.000</td><td>2%</td><td>.001</td><td>8%</td></tr><tr><td>Oxygen requirement</td><td>57%</td><td>.000</td><td>25%</td><td>.000</td><td>41%</td></tr><tr><td>Malignancy</td><td>9%</td><td>.000</td><td>2%</td><td>.000</td><td>10%</td></tr><tr><td>Chronic respiratory disease</td><td>38%</td><td>.000</td><td>20%</td><td>.000</td><td>36%</td></tr><tr><td>Renal insufficiency</td><td>8%</td><td>.001</td><td>2%</td><td>.000</td><td>8%</td></tr><tr><td>Congestive heart failure</td><td>19%</td><td>.000</td><td>4%</td><td>.000</td><td>19%</td></tr><tr><td>Diabetes</td><td>20%</td><td>.000</td><td>3%</td><td>.000</td><td>16%</td></tr><tr><td>Respiratory sample obtained*</td><td>42%</td><td>.000</td><td>58%</td><td>.000</td><td>30%</td></tr><tr><td>Leucocytes (median)/μl</td><td>13 200</td><td>.000</td><td>8850</td><td>.000</td><td>11 000</td></tr><tr><td>CRP (median) mg/l</td><td>173</td><td>.000</td><td>60</td><td>.001</td><td>73</td></tr><tr><td>Duration of antibiotic therapy(∅ ± SD)</td><td>13 ± 6 days</td><td>.000</td><td>11 ± 4 days</td><td>ns</td><td>11 ± 5 days</td></tr><tr><td>LOS in hospitalized patients(∅ ± SD)</td><td>14 ± 11 days</td><td>.000</td><td>9 ± 5 days</td><td>.000</td><td>12 ± 9 days</td></tr><tr><td>Deaths within 30 days</td><td>54 (8.7%)</td><td>.000</td><td>2 (0.7%)</td><td>.000</td><td>234 (6.5%)</td></tr></table> |
6d72ef0e953c2f5b069487b08cef549e3a5ab614fd1e429a9652aba82c2d873a.png | simple | <table><tr><td>Gene name</td><td>Control Fold change Peak to Trough</td><td>Alcohol Fold change Peak to Trough</td><td>Ratio (Alcohol fed/control)</td></tr><tr><td><i>clock</i></td><td>3.1</td><td>3.5</td><td>1.1</td></tr><tr><td><i>Bmal1</i></td><td>14.9</td><td>10.7</td><td>0.7</td></tr><tr><td><i>Npas2</i></td><td>38.5</td><td>8.0</td><td>0.2</td></tr><tr><td><i>per1</i></td><td>5.9</td><td>6.2</td><td>1.1</td></tr><tr><td><i>per2</i></td><td>6.2</td><td>3.3</td><td>0.5</td></tr><tr><td><i>per3</i></td><td>23.5</td><td>9.6</td><td>0.4</td></tr><tr><td><i>cry1</i></td><td>4.8</td><td>8.9</td><td>1.9</td></tr><tr><td><i>cry2</i></td><td>9.9</td><td>4.0</td><td>0.4</td></tr><tr><td><i>Rev-erbα</i></td><td>17.0</td><td>11.0</td><td>0.6</td></tr><tr><td><i>Rev-erbβ</i></td><td>6.9</td><td>2.1</td><td>0.3</td></tr></table> |
60559c87ac709ed3812c88cd82505594434dd8e5fab5f6455127de32127739dc.png | simple | <table><tr><td></td><td>AUC</td><td>Cut-off value</td><td>Sensitivity, % (95 % CI)</td><td>Specificity, % (95 % CI)</td><td>Likelihood ratio</td></tr><tr><td>BAFF</td><td>0.823</td><td>1.7 ng · mL<sup>−1</sup></td><td>67.6 (49.4 to 82.6)</td><td>94.7 (73.9 to 99.8)</td><td>12.85</td></tr><tr><td>KL-6</td><td>0.566</td><td>1562 U · mL<sup>−1</sup></td><td>79.4 (62.1 to 91.3)</td><td>52.6 (28.8 to 75.5)</td><td>1.67</td></tr><tr><td>SP-D</td><td>0.643</td><td>158 ng · mL<sup>−1</sup></td><td>47.1 (29.7 to 64.8)</td><td>77.7 (52.3 to 93.5)</td><td>2.11</td></tr></table> |
5402eef10c956c426a8b461dc39d2de3259a7117b8c79f03550cb59bc7946d38.png | simple | <table><tr><td>Parameters</td><td><i>df</i></td><td><i>F</i>-Value</td><td><i>p</i>-value</td></tr><tr><td>Drug</td><td>1</td><td>2.288</td><td>0.138</td></tr><tr><td>Timepoint</td><td>6.932</td><td>2.163</td><td>0.038*</td></tr><tr><td>Stimulation</td><td>3</td><td>11.423</td><td>0.001*</td></tr><tr><td>Drug × stimulation</td><td>3</td><td>8.673</td><td>0.001*</td></tr><tr><td>Timepoint × stimulation</td><td>30</td><td>2.056</td><td>0.001*</td></tr><tr><td>Drug × timepoint</td><td>5.446</td><td>1.478</td><td>0.192</td></tr><tr><td>Drug × timepoint × stimulation</td><td>30</td><td>1.831</td><td>0.027*</td></tr></table> |
c1247312317683ef466faf59819d70b05f5436823437960516f261d16ac8f71e.png | simple | <table><tr><td>Pathway<i><sup>2</sup></i></td><td>Sex</td><td>Diet</td><td><i>PAPOLG</i> genotype</td><td>Sex × diet</td><td>Sex × gene</td><td>Diet × gene</td></tr><tr><td>Amino acids (85)</td><td>11<i><sup>2</sup></i><i><sup>3</sup></i></td><td>3</td><td>8</td><td>1</td><td>2</td><td>4</td></tr><tr><td>Carbohydrates (23)</td><td>9</td><td>0</td><td>3</td><td>2</td><td>1</td><td>0</td></tr><tr><td>Cofactors and vitamins (15)</td><td>3</td><td>1</td><td>4</td><td>0</td><td>1</td><td>0</td></tr><tr><td>Energy (9)</td><td>1</td><td>0</td><td>1</td><td>1</td><td>0</td><td>1</td></tr><tr><td>Lipids (141)</td><td>15</td><td>7</td><td>29</td><td>6</td><td>6</td><td>31</td></tr><tr><td>Nucleotides (14)</td><td>1</td><td>2</td><td>3</td><td>0</td><td>0</td><td>2</td></tr><tr><td>Peptides (14)</td><td>0</td><td>1</td><td>0</td><td>0</td><td>0</td><td>0</td></tr><tr><td>Xenobiotics (46)</td><td>4</td><td>3</td><td>1</td><td>6</td><td>0</td><td>1</td></tr><tr><td>Total (347)</td><td>44</td><td>17</td><td>50</td><td>16</td><td>10</td><td>39</td></tr><tr><td>Median number after Y scrambling<i><sup>3</sup></i></td><td>20</td><td>17</td><td>20</td><td>20</td><td>20</td><td>20</td></tr><tr><td><i><sup>4</sup></i></td><td><0.001</td><td>NS</td><td><0.001</td><td>NS</td><td><0.001</td><td><0.001</td></tr></table> |
d8471c02c6f586fd7f1b427a9ade1984991b83943779a9ca4a31db1b42277e43.png | simple | <table><tr><td> </td><td>Hexanoyl-carnitine</td><td>Octenoyl-carnitine</td><td>Octanoyl-carnitine</td><td>Decenoyl-carnitine</td><td>Decanoyl-carnitine</td><td>Dodecenoyl-carnitine</td><td>Tetradecenoyl-carnitine</td><td>Linoleyl-carnitine</td><td>Stearoyl-carnitine</td></tr><tr><td>Hexanoylcarnitine</td><td>1</td><td>0.26</td><td>0.94</td><td>0.82</td><td>0.94</td><td>0.73</td><td>0.58</td><td>0.16</td><td>0.19</td></tr><tr><td>Octenoylcarnitine</td><td>0.26</td><td>1</td><td>0.18</td><td>0.50</td><td>0.19</td><td>0.35</td><td>0.27</td><td>0.28</td><td>0.10</td></tr><tr><td>Octanoylcarnitine</td><td>0.94</td><td>0.18</td><td>1</td><td>0.81</td><td>0.99</td><td>0.69</td><td>0.57</td><td>0.12</td><td>0.14</td></tr><tr><td>Decenoylcarnitine</td><td>0.82</td><td>0.50</td><td>0.81</td><td>1</td><td>0.83</td><td>0.82</td><td>0.60</td><td>0.28</td><td>0.16</td></tr><tr><td>Decanoylcarnitine</td><td>0.94</td><td>0.19</td><td>0.99</td><td>0.83</td><td>1</td><td>0.75</td><td>0.61</td><td>0.11</td><td>0.15</td></tr><tr><td>Dodecenoylcarnitine</td><td>0.73</td><td>0.35</td><td>0.69</td><td>0.82</td><td>0.75</td><td>1</td><td>0.72</td><td>0.22</td><td>0.21</td></tr><tr><td>Tetradecenoylcarnitine</td><td>0.58</td><td>0.27</td><td>0.57</td><td>0.60</td><td>0.61</td><td>0.72</td><td>1</td><td>0.20</td><td>0.18</td></tr><tr><td>Linoleylcarnitine</td><td>0.16</td><td>0.28</td><td>0.12</td><td>0.28</td><td>0.11</td><td>0.22</td><td>0.20</td><td>1</td><td>0.59</td></tr><tr><td>Stearoylcarnitine</td><td>0.19</td><td>0.10</td><td>0.14</td><td>0.16</td><td>0.15</td><td>0.21</td><td>0.18</td><td>0.59</td><td>1</td></tr></table> |
29ad2d97733be0d815a42e2f173cf4d60492e50868f3bafcb3caa50c06f40473.png | complex | <table><tr><td></td><td colspan="4">Coefficient (Standard Error)</td></tr><tr><td>Independent Variable</td><td>Initial Family Lifestyle</td><td>Family LifestyleAge 3</td><td>Family LifestyleAge 5</td><td>Family LifestyleAge 7</td></tr><tr><td></td><td colspan="4">α (Eq. 4)</td></tr><tr><td>Previous Latent Family Lifestyle, α</td><td>–</td><td>1.094<sup>***</sup> (0.007)</td><td>1.094<sup>***</sup> (0.007)</td><td>1.094<sup>***</sup> (0.007)</td></tr><tr><td></td><td colspan="4">β(Eqs. 3 and 4)</td></tr><tr><td>Currently High SES</td><td>0.028<sup>***</sup> (0.008)</td><td>–</td><td>–</td><td>–</td></tr><tr><td>Currently Low SES</td><td>−0.072<sup>***</sup> (0.008)</td><td>–</td><td>–</td><td>–</td></tr><tr><td>Maternal Education at Birth</td><td>0.013<sup>***</sup> (0.003)</td><td>–</td><td>–</td><td>–</td></tr><tr><td>Single Parent</td><td>−0.044<sup>***</sup> (0.010)</td><td>−0.002 (0.007)</td><td>− 0.003 (0.005)</td><td>−0.012<sup>**</sup> (0.005)</td></tr></table> |
e61dfbbf214190fa409d553222ee2829057c50bd7c6e66c66f8c22404e5a2ad2.png | simple | <table><tr><td>Patient</td><td>Age (years)</td><td>Gender</td><td>Location</td><td>Primary malignancy</td><td>Metastases type</td><td>Treatment for primary malignancy</td></tr><tr><td>1</td><td>69</td><td>M</td><td>Right</td><td>Kidney cancer</td><td>S</td><td>Surgery, chemotherapy</td></tr><tr><td>2</td><td>65</td><td>F</td><td>Left</td><td>Lung cancer</td><td>M</td><td>Surgery, chemotherapy</td></tr><tr><td>3</td><td>46</td><td>M</td><td>Right </td><td>Melanoma</td><td>M</td><td>Surgery, chemotherapy</td></tr><tr><td>4</td><td>70</td><td>F</td><td>Left </td><td>Kidney cancer</td><td>M</td><td>Surgery</td></tr><tr><td>5</td><td>80</td><td>M</td><td>Right </td><td>Colon cancer</td><td>S</td><td>Surgery, chemotherapy</td></tr><tr><td>6</td><td>81</td><td>F</td><td>Right </td><td>Colon cancer</td><td>M</td><td>Surgery, chemotherapy </td></tr><tr><td>7</td><td>60</td><td>M</td><td>Left </td><td>Kidney cancer</td><td>S</td><td>Surgery</td></tr><tr><td>8</td><td>68</td><td>F</td><td>Left </td><td>Kidney cancer </td><td>S</td><td>Surgery</td></tr><tr><td>9</td><td>59</td><td>M</td><td>Left </td><td>Stomach cancer</td><td>S</td><td>Surgery, chemotherapy</td></tr></table> |
f2f6311a8f810716f9fc62cf214cd8c8ceceb130e4bccca8147f1ffba451cc76.png | complex | <table><tr><td>Hip bearing surface</td><td>Femoral head size (mm)</td><td>Number of hips implanted</td><td>Number of hips revised for ARMD</td><td>Risk of ARMD revision surgery (%) (95% CI)</td><td>Relative risk (95% CI) of ARMD revision with 36 mm head size (vs. 28/32 mm)</td><td><i>p</i>-value (36 mm vs. 28/32 mm for same bearing surface)</td></tr><tr><td>MoP</td><td>28 & 32</td><td>407,412</td><td>85</td><td>0.021 (0.017–0.026)</td><td rowspan="2">2.80 (1.74–4.36)</td><td rowspan="2"><0.001</td></tr><tr><td>MoP</td><td>36</td><td>46,258</td><td>27</td><td>0.058 (0.038–0.085)</td></tr><tr><td>CoC</td><td>28 & 32</td><td>61,937</td><td>35</td><td>0.057 (0.039–0.079)</td><td rowspan="2">0.92 (0.56–1.51)</td><td rowspan="2">0.725</td></tr><tr><td>CoC</td><td>36</td><td>67,373</td><td>35</td><td>0.052 (0.036–0.072)</td></tr><tr><td>CoP</td><td>28 & 32</td><td>96,286</td><td>24</td><td>0.025 (0.016–0.037)</td><td rowspan="2">0.82 (0.24–2.19)</td><td rowspan="2">0.683</td></tr><tr><td>CoP</td><td>36</td><td>24,513</td><td>5</td><td>0.020 (0.007–0.048)</td></tr></table> |
af399431d8cec80dc4055c8b430c3d9270cdd2c49a03700d74aae8ff487d6af7.png | complex | <table><tr><td></td><td colspan="2">Model I*</td><td colspan="2">Model II**</td></tr><tr><td>Variable names</td><td>HR (95% CI)</td><td>P</td><td>HR (95% CI)</td><td>P</td></tr><tr><td>Care recipient's gender</td><td></td><td></td><td></td><td></td></tr><tr><td> Female</td><td>1.00</td><td></td><td>1.00</td><td></td></tr><tr><td> Male</td><td>3.97 (1.17 - 13.42)</td><td>0.027</td><td>5.13 (2.25 - 11.69)</td><td>< 0.0001</td></tr><tr><td>Informal care-giving arrangement</td><td></td><td></td><td></td><td></td></tr><tr><td> Spousal care</td><td>1.00</td><td></td><td>1.00</td><td></td></tr><tr><td> Daughter-in-law care</td><td>4.09 (1.23 - 13.58)</td><td>0.022</td><td>4.40 (1.60 - 12.10)</td><td>0.004</td></tr><tr><td> Other categories (biological daughter care/other relative care/living alone)</td><td>1.55 (0.45 - 5.39)</td><td>0.491</td><td>1.26 (0.55 - 2.90)</td><td>0.580</td></tr><tr><td>Interaction</td><td></td><td></td><td></td><td></td></tr><tr><td> Male gender * Daughter-in-law care</td><td>0.09 (0.01 - 0.57)</td><td>0.011</td><td>0.08 (0.02 - 0.46)</td><td>0.004</td></tr><tr><td> Male gender * Other categories</td><td>0.66 (0.14 - 3.11)</td><td>0.601</td><td></td><td></td></tr></table> |
2630867b7f64e6dac50abf5e2c9abd110e976cde8a349997c1e15e8c90d0f789.png | complex | <table><tr><td rowspan="2">Characteristics</td><td colspan="2">Adjusting for age and gender</td><td colspan="2">Simple logistic regression</td><td colspan="2">Multiple logistic regression</td></tr><tr><td>OR (95% CI)</td><td><i>P</i></td><td>OR (95% CI)</td><td><i>P</i></td><td>OR (95% CI)</td><td><i>P</i></td></tr><tr><td>Age (years)</td><td>1.001 (0.978–1.024)</td><td>0.961</td><td>1.010 (0.989–1.031)</td><td>0.373</td><td>—</td><td>—</td></tr><tr><td>Gender (M/F)</td><td>1.167 (0.673–2.024)</td><td>0.583</td><td>1.036 (0.626–1.715)</td><td>0.891</td><td>—</td><td>—</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>—</td><td>—</td><td>1.029 (0.960–1.103)</td><td>0.414</td><td>—</td><td>—</td></tr><tr><td>SBP (mmHg)</td><td>—</td><td>—</td><td>1.024 (1.012–1.035)</td><td><0.001</td><td>1.024 (1.006–1.041)</td><td>0.008</td></tr><tr><td>DBP (mmHg)</td><td>—</td><td>—</td><td>1.030 (1.011–1.048)</td><td>0.001</td><td>1.007 (0.980–1.035)</td><td>0.618</td></tr><tr><td>HbA1c (%)</td><td>—</td><td>—</td><td>1.093 (0.911–1.311)</td><td>0.340</td><td>—</td><td>—</td></tr><tr><td>TG (mmol/L)</td><td>—</td><td>—</td><td>1.126 (0.931–1.362)</td><td>0.221</td><td>—</td><td>—</td></tr><tr><td>TC (mmol/L)</td><td>—</td><td>—</td><td>1.298 (1.027–1.641)</td><td>0.029</td><td>1.888 (0.710–5.020)</td><td>0.203</td></tr><tr><td>HDL-C (mmol/L)</td><td>—</td><td>—</td><td>1.419 (0.494–4.071)</td><td>0.515</td><td>—</td><td>—</td></tr><tr><td>LDL-C (mmol/L) </td><td>—</td><td>—</td><td>1.339 (1.010–1.775)</td><td>0.043</td><td>0.665 (0.203–2.176)</td><td>0.500</td></tr><tr><td>BUN (nmol/L)</td><td>—</td><td>—</td><td>1.346 (1.165–1.555)</td><td><0.001</td><td>1.380 (1.111–1.714)</td><td>0.004</td></tr><tr><td>Cr (<i>μ</i>mol/L) </td><td>—</td><td>—</td><td>1.016 (1.005–1.028)</td><td>0.004</td><td>1.003 (0.982–1.024)</td><td>0.802</td></tr><tr><td>GFR (mL/min/1.73 m<sup>2</sup>)</td><td>—</td><td>—</td><td>0.991 (0.984–0.999)</td><td>0.019</td><td>1.010 (0.998–1.021)</td><td>0.095</td></tr><tr><td>Adropin (ng/mL)</td><td>0.285 (0.180–0.452)</td><td><0.001</td><td>0.288 (0.183–0.453)</td><td><0.001</td><td>0.270 (0.160–0.455)</td><td><0.001</td></tr><tr><td>MetS</td><td>—</td><td>—</td><td>1.506 (0.865–2.621)</td><td>0.148</td><td>—</td><td>—</td></tr></table> |
01fd7e09849dabdc6113ec8f9276a113e460d547d03b9d3bbd60a1dab0f7c6f9.png | simple | <table><tr><td>Condition</td><td>Femoral Taper Mean + Standard Deviation (Newtons)</td><td>Acetabular Taper Mean + Standard Deviation (Newtons)</td></tr><tr><td>10 million cycles dynamic fatigue</td><td>12,957 + 1797</td><td>3429 + 347</td></tr><tr><td>50 million cycles dynamic fatigue</td><td>12,506 + 774</td><td>4329 + 443</td></tr></table> |
8ddcc77ba88032929425220e5e17ce2cd6b893cfb73da6861c4528eec6516cf2.png | simple | <table><tr><td>Characteristics</td><td>No of patients</td><td>%</td><td>TIMP-1 negativeN (%)</td><td>TIMP-1 positiveN (%)</td><td><i>P</i></td></tr><tr><td>Age</td><td></td><td></td><td></td><td></td><td>0.34</td></tr><tr><td> <50</td><td>47</td><td>28.8</td><td>44 (93.6)</td><td>3 (6.4)</td><td></td></tr><tr><td> 51-65</td><td>94</td><td>57.7</td><td>80 (85.1)</td><td>14 (14.9)</td><td></td></tr><tr><td> > 65</td><td>22</td><td>13.5</td><td>19 (86.4)</td><td>3 (12.3)</td><td></td></tr><tr><td>Median 55.2</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Range 29-70</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>FIGO stage</td><td></td><td></td><td></td><td></td><td>0.36</td></tr><tr><td> I</td><td>0</td><td>0</td><td></td><td></td><td></td></tr><tr><td> II</td><td>26</td><td>15.9</td><td>25 (96.2)</td><td>1 (3.8)</td><td></td></tr><tr><td> III</td><td>123</td><td>75.5</td><td>106 (86.2)</td><td>17 (13.8)</td><td></td></tr><tr><td> IV</td><td>14</td><td>8.6</td><td>12 (85.7)</td><td>2 (14.3)</td><td></td></tr><tr><td>Tumour grade</td><td></td><td></td><td></td><td></td><td>0.32</td></tr><tr><td> 1</td><td>34</td><td>20.9</td><td>28 (82.4)</td><td>6 (17.6)</td><td></td></tr><tr><td> 2</td><td>49</td><td>30.1</td><td>43 (87.8)</td><td>6 (12.2)</td><td></td></tr><tr><td> 3</td><td>66</td><td>40.5</td><td>61 (92.4)</td><td>5 (7.6)</td><td></td></tr><tr><td> Not graded (clear cell or metastatic biopsy/cytology only)</td><td>14</td><td>8.6</td><td></td><td></td><td></td></tr><tr><td>Histopathologic cell type</td><td></td><td></td><td></td><td></td><td>0.00004</td></tr><tr><td> Serous</td><td>129</td><td>79.1</td><td>119 (92.2)</td><td>10 (7.8)</td><td></td></tr><tr><td> Endometrioid</td><td>11</td><td>6.8</td><td>9 (81.8)</td><td>2 (18.2)</td><td></td></tr><tr><td> Clear cell</td><td>5</td><td>3.1</td><td>4 (80.0)</td><td>1 (20.0)</td><td></td></tr><tr><td> Mucinous</td><td>9</td><td>5.5</td><td>4 (44.4)</td><td>5 (55.6)</td><td></td></tr><tr><td> Undifferentiated</td><td>6</td><td>3.7</td><td>6 (100)</td><td>0 (0.0)</td><td></td></tr><tr><td> Carcinosarcoma</td><td>3</td><td>1.8</td><td>1 (33.3)</td><td>2 (66.7)</td><td></td></tr><tr><td>Residual postoperative tumour</td><td></td><td></td><td></td><td></td><td>0.95</td></tr><tr><td> ≤ 1 cm</td><td>60</td><td>44.4</td><td>53 (88.3)</td><td>7 (11.7)</td><td></td></tr><tr><td> > 1 cm(Unknown: 28)</td><td>75</td><td>55.6</td><td>66 (88.0)</td><td>9 (12.0)</td><td></td></tr><tr><td>TIMP immunostaining</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Negative</td><td>143</td><td>87.7</td><td>NA</td><td>NA</td><td>NA</td></tr><tr><td> Positive</td><td>20</td><td>12.3</td><td></td><td></td><td></td></tr><tr><td> (<0.1%: 26)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> (0.1-10%: 80)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> (>10-25%: 30)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> (>25-50%:17)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> (>50%: 10)</td><td></td><td></td><td></td><td></td><td></td></tr></table> |
83d223617f2797acd509f3399e7ae0ac75efb00cf95e427230d826b924df0584.png | complex | <table><tr><td></td><td colspan="3">Lctg (<i>n</i> = 7)</td><td colspan="3">Fccg (<i>n</i> = 9)</td></tr><tr><td></td><td>Pre</td><td>Post</td><td>Difference</td><td>Pre</td><td>Post</td><td>Difference</td></tr><tr><td colspan="7">ONE LEG PRESS (1 RM<sup>*</sup> IN kg)</td></tr><tr><td>Right</td><td>151 ± 31</td><td>152 ± 34</td><td>1 ± 4</td><td>128 ± 14</td><td>130 ± 18</td><td>2 ± 8</td></tr><tr><td>Left</td><td>150 ± 38</td><td>148 ± 37</td><td>−1 ± 5</td><td>122 ± 12</td><td>123 ± 14</td><td>1 ± 7</td></tr><tr><td colspan="7">ONE LEG EXTENSION (1 RM<sup>*</sup> IN kg)</td></tr><tr><td>Right</td><td>47 ± 8</td><td>46 ± 7</td><td>−1 ± 2</td><td>44 ± 6</td><td>45 ± 8</td><td>1 ± 3</td></tr><tr><td>Left</td><td>45 ± 8</td><td>44 ± 9</td><td>0 ± 3</td><td>41 ± 7</td><td>43 ± 8</td><td>2 ± 3</td></tr></table> |
2ff4d9353dee0d3549f9dde2fdc7b3f19340f451fcb35b986f969747d159ac6b.png | simple | <table><tr><td>Specimen No.</td><td>Tensile Strength (MPa)</td><td>Modulus of Elasticity (GPa)</td><td>Strain to Failure (%)</td></tr><tr><td>1</td><td>42.65</td><td>0.68</td><td>6.27</td></tr><tr><td>2</td><td>38.24</td><td>0.67</td><td>5.71</td></tr><tr><td>3</td><td>48.04</td><td>0.68</td><td>7.11</td></tr><tr><td>4</td><td>44.44</td><td>0.68</td><td>6.51</td></tr><tr><td>5</td><td>44.22</td><td>0.64</td><td>6.88</td></tr><tr><td>6</td><td>46.43</td><td>0.72</td><td>6.41</td></tr><tr><td>7</td><td>45.70</td><td>0.71</td><td>6.40</td></tr><tr><td>8</td><td>37.39</td><td>0.65</td><td>5.78</td></tr><tr><td>9</td><td>39.20</td><td>0.73</td><td>5.37</td></tr><tr><td>10</td><td>33.87</td><td>0.67</td><td>5.03</td></tr><tr><td>11</td><td>42.13</td><td>0.62</td><td>6.74</td></tr><tr><td>12</td><td>44.94</td><td>0.61</td><td>7.37</td></tr><tr><td>13</td><td>41.00</td><td>0.72</td><td>5.70</td></tr><tr><td>14</td><td>37.46</td><td>0.64</td><td>5.82</td></tr><tr><td>15</td><td>39.48</td><td>0.73</td><td>5.38</td></tr></table> |
1c303682b5354605ed2646a678205ff295c01d38fa9de178801fc8549b8ef1c4.png | simple | <table><tr><td>Genotype</td><td>α<sup>+</sup>/β<sup>+</sup>/γ<sup>+</sup></td><td>α<sup>−</sup>/β<sup>+</sup>/γ<sup>+</sup></td><td>α<sup>+</sup>/β<sup>−</sup>/γ<sup>+</sup></td><td>α<sup>+</sup>/β<sup>+</sup>/γ<sup>−</sup></td><td>α<sup>−</sup>/β<sup>+</sup>/γ<sup>−</sup></td><td>α<sup>+</sup>/β<sup>−</sup>/γ<sup>−</sup></td><td>α<sup>−</sup>/β<sup>−</sup>/γ<sup>+</sup></td><td>α<sup>−</sup>/β<sup>−</sup>/γ<sup>−</sup></td></tr><tr><td>DOPAC:DA</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Average</td><td>0.1019</td><td>0.1044</td><td>0.0940</td><td>0.0981</td><td>0.1150</td><td>0.0893</td><td>0.0807<sup>∗</sup></td><td>0.1608<sup>∗∗</sup></td></tr><tr><td> SEM</td><td>0.0062</td><td>0.0046</td><td>0.0047</td><td>0.0072</td><td>0.0043</td><td>0.0051</td><td>0.0053</td><td>0.0091</td></tr><tr><td>HVA:DA</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Average</td><td>0.0827</td><td>0.0814</td><td>0.0908</td><td>0.0832</td><td>0.0969</td><td>0.0911</td><td>0.0980</td><td>0.1090<sup>∗</sup></td></tr><tr><td> SEM</td><td>0.0136</td><td>0.0059</td><td>0.0033</td><td>0.0059</td><td>0.0058</td><td>0.0080</td><td>0.0060</td><td>0.0026</td></tr></table> |
fa6f4c5ed3cb7f522a01893772a420b9a7574c8ecb0a0cd8b080eb9189313f3a.png | complex | <table><tr><td rowspan="2">Variables</td><td colspan="2">All PTB cases</td><td colspan="2">PTB cases with smear results<sup>a</sup></td><td colspan="2">PTB cases without smear results<sup>a</sup></td><td></td></tr><tr><td>n</td><td>%</td><td>n</td><td>%</td><td>n</td><td>%</td><td><i>p</i> value</td></tr><tr><td>Age, years, mean (SD)</td><td>36 ± 12.8</td><td>-</td><td>35 ± 13.1</td><td>-</td><td>37 ± 12.3</td><td></td><td><i>p</i> < 0.0001</td></tr><tr><td>Gender</td><td></td><td></td><td></td><td></td><td></td><td></td><td><i>p</i> < 0.0001</td></tr><tr><td> Female</td><td>7556</td><td>39.35</td><td>5130</td><td>40.26</td><td>2424</td><td>37.56</td><td></td></tr><tr><td> Male</td><td>11,641</td><td>60.65</td><td>7612</td><td>59.74</td><td>4029</td><td>62.44</td><td></td></tr><tr><td>HIV status</td><td></td><td></td><td></td><td></td><td></td><td></td><td><i>p</i> < 0.0001</td></tr><tr><td> Negative</td><td>13,086</td><td>68.17</td><td>9047</td><td>71.00</td><td>4039</td><td>62.59</td><td></td></tr><tr><td> Positive</td><td>4256</td><td>22.17</td><td>2720</td><td>21.35</td><td>1536</td><td>23.80</td><td></td></tr><tr><td> Unknown</td><td>1853</td><td>9.65</td><td>975</td><td>7.65</td><td>878</td><td>13.61</td><td></td></tr><tr><td colspan="3">Disease classification</td><td></td><td></td><td></td><td></td><td><i>p</i> = 0.061</td></tr><tr><td> PTB</td><td>19,024</td><td>99.11</td><td>12,640</td><td>99.20</td><td>6384</td><td>98.93</td><td></td></tr><tr><td> PTB and EPTB</td><td>171</td><td>0.89</td><td>102</td><td>0.80</td><td>69</td><td>1.07</td><td></td></tr><tr><td> TB classification</td><td></td><td></td><td></td><td></td><td></td><td></td><td><i>p</i> < 0.0001</td></tr><tr><td> New</td><td>12,833</td><td>66.86</td><td>10,574</td><td>82.99</td><td>2259</td><td>35.01</td><td></td></tr><tr><td> Re-treatment</td><td>6362</td><td>33.14</td><td>2168</td><td>17.01</td><td>4194</td><td>64.99</td><td></td></tr><tr><td colspan="2">Smear conversion status<sup>a</sup></td><td></td><td colspan="2"></td><td></td><td></td><td></td></tr><tr><td> Negative</td><td>11,115</td><td>87.23</td><td>11,115</td><td>87.23</td><td>-</td><td>-</td><td></td></tr><tr><td> Positive</td><td>1627</td><td>12.77</td><td>1627</td><td>12.77</td><td>-</td><td>-</td><td></td></tr><tr><td colspan="4">Pre-treatment smear grading</td><td></td><td></td><td></td><td><i>p</i> = 0.053</td></tr><tr><td> Scanty</td><td>1670</td><td>8.70</td><td>1101</td><td>8.64</td><td>569</td><td>8.82</td><td></td></tr><tr><td> AFB+</td><td>3991</td><td>20.79</td><td>2665</td><td>20.92</td><td>1326</td><td>20.55</td><td></td></tr><tr><td> AFB++</td><td>3983</td><td>20.75</td><td>2659</td><td>20.87</td><td>1324</td><td>20.52</td><td></td></tr><tr><td> AFB+++</td><td>8575</td><td>44.67</td><td>5712</td><td>44.83</td><td>2863</td><td>44.37</td><td></td></tr><tr><td> Not recorded</td><td>976</td><td>5.08</td><td>605</td><td>4.75</td><td>371</td><td>5.75</td><td></td></tr><tr><td>Sub-district</td><td></td><td></td><td></td><td></td><td></td><td></td><td><i>p</i> = 0.887</td></tr><tr><td> Bitou</td><td>1662</td><td>8.66</td><td>1119</td><td>8.78</td><td>543</td><td>8.41</td><td></td></tr><tr><td> George</td><td>7101</td><td>36.99</td><td>4731</td><td>37.13</td><td>2370</td><td>36.73</td><td></td></tr><tr><td> Hessequa</td><td>1245</td><td>6.49</td><td>818</td><td>6.42</td><td>427</td><td>6.62</td><td></td></tr><tr><td> Kannaland</td><td>940</td><td>4.90</td><td>615</td><td>4.83</td><td>325</td><td>5.04</td><td></td></tr><tr><td> Knysna</td><td>2088</td><td>10.88</td><td>1388</td><td>10.89</td><td>700</td><td>10.85</td><td></td></tr><tr><td> Mossel Bay</td><td>3090</td><td>16.10</td><td>2028</td><td>15.92</td><td>1062</td><td>16.46</td><td></td></tr><tr><td> Oudtshoorn</td><td>3069</td><td>15,99</td><td>2043</td><td>16.03</td><td>1026</td><td>15.90</td><td></td></tr></table> |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.